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ABSTRACT 
 
 
Clonally derived liver tumours and an ovarian cyst developed in mice following 
EIAV and FIV delivery in utero. LAM PCR and 454 sequencing was used to retrieve 
proviral insertion sites. TaqMan analysis revealed gene expression changes in 
lentiviral infected tumours. STRING and IPA networks identified links between 
genes flanking the lentivirus provirus and oncogenic pathways supporting the role of 
insertional mutagenesis in Hepatocellular Carcinoma (HCC). 
Global methylation analysis demonstrated increased relative methylation levels in 
lentivirus (EIAV, FIV, and HIV) infected normal and tumour samples. This provided 
strong evidence for host defence against lentivirus infection by epigenetic means. 
Microarray data showed altered expression of Dnmt1 and Dnmt3b and TaqMan 
analysis revealed specific changes in Dnmts levels when compared to uninfected 
liver.
The evidence found for involvement of DNA methylation associated with lentivirus 
infection and possibly tumour development required that this study be repeated in 
vitro. DNA methylation was investigated at early time points after lentivirus and 
retrovirus infection in HepG2 cells. Results revealed sharp increases in global 
methylation and Dnmt levels at 24 and 30hrs post infection. E2F targets play a key 
role in the regulation of gene expression and aberrations result in the development of 
cancer. 
Of the 94 E2F target genes analysed 77.7% were involved in DNA damage and 
repair mechanisms, 21.3% were known oncogenes or shown to exert oncogenic 
activity and 80.9% were categorised as HCC target genes. 
The fact that all lentiviral/retroviral vectors used in this study were found to cause 
changes in methylation and gene expression in vivo and in vitro suggests that these 
vectors, at least in the mouse, are genotoxic.  
Findings here support the use of the fetal animal model to identify vector 
genotoxicity and the mechanisms of lentiviral vector-induced tumorigenesis.  
This model may be a valuable tool to evaluate the safety of lentiviruses for gene 
therapy. 
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TBE tris borate acid 
TE tris-EDTA 
TM transmembrane subunit 
tRNA transfer ribonucleic acid 
U3 unique 3' 
U5 unique 5' 
UGT1A1 UDP-glucuronyltranferase 1A1 
VCN vector copy number 
VPR viral protein R 
VPU viral protein U 
VPX viral protein X 
VSV-G vesicular stomatitis virus G glycoprotein 
WHO world health organization 
WPRE woodchuck hepatitis virus posttranscriptional regulatory 
element 
X-Gal 5-bromo-4-chloro-3-indolyl β-D-galactoside 
X-SCID x-linked severe combined immunodeficiency 
18SRNA 18S ribosomal RNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ACKNOWLEDGEMENTS 
 
vii 
 
 
 
ACKNOWLEDGEMENTS 
 
Firstly I would like to thank my supervisor Dr. Michael Themis for contributing to 
my personal and academic growth over the past four years. Under your supervision I 
have learnt a lot about what it means to be a scientist and the value of good research.  
I would also like to thank Dr. Rhona Anderson, my second supervisor for overseeing 
my studies. 
 
I would like to acknowledge the generosity of several collaborators; in particular 
Dr. Manfred Smidth and Dr. Robert Andrews for their contribution to 454 
sequencing and Microarray analysis described in Chapter 5. 
 
I would like to thank Brunel’s Biosciences department for making it a great place to 
work in but in particularly several members who gave me practical advice, training 
and reagents when needed including Dr. Mark Pooks group, Mr. Derek Fisher, Ms. 
Denise May, Ms. Helen Cox, and Ms.Christine Newton. I would particularly like to 
acknowledge Ms. Safia Reja for her help with many things including the 
maintenance of the HepG2 cells (Kindly provided by Dr. Amanda Harvey). 
 
I am grateful to Drs. Laurence Bugeon, Terry Roberts and Helen Foster for their 
technical advice on QPCR analysis.  
 
I am very thankful for the contribution of Dr. Evgeny Makarov for his advice and 
training on all things splicing and Ms Romana Linkova for her contribution to IPA 
analysis. 
 
I am especially grateful to Dr. Matthew Themis for training me on several techniques 
including LAM PCR and his advice on all things that fall under the umbrella of life. 
 
I have met some great people who have shared this era of my life and kept me 
grounded. Thank you especially Ms Elena Zachariades and Ms. Safia Reja for your 
friendship and support. 
 ACKNOWLEDGEMENTS 
 
vii 
 
Thank you to my friends outside of Brunel who despite my absence still encouraged 
me to stay focused. 
 
Last but not least I would like to acknowledge my wonderful family – Dad, Mum, 
Jessica, Benedicta, Edwin and Emmanuel. You have been my constant support 
system throughout my studies. Without you all I would have lost my mind. Thank 
you for believing in me, helping me to laugh when things got tough and picking me 
up from various locations when my car got tired of doing its job. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 DECLARATION 
 
viii 
 
DECLARATION 
 
 
I, Emma Awele Osejindu, hereby declare that the work presented in this thesis was 
carried out by myself unless otherwise stated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
INTRODUCTION CHAPTER 1 
 
1 
 
 
1.1  Gene therapy 
 
Current statistics indicate that 13,000 births a year in the UK are affected by 
congenital or genetically determined abnormalities 
(http://www.geneticalliance.org.uk/education3.htm). 
Gene therapy has emerged as a promising way to treat genetic diseases by 
introducing a ‘normal’ version of a gene into patient cells to modify host gene 
expression and reach a therapeutic effect. For some diseases stem cell therapy is 
possible, however, the uncertainty and risk of complications associated with HLA- 
mismatched bone marrow transplantation means treatment using stem cells in a 
autologous manner is important. Hence, gene therapy may be used either on patient 
stem cells or somatically. 
Clinical studies conducted during the 1960’s demonstrated the ability of foreign 
DNA to penetrate mammalian cells and become expressed (Borenfreund and 
Bendich, 1961; Friedman, 1992).  In these early studies, Borenfreund and Bendich 
(1961; Bendich, 1961; Rieke, 1962; Chorąźy et al, 1963; 1964) isolated and labeled 
DNA from pneumococci and human leucocytes with tritium before adding the DNA 
to growing cultures of HeLa cells. Using autoradiography to measure radioactivity in 
the treated cells it was demonstrated that gene transfer of exogenous DNA was 
possible and that incorporation into the nucleus of mammalian cells occurred within 
6-24 hours post treatment. Once the genetic code was the deciphered between 1961 
and 1966 (Nirenberg, 2004; Nienhuis, 2008) interest in genetic engineering and gene 
transfer methods has mounted and made possible the characterisation and delivery of 
therapeutic genes. More recently, gene delivery has been improved by using viruses 
as vectors. One such virus is the RV and understanding retroviral biology has 
facilitated and promoted the use of these viruses to carry out gene transfer in a more 
efficient way. In order to discuss the use of these viruses in gene therapy an 
overview of retroviral biology is firstly presented.  
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1.1.1  Retroviruses an overview 
 
The term retroviruses (RV) are used to describe a large family of RNA viruses with 
similar structures (Figure 1). 
 
 
Figure 1. The genomic organisation of murine leukaemia virus (MLV), Human 
immunodeficiency virus type 1 (HIV-1), Human immunodeficiency virus type 2 (HIV-2), Simian 
immunodeficiency virus (SIV), Equine infectious anaemia (EIAV) and Feline immunodeficiency 
virus (FIV) are shown above.  
Several similarities between the RV’s have been found. These include the long terminal repeat 
(LTR), the group specific antigen (gag) gene, the polymerase gene (pol) and the gene coding 
for the viral envelope (env). The LTR, gag, pol and env genes play important roles in 
generating viral particles by producing an RNA genome that drives gene expression. The RT 
enzymes are used to convert the genome into DNA and integrate it into the host genome. Env 
genes produce virus glycoproteins which are needed to coat the virus with glycoprotein 
receptors to allow infection of new host cells. The main difference between RV’s is the presence 
of the accessory gene Regulatory of virion (rev) in HIV, SIV, EIAV and FIV and not MLV 
genomes. Additional accessory genes: Transcriptional activator (tat), Negative regulatory 
factor (nef) and Viral protein R (vpr) exist in several RV’s but not the MLV genome. The HIV-1 
and HIV-2/SIV are the only RV genomes that contain a Viral protein U (vpu) gene. In addition, 
Viral protein X (vpx) is found in SIV and HIV-2 but not in HIV-1. Image taken from Tang, 
Kuhen and Wong-Staal, (1999). 
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RV particles are typically 80-100nm in size and consist of RNA encapsulated by a 
lipid envelope and viral glycoproteins (Coffin, Huges and Varmus, 1997). The RV 
genome contains two single, linear strands of RNA which possess positive polarity 
(Coffin, 1996). Positive stranded viral RNA has the same sequence as mRNA. Hence 
these viruses can use their RNA genome directly as mRNA that can be translated by 
the host cell (Levinson, 2006). The defining feature of RV’s is its replicative strategy 
which does not result in death of the host cell (Coffin, 1979). RV’s transcribe their 
RNA into a complementary DNA (cDNA) that can be integrated into the host 
genome following infection via a viral encoded protein called the integrase. This 
ability to alternate genetic material between RNA in the virion and DNA in infected 
cells is a crucial feature of the viral life cycle (Temin et al, 1993). The RV family 
can be subdivided into seven groups (Table 1) according to their nucleotide sequence 
composition and distinctive features which can be visualised by transmission 
electron microscopy (Coffin, Huges and Varmus, 1997; Brenner and Malech, 2003).  
 
Number Genus Example Genome Oncogenic 
potential 
1 Avian - leukosis sarcoma 
viral group 
Rous sarcoma virus 
  
2 Mammalian – B type viral 
group 
Mouse mammary 
tumour virus   
3 Murine leukaemia related 
viral group 
Moloney murine 
leukaemia virus   
4 D-type viral group Mason – Pfizer monkey 
virus   
5 Human T cell leukaemia-
bovine leukaemia viral group 
Human T ell leukaemia 
Virus 
  
6 Spumaviruses Foamy virus 
 
 
7 Lentiviruses (LV) Feline 
Immunodeficiency virus 
 
 
 
Table 1. RV family. Simple RV’s and complex RV’s are represented as orange circles and blue 
circles, respectively. Note RV groups can display oncogenic potential and these are marked by 
red stars and known as oncoRVes.  
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Studies conducted using murine leukaemia virus (MLV) during the 1970s 
contributed greatly to our current knowledge of RV infection and integration 
mechanisms (Baltimore, 1970; Temin, 1980; Miller et al, 1990; Miller, 1997; Daly 
and Chernajovsky, 2000; Kay et al, 2001; Anderson and Hope, 2005). Many RV’s 
contain oncogenes (i.e. myb, v-myc and ras) that were believed sequestered over 
several rounds of their life cycle involving integration and then generation of new 
particles that became responsible for the initiation and maintenance of neoplastic 
transformation of target cells (Spector, Varmus and Bishop, 1978; Sheiness and 
Bishop, 1979; Gonda, Sheiness and Bishop 1982; Bishop, 1983; Varmus, 1984; 
Vanin et al, 1994).  RV’s which possess oncogenic potential are collectively known 
as oncoRVes (Table 1). RV’s are further classified into two groups called complex 
and simple viruses according to their genomic structures (Table 1). The RV genome 
common to all RV’s consists of three coding genes called gag, pol and env required 
for viral replication of simple and complex RVes (Figures 1 and 2). The gag gene 
encodes the structural proteins that form the structural matrix, capsid and 
nucleoproteins found in the viral core. The pol gene yields the viral enzymes reverse 
transcriptase, RNase H and integrase responsible for cDNA production and 
integration, respectively. The env gene encodes the glycoproteins that protrude from 
the lipid bilayer surrounding the viral particle (Figure 3). These proteins are used to 
attach virus particles to receptors on the surface of host cells and determine the viral 
tropism (Brenner and Malech, 2003; Peifer and Verma, 2001). The RV genome is 
flanked by duplicated regions in the 5’ and 3’ ends termed Long Terminal Repeats 
(LTR) (Temin, 1993).  The LTR is composed of U3 (unique 3), R (repeat) and U5 
(unique 5) sequences required for viral gene expression and production of new 
genomes (Figure 1). Table 2 provides details of the genes carried by RV’s. 
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Table 2. Basic components of the RV genome 
 
Gene Function 
Gag 
 
Production of Gag polyproteins required for the construction of RV particles. 
Production of viral matrix, capsid and nucleocapsid proteins.  
Pol Encodes the enzymes protease, reverse transcriptase (rt) and integrase enzymes which 
are required for cleavage of viral polyproteins into mature proteins; replication of viral 
RNA into DNA and integration of viral DNA into the host genome respectively. 
Env Encodes the viral glycoproteins present on the surface of the virus particle. The 
envelope precursor molecule breaks down into the surface glycoprotein and 
transmembrane structures.  
LTR Drives viral gene expression required for replication, reverse transcription and 
production of new viral genomes. Composed of 3 essential sequences:  U3, R and U5. 
Repeat - 
R 
Essential for reverse transcription and replication. Also provides polyadenylation 
signal in MLV and interacts with a transaactivation response region in HIV-1. 
Unique 3 - 
U3 
Contains essential promoter and transcriptional enhancer sequences. 
Unique 5 - 
U5 
Consists of sequences required for initiation of reverse transcription.  
 
Three major coding domains present in the wild type configuration of all RV vectors are shown. 
These genes are required for successful gene transfer and completion of the viral life cycle.  
 
 
 
Figure 2. A schematic overview of the RV genome. The viron RNA is typically 7-12Kb in size. 
The genomic structure of RNA consists of the gag gene located in the 5’ end of the viral 
genome followed by the pol and env genes. The RNA genome is flanked by the LTR regions. 
The gag gene encodes the matrix protein (MA), capsid protein (CA) and nucleoplasmid (NC). 
The pol gene encodes reverse transcriptase (RT), protease (PR), integrase (IN) and 
deoxyuridine triphosphatases 
(dUTPases). The env gene encodes the surface subunit (SU) and transmembrane subunit (TM).  
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Figure 3. A schematic overview of the RV’s structure. The RV particle is composed of an RNA 
genome packaged in capsid proteins and surrounded by a lipid envelope. The RNA genome 
consists of two single stranded RNA molecules. The gag gene encodes several gag core 
proteins. The pol gene codes for the production of enzymes reverse transcriptase, protease 
and integrase. The env gene provides the genetic code for envelope glycoprotein structures. 
These glycoprotein structures are deposited in the lipid bilayer of the cell and surround the 
virus particle after budding of the virus from the host cell membrane. The viral particle is 
typically 100nm in size. A modification of an image created by Silverman et al, (2010). 
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1.1.2 The RV life cycle 
 
Cell binding and entry steps  
 
The life cycle of a RV is shown in Figure 4 and begins with attachment of the virus 
to the host cell membrane via specific virus ligand/ host receptor interaction.  
The virus envelope protein recognises specific host cell receptors (for example CD4, 
CD9 and Rec1) and uses cell surface proteins/molecules to facilitate entry into target 
cells (Miller, 1996). The envelope protein is encoded as a polyprotein precursor 
which is cleaved into a surface unit (SU) and a transmembrane (TM) domain 
(Overbaugh et al, 2001). The SU protein is located on the outside of the virus 
particle and the TM protein anchors the SU to the viral membrane. The SU protein 
initiates entry of the RV particle by binding to specific cell surface proteins 
(Overbaugh et al, 2001). The SU molecule then induces a conformational change 
that exposes fusion proteins present in the TM (Cosset et al, 1995; Damico and 
Bates, 2000). Exposure of the viral core facilitates interaction between viral and 
specific host cellular proteins via direct fusion or endocytosis. This process depends 
on the virus envelope ligand and cell receptor used for entry. Binding of the HIV 
gp120 envelope glycoprotein to the CD4 structures in host cells induces 
conformational changes in the HIV gp120 glycoprotein. These changes results in the 
exposure of specific chemokine receptors including CCR5 and CXCR4 that allows 
virus entry (Kwong et al, 1999).  In contrast Tva serves as the cellular receptor for 
the RV subgroup A avian sarcoma and leukosis virus (ASLV-A). The interaction 
between Tva and the ASLV-A specific protein EnvA has been well characterised by 
several studies (Bates et al, 1993; Mothes et al, 2000; Wang et al, 2001).  Several 
groups have also reported the importance of pH conditions in RV cell binding. RV’s 
such as HIV-1, and MLV fuse with the plasma membrane of host cells in a pH 
independent manner (Wang et al, 2001).  In contrast RV’s such ASLV-A are 
described as pH dependent viruses that require low pH conditions to proceed with 
receptor mediated endocytosis (Kizhatil and Albritton, 1997; Hernandez  et al, 1997; 
Damic and Bates, 2000; Katen et al, 2001; Wang et al, 2001). After entering the cell 
membrane the retroviral nucleoprotein core particle is delivered into the cytoplasm 
of the cell.  
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Figure 4. The viral life cycle begins with the infection of a host cell. Cell entry is facilitated by 
fusion of the virus with the host cell membrane. The virus particle uncoats and deposits its 
proteins into the cytoplasm of the target cell. CDNA synthesis (reverse transcription) and 
integration of viral cDNA are catalysed by viral polymerases including reverse transcriptase. 
After integration virus proteins are assembled and viral particles are released from the host cell 
via budding pathways. Image taken from ncbi website: http://www.ncbi.nlm.nih.gov/RVes/ 
 
Reverse transcription  
 
The production of linear double stranded DNA from RNA molecules by reverse 
transcription is a pre-requisite for the integration of the double stranded DNA 
(provirus) into the host cell nuclear DNA. The retroviral nucleoprotein containing 
two copies of (+) viral RNA is uncoated in order to allow reverse transcription to 
occur (Figure 5 and 6). 
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Figure 5. The overall mechanisms involved in reverse transcription of the viral RNA genome to 
produce a linear DNA duplex in RVes. The polypurine tract (PPT) and the primer-binding site 
(PBS) are shown above. 1. Priming by cellular tRNA is followed by initiation of minus-strand 
DNA synthesis (light blue). 2. RNA template (excluding the PPT region) is cleaved by the viral 
enzyme RNase H. Cleavage may be non specific (short arrows) or highly specific (long arrows) 
3. Plus strand synthesis (dark blue). 4. RNase H cleavage of RNA template and removal. 5. The 
plus strand DNA (U3 –U5) is used as a template for the completion of plus strand synthesis. 6. 
DNA duplex (provirus) used for integration into the host genome of the target cell. The double 
stranded DNA contains duplications of the U3 and U5 regions at both ends. Image taken from 
Johnson, (2007). 
 
Nuclear entry 
 
Proviral DNA is assembled with other viral and cellular proteins in a pre-integration 
complex (PIC).  It is thought that PIC interacts with the microtubule networks to 
allow transportation towards the nucleus. The PIC’s of lentiviral complexes can be 
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transported across the nuclear pore without the breakdown of the nuclear envelope 
(Miller, Adam and Miller, 1990; Nisole and Saib, 2005).  The cis-acting element 
cPPT plays a key role in assisting nuclear import of lentiviral PIC’s in non-dividing 
cells (Skasko and Kim, 2008). In comparison, simple retroviral complexes such as 
MLV are dependent on the breakdown of the nuclear envelope during mitosis before 
transportation of PIC’s to the cytoplasm can occur.  
 
Integration 
 
Integration of reverse 
transcribed retroviral DNA into 
the host cell genome is 
classified into 5 key steps 
Figure 6 a-e. a) The PIC 
composed of a double cDNA 
template (red lines). b) The 
integrase enzyme removes two 
nucleotides from the 3’ end of 
viral DNA. This exposes recessed 
hydroxyl (OH) groups at the 3’ 
end. c)  Recessed OH groups are 
attached to host cell DNA via 
transestrification reactions. d) 
Base pairing between gaps are 
caused by unpairing between host 
and viral DNA junctions. e) Gaps 
are repaired resulting in 
integrated proviral DNA. Image 
taken from Bushman et al, 2008.  
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Viral gene expression, particle assembly and budding 
 
Transcription of the provirus generates full length and spliced products. Full length 
viral transcripts may be packaged into new viral particles using a RNA sequence 
known as the packaging signal (Ψ). Alternatively full length viral transcripts also 
serve as templates for translation of viral proteins. Viral transcripts are then 
assembled at the cell periphery and released by budding off the plasma membrane.  
 
1.1.3 Lentiviruses  
 
Lentiviruses are a family of RVes described as agents of slow disease syndromes due 
to their long latency before clinical signs of chronic disease manifestation (Narayan 
and Clements, 1989). Lentiviral infection can cause disease in sheep, goats, cats, 
cattle, horses, monkeys and human species due to viral infection with Maedi-Visna 
virus, (MVV) caprine arthritis-encephalomyelitis virus (CAEV), feline 
immunodeficiency virus, (FIV) bovine immunodeficiency virus, equine infectious 
anemia virus, (EIAV) simian immunodeficiency virus, (SIV) and human 
immunodeficiency virus (HIV), respectively (Narayan and Clements, 1989; 
Clements and Zink, 1996). Lentiviral infection is associated with various pathogenic 
diseases including degeneration of haematological systems (EIAV), neurological 
systems (HIV and FIV), multi-organ failure and cancer (HTLV) which can 
ultimately result in death (Tang et al, 1999). The lentivirus genome is complex due 
to the presence of additional genes that contribute to efficient virus replication and 
infection (Pfeifer and Verma. 2001; Brenner and Malech, 2003). Regulatory genes 
(tat and rev) and auxiliary (‘accessory’) genes (vif, vpr, vpu and nef) are absent in 
simple RV such as MLV (Table 3; Pfeifer and Verma, 2001). A representation of the 
lentivirus genome is presented in Figure 7 and differences and similarities between 
the genes carried by these viruses are shown in Table 3. 
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Table 3. Components of the lentivirus genome 
Lentiviral 
gene 
Function Simple 
RV 
Lentivirus 
Structural genes 
Gag See Table 2 
  
Pol See Table 2 
  
Env See Table 2 
  
LTR 
(R,U3,U5) 
See Table 2 
  
Regulatory genes 
Tat Involved in activation of LTR during viral replication 
stages. Increases initiation and elongation of viral RNA 
transcription. Binds to the TAR region of viral RNA 
and to host proteins. 
 
 
Rev Promotes nuclear transport and translation of unspliced 
and partially spliced viral transcripts across nuclear 
membrane. Interacts with transcripts containing rev 
responsive element (RRE). 
 
 
                 Accessory genes and elements 
Vif Vif increases infectivity and pathogenicity of HIV-1 
and FIV. Increases infectivity also stabilises the pre-
integration provirus. Vif also targets the APOBEC3 
family of proteins which act as inhibitors of retroviral 
replication.  
 
 
Vpr Aids infectivity and pathogenesis of HIV-1. Binds to 
nuclear pore complex and assists infection in non-
dividing cells. 
 
 
Vpu Functions in infectivity and virulence of HIV-1.  
Enhances the assembly and release of virions from 
human cells following infection. Triggers CD4 
degradation.  
 
 
Nef Involved in viral replication where it facilitates the 
ability of virus to evade host defense and reverse 
transcription. Down regulates the CD4 receptor. 
 
 
Packaging 
signal  Ψ 
Sequence positioned between the ATG codon within 
gag and the major splice donor site. Essential for 
transgene expression and encapsidation mechanisms.   
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The lentiviral superfamily are characterised by their complex genomes. Several genes are 
contained in the wild type configuration of all lentivirus vectors. Accessory genes facilitate the 
steps required for successful gene transfer and completion of the viral life cycle.  Several 
auxiliary genes are species specific. HIV2 and EIAV differ from other lentiviral counterparts as 
they lack the vpu gene. In addition FIV lacks the Tat gene although it contains a putative Tat 
gene called Orf2. Regulator and accessory proteins are often modified or eliminated from 
lentiviral constructs used for gene transfer. 
The presence of genes in the genome of simple and complex lentiviruses are represented by 
black ticks. The presence of genes in EIAV, FIV and HIV are represented as brown, pink and 
blue circles, respectivley. 
 
1.1.3.1 Human immunodeficiency virus (HIV)  
 
HIV has been extensively studied since the occurrence of the acquired immune 
deficiency syndrome AIDS epidemic in the 1980’s. The HIV genome is 
approximately 10kb in size and exists in two forms known as HIV-1 and HIV-2. 
HIV-1 primarily infects CD4 T cells and macrophages (Delassus et al, 1991). HIV 
infection is a major cause of morbidity and mortality in many parts of the world. 
According to global reports produced by the world health organisation (WHO) in 
2009, 33.3 million people were living with HIV. Out of this population 15.9 million 
were women http://www.who.int/hiv/data/2009_global_summary.png. A substantial 
proportion of those infected with HIV develops acquired immune deficiency 
syndrome (AIDS) and ultimately die.  1.8 million people died as a result of HIV 
infection in 2009 http://www.who.int/hiv/data/2009_global_summary.png. Research into 
HIV has allowed a detailed understanding of the HIV life cycle and the importance 
of key proteins required for virus propagation. This has been useful for lentivirus 
vector (LV) design (Ellison et al, 1990; Wu, 2004; Wodarz and Levy, 2007) and has 
allowed a focus on the use of HIV vectors as gene transfer tools (Figure 7). The first 
efficient LV expression system was derived from HIV-1 (Naldini et al, 1996a and b; 
Osten et al, 2006). Current studies suggest that the removal of HIV regulatory genes 
and the generation of recombinant HIV constructs will eliminate the risk of HIV 
pathogenesis and support the use HIV as gene transfer vectors. Kafri et al, 1997 
demonstrated sustained gene expression in liver and muscle using HIV based 
vectors. Trobridge et al, (2008) reported the transduction of haemopoetic stem cells 
in pig tailed macques (Macca nemestrina) using short term ex vivo transduction 
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methods. Results showed a large number of polyclonal integrations. HIV based 
vectors may also be used to treat disease. Humeau et al, (2004) reported the stable 
transduction (+/-94.5%) and vector mediated inhibited HIV replication in CD4 T 
cells derived from HIV+ patients. An anti-HIV molecule that targets the env gene 
was delivered to CD4 T cells using a HIV based vectors. This study demonstrated 
the clinical application of HIV vectors in treatment of HIV and potentially delaying 
the onset of AIDS. 
 
1.1.3.2 Equine infectious anemia virus (EIAV) 
 
This non-primate virus was first described in French memoirs written by Ligne in 
1843 (Leroux et al, 2005). Vallee and Carre demonstrated the viral etiology of 
persistent equine infection in 1904 by showing the causative agent was filterable 
(Studdert, 1996). However, EIAV exhibits unique signs of infection and associated 
symptoms which have not been described for other lentiviruses. This includes the 
occurrence of recurrent autoimmune haemolytic anaemia and fever which appears in 
the first year following infection. As a result EIAV was initially excluded from the 
RV family. However, EIAV was later confirmed as an RNA virus (Olsen, 1998). At 
8.6kb the EIAV genome is the simplest and smallest of the lentivirus family (Leroux, 
Cadorè and Montelaro, 2004). Several studies have explored the potential use of 
EIAV vectors in gene therapy (Fig 6; Ikeda et al, 2002; Azzouz and Mazarakis, 
2004; Gregory et al, 2004; Lamikanra et al, 2005). Balaggan et al (2006) reported 
the efficient and stable transduction of ocular cells following intraocular delivery of 
EIAV vectors by administration subretinally/intravitenally to mice. Results showed 
stable expression in retinal pigment epithelial (RPE) cells and photoreceptors up to 
16 months post infection. McKay et al, (2006) also demonstrated efficient 
transduction of mouse tracheal cells in vitro and in vivo using EIAV vector 
constructs pseudotyped with influenza envelope proteins.  
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1.1.3.3 Feline immunodeficiency virus (FIV)  
 
FIV (previously feline T-lymphotrophic lentivirus) infection was first diagnosed in 
cat sera in 1968 (Shelton et al, 1990).  FIV was later described in 1987 soon after the 
AIDS epidemic (Bennet and Symth, 1992; Bendinelli et al, 1995; Barraza and 
Poeschla, 2008). 
FIV infection manifests specifically in the domestic cat population (Poeschla et al, 
1998) and cannot be transmitted to human populations. The FIV particle is 125 nm 
in diameter. The FIV virion is also highly glycosylated yielding surface and 
transmemebrane glycol proteins gp85 and gp40 respectively. Interestingly, FIV 
displays similar tropism, accessory proteins (Vif and RRE) and viral infection 
capabilities with its HIV counterpart. Similarities between HIV and FIV have made 
this non primate LV vector (Figure 7) ideal for gene therapy because FIV has no 
known pathogenesis in humans. It is hoped that FIV genotoxicity models will 
facilitate understanding of HIV pathogenesis and AIDS progression (Buchschacher 
and Wong-Staal, 2000; Sauter and Gasmi, 2000; Sauter, Gasmi and Dubensky, 
2003). Stein et al, 2001 intravenously delivered FIV based vectors to the hepatocytes 
of factor VIII or β-glucoronidase deficient mice. This study reported the correction 
of the lysomal storage disease (mucopolysaccharidosis type VII) and hameophilliac 
mice and efficient transduction of transgenes into the liver of infected mice. Kang et 
al, 2005 also reported persistent factor VIII expression and partial correction of 
haemophilia A following the administration of FIV based vectors. Shai et al 2005 
demonstrated the efficient and stable transduction of murine salivary glands using 
FIV based vectors for up to 80 days post infection.  These studies all suggest the use 
of FIV based vectors in the treatment of disease. 
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Figure 7. Genomic structure of lentiviruses that have been used in gene transfer studies. 
Lentiviral genome structure consists of a collection of essential structural, regulatory and 
accessory genes. Accessory genes are represented in white boxes and structural and 
regulatory genes in grey boxes respectively. Image taken from Delanda, (2004).  
 
1.1.4  Retroviruses and lentiviruses in gene therapy 
 
Although early gene therapy protocols relied heavily on gammaRVes these RVs are 
unable to penetrate the nuclear membrane of non proliferating cells such as 
hepatocytes, haemopoetic stem cells (HSC) and neurons (Naldini et al, 1996a). In 
contrast, lentiviruses can translocate their pre-integration complexes across the 
nuclear envelope independently of mitosis making them more favourable for somatic 
gene therapy. Naldini and coworkers (Naldini et al, 1996b) pioneered the effective 
transduction of cells both in vitro and in vivo using the HIV virus.  However, 
lentiviruses exhibit reduced transduction efficiency of quiescent cells such as 
fibroblasts (Naldini, et al, 1996a,b). LV transduction studies facilitated the 
development of the first LV for clinical trials (Manilla et al, 2005). Recent studies 
have also focused on developing FIV and EIAV LV constructs for gene therapy. 
Problems affecting the use of LVs in gene therapy include the generation of an 
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immune response to the transgene product and the viral promoter driving gene 
expression that may be silenced. Further restrictions to retro/lentiviral integration 
include the action of host proteins such as Ref1 and TRIM5α since these protect 
mammalian cells from retroviral infection and integration by binding directly to viral 
capsids accelerating degradation and increasing the recognition of viral proteins as 
foreign agents (Saenz et al, 2005; Emerman, 2006; Lim et al, 2010; Ganser-Pornillos 
et al, 2011). By increasing vector titre the impact of host cell restriction mechanisms 
can be partly overcome (Barraza and Poeschla, 2008); however, this may present an 
increasing risk of vector related genotoxicity (Nienhuis et al, 2006).  
 
1.1.4.1 The production of retroviral/lentiviral vectors for gene 
therapy 
 
For most gene therapy applications it is not desirable to deliver a replication 
competent virus (RCV) to patients in which the vector will multiply and spread viral 
infection to other adjacent tissues (Chen et al, 1999; Hu and Pathak, 2000; Sinn et al, 
2005). To avoid pathogenic infection viral genes (excluding cis-acting elements) are 
removed from the virus genome to form replication defective viruses (RDV) 
(Buchschacher and Wong-Staal, 2000). Cis-acting sequences are required for 
packaging, reverse transcription and integration steps. Helper constructs or co-
transfected plasmids can be used alternatively to express viral genes removed from 
the virus genome in a trans-acting manner such as env and facilitate steps required to 
generate a single round of replication in target cells. Because there is a danger that 
recombination may occur that generates a helper virus in the transfected virus 
producer cells during the manufacturing process, the trans-acting viral genes have 
been placed on more than one plasmid construct. This circumvents the problem of a 
single recombination event between the transgene carrying vector and the packaging 
components in the producer cells generating replication competence (Chong et al, 
1998). Therefore, ensuring whether replication competent RVes (RCR) or 
lentiviruses (RCL) are present is an important primary biosafety hazard that should 
be identified to avoid or reduce the risk of insertional mutagenesis (IM) in the host.  
As a response to this potential problem split packaging systems have been developed 
to construct RDV’s. Several helper and packaging systems exist that includes split 
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genome helper constructs and vector backbone plasmids that can be generated either 
permanently or transiently following transfection of human embryonic kidney 
derived 293 (Hek293) cell lines. For stable cell lines vector and helper constructs are 
integrated into the host cell genome of a packaging cell line (Pear et al, 1993; 
Maetzig et al, 2011). This usually results in the production of high amounts of 
retroviral proteins required for assembling virus particles to achieve high titre (Pear 
et al, 1993; Ory, Neueboren and Mulligan et al, 1996; Poeschla et al, 1998). 
Production of virus particles by stable producer cell lines is time consuming and 
viral components such as the VSV-G envelope may not be tolerated since they are 
cytotoxic. Moreover, the efficiency of stably transfected cell lines depends on the 
long term survival of successfully transfected cells and isolation of high titre 
producer clones from populations of mixed titre producing cells (Brielmeier et al, 
1998). The transient transfection method is an alternative and is flexible and rapid as 
virus particles are harvested within a few days after plasmids transfection of 293T. 
This cell line is widely used in transient transfection systems to express recombinant 
proteins since nearly 90% transfection levels can be achieved (Thomas and Smart, 
2005).  
 
Figure 8. Production of RV vectors for gene therapy. The viral proteins required for transgene 
expression are separated into several packaging plasmids to reduce the risk of generating 
replication competent viruses. Hence, the gag and pol genes are included in one construct, the 
env gene is included in another plasmid and the vector ‘backbone’ carrying the transgene are 
on a third plasmid. Wild type envelope sequences can be replaced with alternative env genes 
in order to alter viral tropism in specific cells or tissues. Expression of the therapeutic gene is 
driven by the strong promoter signals derived from the LTR.  The complete retroviral construct 
is assembled and released from the producer cell for use in in vitro and in vivo studies.  
Helper cell 
Target cell  
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Self Inactivating (SIN) vectors have been designed and used in gene transfer 
methods to reduce the risk of generating replication competent viruses during the 
production of viral vectors (Miyoshi et al, 1998). SIN vectors contain a deletion of 
promoter and enhancer sequences present in the U3 region of the LTR (Yu et al, 
1986; Miyoshi et al, 1998; Suerth et al, 2010). This prevents the production of vector 
length (genomic) transcripts, replication of virus particles and promoter activation of 
host genes adjacent to provirus inserts sites (Olson et al, 1994). 
Dull et al (1998) first reported high titre production of HIV based vectors containing 
a SIN LTR configuration. CMV sequences were used to replace upstream promoter 
sequences and create a 5LTR chimeric transfer construct for the transduction of rat 
brain cells (Dull et al, 1998). Most importantly, SIN vectors are still capable of 
achieving a high level gene transfer and stable gene expression in infected cells 
(Miyoshi et al, 1998).  
 
 
Figure 9.  The sites of sequence deletions are represented by dashed arrows. The removal of 
transcriptional elements is used to generate SIN LTR constructs. Modified U3 sequences are 
indicated by Δ. Image taken from Suerth et al, (2010). 
 
1.1.4.2 Successful gene therapy clinical trials using viral vectors a 
history  
 
In 1990, the first approved human gene therapy trial was performed for the treatment 
of adenosine deaminase (ADA) deficiency by Anderson and co-workers. The ADA 
enzyme is essential for catalysing the deamination of adenosine and the ADA 
substrate 2′-deoxyadenosine (dAdo) into inosine deoxyinosine, respectively (Muul et 
al, 2003). Mutations of the ADA gene results in enzyme deficiency, the 
accumulation of dAdo and lymphoid toxicity (Joachims et al, 2008).  Furthermore 
ADA-deficient mice exhibit severe reductions in T, B and natural killer (NK) cell 
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populations which if untreated results in severe combined immunodeficiency disease 
(SCID) (Blackburn et al, 1996; 2000). Blaese and Anderson (1995) successfully 
achieved retroviral mediated transfer of the ADA gene into T lymphocytes ex vivo. 
Transformed lymphocytes were then returned to the bone marrow of two recipient 
children restoring T cell populations and ADA gene expression (Kohn et al, 1989; 
Culver et al, 1991; Blaese et al, 1995).  A follow up study by Muul et al, (2003) 
reported the persistent expression of ADA genes driven by first generation retroviral 
vectors 12 years after treatment.  This result supports the long lasting effects of 
retroviral mediated gene transfer. Furthermore no adverse effects were reported in 
both patients. However, both patients continued to receive a reduced dose of enzyme 
replacement treatment with polyethylene glycol-conjugated bovine ADA (PEG-
ADA) which demonstrates that only partial correction of metabolic abnormalities 
had occurred.  
Unfortunately, in 1999 gene therapy saw its first setback with the death of Jesse 
Gelsinger after treatment for ornithine transcarbamylase deficiency (OTC) using first 
generation adenovirus (Smith and Byers, 2002; Thacker, Timares and Matthews, 
2009).  In 2000, however, gene therapy re-emerged as a plausible therapeutic 
technique following successful clinical treatment of X-linked severe combined 
immuno-deficiency (X-SCID) disorder (Cavazzana-Calvo et al, 2001). This trial, 
conducted in France by Marina Cavazzana-Calvo and Alain Fischer demonstrated 
the ability to correct the disease phenotype by ex-vivo gene transfer to patient cells 
using a Moloney RV derived vector (Cavazzana-Calvo et al, 2000). Other promising 
developments in gene therapy have been observed for the treatment of X-SCID 
(Gaspar et al, 2004;  Fischer, Hacein-Bey-Abina and Cavazzana-Calvo, 2010; Baum 
et al, 2011; Gaspar et al, 2011; Kennedy et al, 2011),  ADA SCID (Aiuti et al, 
2002a,b; 2009) and individuals suffering from chronic granulomatous disorder 
(CGD) (Malech et al, 1997; Seger, 2008; 2010) cancer (Ciceri et al, 2005; Morgan et 
al, 2006), haemophillia (Lu et al, 1993; Mátrai et al, 2010) congenital blindness 
(Hauswirth et al, 2008; Smith et al, 2009; Bainbridge, 2009) muscular dystrophy 
(Wells, 2006; Brolin and Shiraishi, 2011; Pichavant et al, 2011) and viral infections 
(Von Laer et al, 2009).  Years after the successful correction of X-SCID gene 
therapy underwent a second setback with the development of leukaemias in 5 (4 in 
French trial and 1 in British trial) out of 19 patients treated for X-SCID (Davé et al, 
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2009; Qasim et al, 2009).  This provoked several studies that aimed to characterise 
the factors that may be involved in oncogenesis. 
 
1.1.5  Retroviruses and genotoxicity in the host 
 
Viral integration can occur in a large selection of genes with various functions. 
Several studies have shown that retroviral integration is a semi-random event and 
may contribute to IM (Mitchell et al, 2004; Deichmann et al, 2007).  
Insertion of DNA fragments is an important step in retroviral infection and occurs 
naturally during transposition of mobile elements; however, retroviral integration can 
disrupt host genomic sequences (Singhal et al, 2011).   
In addition to earlier genotoxicity studies (Mirsalis et al, 1995; Recio et al, 1995) 
models have been developed that assess genotoxicity with a focus on identifying 
genes such as proto-oncogogenes that may be associated with IM. From these studies 
it has become apparent that viral integration and the risk of IM are influenced by 
target site selection. Target site selection is crucial to virus insertion and influences 
host responses following infection (Holman and Coffin, 2005). Therefore, 
understanding integration patterns is central to the future clinical use of viral vectors 
in human gene therapy trials. RV integration is not random nor sequence specific as 
previously demonstrated (Wu et al, 2003; Shröder et al, 2002; Ciuffi et al, 2005). 
This is despite the identification of weak pallindromic sequences found associated 
with HIV-1, EIAV and RV integration (Carteau et al, 1998; Wu and Burgess, 2004; 
Holman and Coffin, 2005; Hacker et al, 2006).   
Shröder et al (2002) analysed over 500 integration events of HIV-1 and RV vectors 
following infection of a human T cell line. Mitchell et al (2004) investigated 3,127 
integration sites of ASLV, MLV and HIV-1 infection and together with several other 
integration studies also involving ASLV, oncoRVes and lentiviruses unique 
integration patterns have been revealed (Bushman, 2003; Wu et al, 2003). 
Gamma RVes such as MLV prefer to integrate into the vicinity of transcription start 
sites, promoter regions and CpG islands which facilitate gene regulation (Wu et al, 
2003; Bushman et al, 2005; Lewinski et al, 2006). This greatly increases the 
potential for RV mediated IM. These integration patterns have been supported by 
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cross species integration patterns identified in Human and Rhesus-Macaque infected 
cells (Bushman et al, 2005).  
In contrast, lentiviruses such as HIV and EIAV prefer integration into gene 
transcription units which is believed to be safer for gene therapy (Shröder et al, 
2002; Bushman et al, 2005; Hacker et al, 2006; Cherepanov, 2007).  The insertion 
profile for EIAV vectors, described by Hacker et al (2006) showed that these viruses 
favour integration into gene dense and highly expressing genes and therefore it may 
be suspected these vectors could be more likely to disrupt gene expression than HIV 
based vectors. In comparison ASLV viruses exhibit weak preferences for integration 
into transcriptional units and appear to randomly integrate into the host genome.  
Studies conducted by Lewinski et al (2006) implicated the role of viral sequences 
such as those of the integrase and gag genes being involved in target site selection. 
However, tethering interactions between viral proteins and cellular proteins may also 
influence viral target site selection. Lens epithelium-derived growth factor (LEDGF) 
is a nuclear chromatin associated protein that binds to integrase (Cherepanov, 2007). 
It has been suggested that LEDGF acts as a tethering factor for integration of 
lentiviruses although this is only known for HIV (Ciuffi and Bushman, 2006). HIV 
infected cells depleted of LEDGF1/p75 protein (by RNA interference) exhibit a 
lower frequency of integration into transcription units when compared to cells 
containing these proteins (Lewinski et al, 2006; Kang et al, 2006; Ciuffi et al, 2006).  
The viral enzyme integrase has also been shown to play a direct role in tethering 
interactions and target site selection. Lewinski et al, (2006) found that transferring 
the MLV integrase into HIV vector constructs caused the hybrid to develop MLV 
integration patterns. In addition the inclusion of both MLV gag and integrase genes 
into HIV LV constructs further increased the similarity of target site selection to that 
of RV vectors. 
Integration into centromeric heterochromatin has also been shown to be 
unfavourable for HIV integration (Bushman et al, 2005) suggesting that the 
transcriptional activity of target cells plays a crucial role in integration target site 
selection (Alabanese et al, 2008).   
Recently Biasco et al, (2011) investigated the effects of MLV integrations on clonal 
expansion and the frequency of common insertion sites (CISs) in haematopoietic 
cells following gene therapy. This study was conducted in five ADA-SCID patients 
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who received haemopoetic stem cell gene therapy without any observable adverse 
effects. The insertion profile of MLV was analysed in both peripheral blood and 
HSC samples taken from patients before and several years after treatment. This study 
revealed cell specific insertion patterns in peripheral blood lymphocytes (PBL) when 
compared to haemopoetic stem cells (HCS’s). Increased numbers of integrations into 
genes involved in the immune systems and DNase hypersensitive sites were 
favoured in PBL’s when compared to HSC’s. IM of host candidate cancer genes is 
believed to play a key role in uncontrolled cellular proliferation and malignant 
growth. However, other cellular intrinsic factors may contribute to oncogenesis 
following viral integration. Epigenetic regulation occurs via mechanisms such as 
methylation that control gene expression. It is possible that lentivirus integration 
represents a foreign agent that elicits an epigenetic response and induces 
uncontrolled cellular proliferation.   Biasco et al, (2011) demonstrated that vector 
insertions are cell specific but an increasing number of insertions were observed in 
transcriptionally active chromatin sites marked by histone modifications. This 
supports the possibility that virus integration may elicit an epigenetic response. 
Another factor which may influence target site selection is DNA distortions. DNA 
bending proteins such as nucleosomes may distort DNA targets prior to integration 
and this activity can promote integration (Shröder et al, 2002).  
 
1.1.5.1  Genotoxicity following RV and LV infection of the host genome 
 
Previously Soriano, Gridley and Jaenisch (1987) showed that retroviral insertion into 
a specific locus can induce a recessive lethal mutation resulting in embryonic death. 
IM is used to describe the modification of target DNA via the incorporation of 
additional bases (Singhal et al, 2011). IM often occurs due to virus integration into 
regulatory and coding sequences required for ‘normal’ gene expression. IM may also 
disrupt target DNA by inducing chromosomal rearrangements and recombination 
that promote chromosome instability (Bardwell 1989; Themis et al, 2003; Baum et 
al, 2004; Uren et al, 2005; Suzuki et al, 2006). Hence, several mechanisms of IM 
exist. Before discussing the risks of virus-mediated IM in gene therapy it is 
important to describe the currently views on mechanisms that appear associated with 
IM.  
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1.1.5.2 Retroviruses and aberrant splicing 
 
Integration by proviruses (Figure 10 a-b) into gene coding sequences may ultimately 
generate proteins with oncogenenic potential due to deletion of either the N terminal 
(NH2-) or C terminal (COOH) domains (Uren et al, 2005). Jiang et al (1997) 
reported the truncation of the proto-oncogene c-myb following proviral integration of 
a recombinant ALV vector. In this case the truncated Myb protein was found to be 
highly oncogenic due to deletion of the N terminal domain which resulted in the 
induction of several tumours and B cell lymphomas. Truncation may be caused by 
aberrant splicing or 3’ promoter activation after insertion within a gene or genome 
rearrangements involving viral sequences (Ceci et al, 1997; Jiang et al, 1997; Uren 
et al, 2005). 
 
1.1.5.3 Retroviruses and promoter activation 
 
Temin et al (1993) previously described the importance of retroviral LTR sequences 
for integration and termination of transcription and polyadenylation of RNA. 
Integration of retroviral sequences can result in transcriptional activation of 
neighbouring genes via retroviral promoters and enhancers (Figure 10c). The RV 
must integrate in the same transcriptional orientation as the neighboring host genes 
before activation of transcription by promoter sequences can occur (Mölder et al, 
1985). LTR insertion can result in proto-oncogene activation from either 5’ or 3’ 
LTR promoter. Herman and Coffin (1987) transduced chicken embryo fibroblasts 
with RVes and found that the promoter activity of the 5LTR was 50 times higher 
than that of the 3LTR in wild type ALV RVes. However, the 3’ LTR promoter is 
thought to play a key role in proto-oncogene activation. Interestingly, a separate 
study demonstrated that ALV can activate c-myc by transcriptional activation from 
the 3’ LTR following provirus integration upstream of the c-myc coding sequences 
(Boerkoel and Kung, 1992). This reduced transcription of the 5’ LTR is thought to 
be due to deletions located close to this LTR.  
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1.1.5.4 Retroviruses and enhancer activation 
 
Activation of transcription by U3 enhancer sequences has a bidirectional effect on 
flanking DNA sequences regardless of the orientation of the integrated virus (Mölder 
et al, 1985). 
Recent studies have demonstrated that a single insertion in combination with 
transgene enhancers may influence oncogene expression up to 100kb from the 
provirus insertion site (Hanlon et al, 2003; Baum et al, 2004; Nienhuis, Dunbar and 
Sorrentino, 2006). 
 
1.1.5.5 Retroviruses and read through transcription 
 
The expression of structurally aberrant proteins can result from chimeric transcripts 
that are initiated within the RV LTR sequence and read-through into downstream 
cellular sequences (Figure 10d; Mölder et al, 1985; Conley et al, 2008). Read-
through transcripts can be packaged into virions as effectively as normal viral RNA. 
These mature chimeric transcripts can result in the increase of viral and flanking 
cellular genes (Herman and Coffin, 1986; Nienhuis, Dunbar and Sorrentino, 2006). 
Singhal et al (2011) have concluded that the removal of the viral polyadenylation 
signal present in the LTR could prevent the occurrence of hybrid RNA generated by 
read-through transcription following integration into intron sequences.  
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Figure 10. Mechanisms of insertional mutagenesis (IM) associated with retroviral integration.  
a, b) Truncation of gene product. Vector insertion can disrupt normal splicing mechanisms 
yielding aberrant gene products. This may result in the inactivation or mutation of protein 
sequences. c) Promoter insertion. Promoter sequences present in the LTR region can result in 
the activation of adjacent cellular promoters and oncogenes. Enhancer and promoter sites 
located within the LTR are annotated in blue and pink respectively. d) Read-through 
transcription. LTR can drive the production of transcripts that read through from proviral 
sequences into downstream cellular genes.  
LTR: Long terminal repeat; Ψ: Packaging signal; hFIX: human factor IX (transgene); WPRE: 
Woodchuck hepatitis post transcription regulatory element; SD: Splice donor; SA: Splice 
acceptor. 
 
1.1.6   Retrovirus genotoxicity in gene therapy trials 
1.1.6.1   X – Linked SCID trials  
The γ-chain is a key component of several cytokines including IL-2 and is important 
for the development of T and natural killer cells (Hacein-Bey-Abina et al, 2002; 
Howe et al, 2008; Ginn et al, 2010). X – Linked SCID is caused by a mutation in the 
gene encoding the IL2-receptor γ-chain (IL2RG). Disruptions in IL-2 receptor 
signalling results in the dramatic reduction of T-cells, natural killer cell populations 
a 
b 
c 
d 
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and non-functional B cells. Reports show that X-Linked SCID accounts for 
approximately 40-50% of all SCID cases (Gaspar et al, 2004; Howe et al, 2008). 
This X-linked disease is particularly obvious in the first year of life due the 
occurrence of recurrent infections (Hacein-Bey-Abina et al, 2003).  Successful 
treatment of this disorder relies on allogenic bone marrow transplantation from HLA 
matched donors to deliver healthy γC genes. This is often followed by administration 
of immunoglobulins (Cavazzana-Calvo et al, 2005; Thrasher et al, 2006). However 
for most patients well-matched donors are not available and bone marrow 
transplantation from mis-matched donors may result in death. To overcome this 
problem research to treat and possibly correct X-SCID has been attempted using 
gene therapy of autologous haemopoetic stem cells. Pre-clinical models of 
haemopoetic gene therapy showed promise for the treatment of X-SCID.  
Restoration of T, B and NK cells was achieved in γC deficient mice following 
retroviral mediated delivery of human γC genes (Lo et al, 1999). However, 
preclinical studies used to assess the safety of gene therapy vectors were slow to 
predict the risk of gene transfer. The failure to predict the likelihood of IM and 
associated oncogenesis was due to three major factors. Short follow up studies, 
analysis of insufficient number of insertion sites and subjective quantitative 
assessment of genotoxic risk (Porteus, Connelly and Preutt, 2006). Human clinical 
trials on gene therapy for X-SCID took place in Paris (Cavazzana-Calvo et al, 2000; 
Hacein-Bey-Abina et al, 2002) and London (Gaspar et al, 2004) and showed 
sustained correction of this disease in several patients. The trials involved 
transduction of autologous CD34+ bone marrow cells with gammaretroviral vectors 
containing the γC gene that were transduced ex vivo and returned to each patient. 
Antibody levels and immune cell populations were measured following treatment 
and both studies reported restoration of cellular and humoral immunity months after 
treatment (Qasim, Gaspar and Thrasher, 2009; Hacein-Bey-Abina et al, 2010). 
Unfortunately, 5 patients that received gene modified bone marrow cells developed 
leukaemia 3-5 years after treatment (Hacein-Bey-Abina et al, 2010). RV insertion 
sites were retrieved using a highly sensitive PCR assay known as linear 
amplification mediated (LAM) polymerase chain reaction (PCR). This technique 
combined with sequencing analysis has been used to find individual insertions into 
host genomic sequences by the provirus. A number of techniques are now used 
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routinely for the detection and profiling of proviral insertion sites that include 
inverse PCR and ligation mediated (LM - PCR) and modifications to these such as 
non-restriction (nr) LAM PCR coupled with 454 pyrosequencing. These allow rapid 
identification of thousands of proviral insertions to characterise insertion site 
preferences and hence the potential for a chosen integrative viral vector to cause IM.  
Using X-SCID patient material follow up studies and integration site analysis 
revealed that RV integration had occurred into proto-oncogenes and genes 
implicated in leukamogenesis. Out of the 5 patients, 3 patients in Paris and 1 in the 
London trial exhibited insertional activation of the proto-oncogene LIM domain only 
2 (LMO2) (Dave et al, 2009; Qasim, Gaspar and Thrasher, 2009; Hacein-Bey-Abina 
et al, 2010). Treatment of large numbers of cells in X-SCID gene therapy is essential 
to achieve efficient immune reconstitution. However, high transgene expression is 
believed to be involved in IM (Kohn et al, 2003; Baum et al, 2004). The over-
expression of IL-2YRG gene can cooperate with LMO2 and induce tumour formation 
following the delivery to X-SCID patients (Dave et al, 2004; 2009; Woods et al, 
2006). In a separate study, Modlich et al (2005) reported that the expression of the 
multidrug resistance gene 1 (MDR1) may be associated with the development of 
leukaemias in mice following retroviral gene transfer. In these studies murine bone 
marrow cells were transduced with retroviral vectors carrying the MDR1 transgene. 
Unfortunately, transduced cells had high transgene copy number and multiple 
insertions were found in proto-oncogenes in malignant clones. Although several 
studies have reported successful transduction of bone marrow cells with MDR1 this 
study revealed several issues. The occurrence of leukaemia may have been driven by 
increased MDR1 expression or genomic instability associated with high vector copy 
number (Modlich et al, 2005).  
X-SCID mouse genotoxicity models have also been developed to assess the cause 
and risk of vector mediated IM that occurred in the X-SCID infants (Qasim, Gaspar 
and Thrasher, 2009). Using the most currently developed models the integration 
profiles of lentiviral vectors such as HIV into the gene transcription unit rather than 
promoter regions suggest lentiviruses have a reduced risk of IM. A study by Ginn et 
al, (2010) investigated the efficiency and safety of SIN lentiviral vectors used to 
drive expression of the human γC transgene in X-SCID mice. Interestingly, results 
showed lymphoma development in 4 out of 14 mice treated with lentiviral vectors. 
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However, this study failed to implicate IM or γC over expression as the cause 
lymphomagenesis. Several studies that demonstrated vector induced oncogenesis 
have also reported transgenic expression of growth promoting signalling molecules 
(Baum et al, 2003). These studies showed that signalling alterations caused by the 
transgene and IM may cooperate to induce activate oncogenes. A mouse study 
conducted by Li et al (2003) introduced a truncated version of the p75 neutrotrophin 
receptor (p75NTR) known as dLNGFR. Both p75NTR and the artificial mutant – 
dLNGFR may associate with the tyrosine kinase receptors (trk) in neutrophins.  
However, the cytoplamic domain located in the p75NTR has important pro-apoptotic 
functions. The retroviral vector inserted and upregulated the proto-oncogene Evi1. Li 
et al (2003) found that interaction between dLNGFR, neurotrophins and trkA 
receptors in Acute Myeloid Leukaemia (AML) cells contributed to the 
transformation of leukemic cells and development of an unusual form of monocytic 
leukaemia. This supports the importance of dysfunctional signalling in oncogenesis. 
A previous study by Hantzopoulos et al, (1994) also showed that interaction between 
dLNGFR, nueurotrophins and trk receptors failed to signal apoptotic/differentiation 
pathways required for balanced cell growth. As a result dLNGFR was able transform 
normal fibroblasts. Meyer et al, (2007) demonstrated the ability of mutant TrkA 
neurotrophin receptors to induce AML.  These studies all highlight the role of signal 
interference induced by the transgene product dLNGFR in mutagenesis. These 
studies also describe the importance of cooperation between vector, transgene and 
host signalling molecules. Deichmann et al, 2007 examined retroviral integration 
sites in CD34+ transduced cells and peripheral blood cell samples obtained from X-
SCID patients. These patients were recipients in the first X-SCID gene therapy trial. 
Their study found that two thirds of insertions occurred commonly in or near to 
genes involved in cell signalling growth and the cell cycle. Other retroviral 
integration studies have revealed unique integration patterns that have occurred as a 
result of influences by the vector or the host that are, as yet, unclear. This has, 
therefore triggered debate on the choice of vectors to be used in gene transfer. 
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1.1.6.2 Chronic Granulomatous Disease (CGD) trial 
 
X-Linked CGD is a recessive inherited immunodeficiency caused by the absence of 
NADPH oxidase activity.  NADPH oxidase is an enzyme that catalyses the 
production of superoxide from oxygen and NADPH (Babior, 2004). NADPH 
oxidase is composed of several genes including p22phox (CYBA); P67phox (NCF2) 
and gp91phox (CYBB). Mutations in these genes result in CGD however, two thirds 
of CGDs are caused by mutations in the gp91phox gene (Björgvinsdóttir et al, 1996; 
Dinauer et al, 1996, 1999; Saulnier et al, 2000; Brenner et al, 2006). In the absence 
of NADPH oxidase activity neutrophils and other phagocytic leukocytes are unable 
to generate superoxides required to kill microbes.  As a result CGD is characterised 
by recurrent severe bacterial and fungal infections (Stein et al, 2010). RV-mediated 
gene transfer of the gp91phox gene into bone marrow cells has been conducted by 
several groups.  
Successful transduction of murine X-CGD bone marrow cells has been reported by 
several groups. Transduced bone marrow cells containing gp91phox genes were used 
to treat X-CGD and NOD/SCID mice (Björgvinsdóttir et al, 1996; Dinauer et al, 
1999; Brenner and Malech, 2003; Sadat et al, 2009). These studies reported 
superoxide production, correction of phagocytes and improved phagocyte function. 
RV mediated delivery of gp91phox genes has also been reported in male rhesus 
monkeys (Brenner et al, 2006). In this study CD34+ cells were isolated from healthy 
rhesus monkeys (Macaca mulatta) and cells were transduced with an MLV vector 
expressing the gp91hox gene.  Analysis of RV of insertions sites revealed integration 
in the vicinity of genes involved in cell cycle and proliferation. However, the use of 
γ-RVes in all of these studies failed to generate the clonal imbalance found in the X-
SCID trials.   
Unfortunately, a similar trial conducted in human patients resulted in clonal 
expansion, myelodyplasia and monosomy of chromosome 7 and death of a patient as 
a result of IM into the MDS1-Evi1 locus. Autologous haemopoetic stem cells had 
been transduced and returned to the patient. Increased gene expression in these 
dominant clones was linked to genome instability and raises an important concern 
that the cause of genotoxicity associated with integration into the host genome is still 
unclear and whether in vivo clonal selection contributes to clonal dominance or not 
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(Cattogolio et al, 2007). In the X-SCID, since out of the 5 patients who developed 
leukemia 4 showed provirus insertion and over-expression of the LMO2 gene it is 
believed that cooperation between the transgene (IL2rg) and LMO2 could have 
contributed to leukomogenesis. Whatever the view, these observations highlight the 
risk of cancer development following gene therapy using retroviral vectors. 
Most recently, clonal dominance has also been identified in 2 adult patients treated 
for CGD 15 and 28 months after treatment. In both CGD patients the retroviral 
vector used for gene transfer has been shown to insert into the MDS1-Evi1 locus. 
Specific clones containing the MDS-Evi1 insertions dominated the CD34+ 
haemopoetic stem and progenitor cells resulting in the over expression of the Evi1 
gene. The expansion of clones containing MDS-Evi1 insertion sites was also seen in 
vitro in bone marrow cells and a rhesus monkey treated with MLV (Calmels et al, 
2005; Du and Copeland, 2005; Ott et al, 2006; Stein et al, 2010). Dunbar and co 
workers (2010) suggest that the up-regulation of the Evi1 gene may promote 
chromosome instability, chromosome abnormalities and disease progression (Dunbar 
and Larochelle, 2010). Interestingly, other studies have reported the absence of 
recurrent MDS1-Evi1 insertions and leukaemias despite ex vivo gammaretroviral 
gene transfer into haemopoetic stem cells (Kuramoto et al, 2004a, b; Brenner et al, 
2006). This suggests that additional factors may be involved in the selection of 
insertional mutants.    
Taken together, the findings of the human X-SCID and CGD clinical trials 
emphasise the importance of genotoxicity and IM in gene therapy resulting from 
integrating viral vectors. Interestingly, Soudais et al, (2000) demonstrated when 
treating X-SCID and recovery of immune function in γc and JAK3-deficient mice 
with RVes carrying the γc gene no adverse effects were found even when alternative 
gene transfer methods were used. When Aviles Mendoza, (2001) also demonstrated 
immune reconstitution in X-SCID deficient mice using five retroviral vectors 
expressing the IL2RG gene no prediction could be made on the risk of IM following 
treatment for SCID – X1 and therefore it was doubtful that pre-clinical models can 
predict vector safety accurately. Hence, although these models are important to 
satisfy regulatory bodies such as the US Food and Drug (FDA) and European 
medicines agency (EMA) no model as yet satisfies fully our understanding of the 
likelihood and causes of genotoxicity. 
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1.1.7 Models for retrovirus genotoxicity 
 
Genotoxic assays have been previously used to assess the mutagenic risk of agents 
including chemicals and retroviral vectors (Mirsalis et al, 1995a, b; Recio et al, 
1995; Okada et al, 1997; Reliene et al, 2003; Modlich et al, 2006). The mouse is the 
leading mammalian model used in genotoxicty research. They are preferred tools 
because of their rapid breeding times and the extensive knowledge of their genetic 
makeup. Larger animals including rhesus monkeys have also been useful as models 
to assess gene therapy safety (Tarrantal et al, 2001). However, other organisms such 
as the Drosophila fly (Cooley, Kelley and Spradling, 1988), rhesus monkeys 
(Seggewiss et al, 2007), Sheep, Pigs, Dogs and Zebrafish (Amsterdam et al, 1999; 
Haffter et al. 1996) and in vitro studies have been used to assess the mutagenic risk 
of retroviral vectors.  
The hprt assay has been widely used in research applications to study the effects of 
single gene mutations on human and rodent cells. The hprt gene present on the X-
chromosome encodes the hypoxanthine-guanine phosphoribosyltransferase (HPRT) 
enzyme which is required in the purine salvage pathway. The HPRT enzyme 
catalyses the transformation of purines to monophosphates which are cytotoxic to 
normal cells. However, the loss of hprt activity and tolerance to treatment with 
harmful purine analogues can be induced by mutations in the hprt gene. King and 
Brookes (1985) described the hprt gene as a useful target for carcinogenic and 
mutagenic agents. King and Brookes (1985) also reported the use of Chinese 
Hamster V79 cells which contain a single copy of the hprt gene to study HPRT 
mutagenesis. This study found that V79 cells treated with the carcinogen MCDE 
induced hprt mutants and resistance to the purine analogue 6-thioguanine (King and 
Brookes, 1985) Hence, cells carrying hprt mutations can be easily distinguished 
from unmutated cells in culture. Tates (1991) described the use of a cloning assay to 
select hprt mutants in T-lympocytes derived from patient samples. T lymphocytes 
were collected from healthy subjects, cancer patients and subjects exposed to the 
carcinogen ethylene oxide (Tates 1991). This study revealed a significant increase in 
mutation frequencies in T-cells containing hprt mutants. This supports the role of 
carcinogens in mutagenesis. In 1995 Lichtenauer-Kaligis et al investigated the 
influence of genomic position on integrated hprt cDNA in the human genome. The 
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hprt cDNA gene was integrated into human lymphoblastoid TK6 cells. Results 
showed a spectrum of 100 mutations in the hprt gene (Lichtenauer-Kaligis et al, 
1995).  Other studies have explored the risk of IM by replication defective RV’s in 
mammalian cells. King et al (1985) found that MoMLV was able to inactivate the 
hprt gene in embryonic carcinoma cells. Goff predicted the frequency of mutations 
induced by a single provirus insertion at a single locus. The estimated frequency 
given was one inactivating mutation in 10
-6
 virally exposed cells (Goff, 1987). 
Themis et al, (2003) demonstrated the ability of RV integration to inactivate the hprt 
gene in haploid V79 Chinese hamster cells. This study confirmed that an attenuated 
defective RV virus was able to induce mutations at a single gene locus. Themis et al, 
(2003) also reported a 2.3 fold increase in the risk of mutagenesis where multiple 
provirus insertions had occurred into the host cell genome and implicate the role of 
vector copy number in insertional mutagenesis. Results showed that the occurrence 
of mutagenesis correlated with high titre and multiplicity of infection (MOI) also 
known as the number of transducing viral particles per cell. 
This supports the notion that virus MOI should be reduced to avoid mutagenesis. 
Kustikova et al, (2003) also investigated the relationship between vector copy 
numbers and gene transfer efficiency in primary CD34+ haemopoetic, peripheral 
blood and K562 leukaemia cells. This in vitro study revealed a linear correlation 
between vector copies and gene transfer efficiency. An increase in vector integration 
and copy number resulted in higher transduction rates. A single vector insertion into 
a cell resulted in a gene transfer rate of less than 30%. However, the occurrence of 9 
vector insertions increased the transduction efficiency to approximately 90%. This 
study also suggested the occurrence of IM may correlate with the number of 
integrated vector (Kustikova et al, 2003) and thus multiple vector insertions can 
promote genotoxic effects such as malignant growth.  Early studies conducted by 
researchers including Stocking et al (1993) were responsible for the predicting low 
(10
-6
-10
-8
) theoretical risk of viral vector mediated mutagenesis (Copeland, 
Hutchison and Jenkins, 1983; Moolten and Cupples, 1992). 
Fehse et al (2004) developed a statistical model based on Poisson’s mathematical 
formulae which could be applied to mutagenesis studies. This model aimed to 
estimate the number of retroviral insertions and assessed the distribution of 
integrated vector copies in a population of cultured cells. This model provided a 
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useful tool for predicting vector copies in cell populations and also found that 
multiple vector insertions increased the risk of IM and oncogenesis. The human 
genome has been reported to contain more than 20, 000 genes (Frazer et al, 2004; 
Stein, 2004; Barry et al, 2007) which may be vulnerable to retroviral integration and 
mutagenesis and hence, increase the potential risk for proto-oncogene activation.   
Modlich et al (2005) investigated the effects of vector dose on retroviral 
transduction.  RV vectors containing the MDR1 gene were used to transduce bone 
marrow cells ex vivo then returned to C57BL/6J mice (Modlich et al, 2005). This 
study again demonstrated that increased vector dose contributed to IM (Modlich et 
al, 2005). Clones containing multiple RV insertions into (or in the vicinity) proto-
oncogenes and signaling genes were over-represented in this study suggesting that 
leukamic growth arose due to the expansion of dominant clones and hence clonal 
imbalance triggered by vector insertion may initiate malignant transformation.  
Modlich et al, (2006) developed a cell culture assay using primary bone marrow 
cells to study the effect of vector dose on IM. Isolation of retroviral insertions 
revealed a correlation between MOI and the incidence of immortalised clones caused 
by insertions into the Evi1 gene. Montini et al, (2009) used a tumour prone 
Cdk2na−/− knockout model to predict the genotoxic risk of viral vectors used for 
clinical studies. The integration of RV and LV vectors into cancer causing genes 
induced tumour development. This study showed that LV vectors carrying active 
LTR’s were 10 times safer than their RV counterparts and this was thought due to 
the integration site selection of RV in target cells. Kustikova et al (2007) used long 
term murine studies to generate a database of RV insertion sites that had caused 
malignant clonal dominance. To do this bone marrow stem cells were cultivated ex 
vivo and delivered to mice. This study suggested that specific RV hits into genes that 
regulate proliferation, apoptosis, signaling and transcription contributed to the 
occurrence of clonal expansion. Researchers including Stocking and co-workers 
(1993) contributed greatly to the development of in vitro models for analysis of 
retroviral IM. Stocking et al (1993) developed a tissue culture system using a human 
myeloid stem cell line (TF-1). Using retroviral vectors to induce mutations a direct 
correlation between retroviral insertions and a mutation frequency of 2.2x10
-7
 was 
demonstrated. 
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It has been suggested that transformation of cell populations with large cell turnover 
such as haemopoetic stem cells may contribute to clonal dominance and expansion 
of clones containing harmful retroviral insertions. Kustikova et al (2009) 
investigated the impact of cell sorting and purification of haemopoetic stem cells on 
IM. HSC’s were subdivided into 2 groups primitive HSC’s (LSK) and purified 
HPC’s (LK). This study found that improved purification of stem cells did not 
reduce the genotoxic effects of γ-retroviral transduction. However, limiting the 
number of HSC’s transduced did reduce the genotoxic risk of retroviral gene 
transfer. In the same study Kustikova et al (2009) used lentiviruses to transduce a 
restricted number of purified HSC’s. This reduced the risk of clonal imbalance 
caused by provirus insertions into proto-oncogenes despite the high transduction 
efficiency of these vectors when compared to γRVes. These findings further 
implicate the role of target cell type, the number of transduced cells and vector type 
as variables to consider when assessing the risk of gene therapy.   
Genotoxicity models are useful tools for uncovering the transforming ability of viral 
vectors and viral integrations which induce cancer development. Large scale analysis 
of vector integration will continue to rely upon previous and current genotoxicity 
models to evaluate the risks and benefits of using RV vector in gene therapy.  
 
1.1.7.1  Fetal gene therapy model 
 
The concept of fetal (in utero) gene therapy is based on the prevention of fatal 
genetic conditions and achieving permanent correction of such diseases by stable 
transduction of cell populations before they manifest in the unborn child (Coutelle et 
al, 2005).  
The application of somatic gene transfer to the foetus is relatively new to the field of 
gene therapy. The efficiency of somatic gene transfer into adult cells is limited by 
various factors including the failure to find MHC compatible donors and the 
development of an immune response mounted against transgene sequences following 
administration of viral vectors. Adult somatic gene therapy is also limited by the 
large target cell to vector ratio. Fortunately, research has shown that these problems 
could be avoided by treating monogenetic disorders in utero.  
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The developing foetus undergoes rapid and continuous cellular proliferation that 
increases the cell population which can be targeted for gene transfer by delivery 
systems such as integrating lentiviral vectors (David and Peebles, 2008). Proof of 
somatic gene transfer in utero was established in Gunn rats expressing Crigler Najjar 
disease (Coutelle et al, 2005). Successful foetal gene therapy has been demonstrated 
in both large and small mammalian models including mice and monkeys via 
intrahepatic, intratracheal and intraamniotic methods (Porada et al, 1998; Walsh, 
1999; Themis et al, 2005; Wagner et al, 2009).  Tarantal and coworkers 
demonstrated successful gene transfer to rhesus monkeys in utero (Jimenez et al, 
2005; Tarantal et al, 2005). MLV and HIV-1 based vectors were administered to 
fetal Rhesus monkeys by intraperitoneal and intrahepatic routes. Results showed 
prolonged transduction and expression of transgenes in multiple organ systems. 
Seppen et al, (2003) investigated the effect of in utero injection of lentiviral vectors 
carrying the hepatic enzyme bilirubin UDP-glucuronyltranferase 1A1 (UGT1A1) 
which is absent in Crigler Najjar type 1 patients.  Results showed sustained 
expression of trangenes and correction of the UGT1A1 deficiency. Several other 
studies have also reported the correction of metabolic disorders, coagulapathies and 
neurological disorders using adenoviral and retroviral vectors. (Mackenzie et al, 
2002; Rucker et al, 2004; Waddington et al, 2004).  
Stable and efficient transduction of several tissues including pulmonary and heart 
cells can be achieved when using RV vectors. This supports the potential for fetal 
gene therapy to reach organs that may be inaccessible after birth.  Gregory et al, 
(2004) also demonstrated the ability of non-primate lentivirus (EIAV) to transduce 
murine skeletal muscles in vivo.   
The foetal immune system is not fully developed until after birth therefore foetal 
models will induce lifelong immune tolerance to transgenes expressing transgenic 
proteins delivered by viral vector constructs.  Waddington et al, (2004) reported the 
correction of human factor IX deficiency in hFIX knock out models when using a 
HIV-1 based lentiviral vector. Vector particles were injected into the fetal liver and 
plasma FIX antigen levels were increased to 5% above normal human plasma levels. 
Importantly, lentiviral mediated delivery of hFIX failed to induce an immune 
response. 
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Unfortunately the high frequency of cell division in the developing fetus may 
increase the risk of IM. In addition, caution is required that no vector transmission 
occurs to the germ line or mother by vector particles (Schneider and Coutelle, 1999, 
Wagner et al, 2009). Lee et al, (2007) demonstrated the transduction of a 
subpopulation of gonadal cells following in utero administration of lentiviral vectors 
highlighting the potential for germline transmission. The semi random insertion 
pattern of RV’s could also have disastrous effects on foetal gene therapy with IM of 
foetal cells resulting in the formation of malignant tumours.  
Key genes involved in processes such as cell cycle metabolism and differentiation 
are also highly expressed in the foetus therefore the risk of integration into cancer 
targets is increased. Indeed, the potential for carcinogenesis induced by IM of viral 
vectors in utero highlights the safety issues associated with in utero gene transfer; 
however this feature also makes the foetus a potentially useful genotoxity model. 
The high levels of gene expression and open chromatin configuration of much of the 
genome in the foetus can be exploited to predict the genotoxic potential of 
integrating viral vectors such as retroviruses. In addition the use of foetal gene 
transfer in genotoxicity studies will improve understanding of foetal development 
and oncogenesis. Themis et al, (2005; 2012 unpublished data) demonstrated a high 
incidence tumour development in foetal models following lentiviral mediated gene 
transfer (2005; 2012 unpublished data). These studies show that the foetus model is 
highly sensitive to vector associated genotoxicity. Moreover, the integration patterns 
of lentiviruses in utero support the use of these models to improve our understanding 
of viral mediated pathogenesis and IM.  
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1.1.8 Modifications to the design of RV vectors to avoid insertional 
mutagenesis 
 
Several models have focused on the modification of RV and LV vectors. 
Modifications to the design of retroviral vectors have been used to increase the 
transduction efficiency of T lymphocytes and selective elimination of RV marked 
cells containing the suicide gene Herpes simplex virus thymidine kinase (HSVtk). An 
immune reaction is often mounted against allogenic T lymphocytes in an event 
known as Graft versus host disease (GVHD).  HSVtk modified cells are able to 
eliminate T lymphocytes in the event of GVHD. Fehse et al (2002) recognised the 
use of a novel ‘sort – suicide’ fusion gene vector for transfusion of T cells. The 
inclusion of a truncated human CD34 marker and a splice corrected version of the 
HSVtk transgene improved the positive selection and elimination of gene modified 
cells respectively.  Hence, the use of suicide genes in gene therapy vectors may 
allow removal of cells that develop clonally dominance. This mode of safety, 
however, removes all vector infected cells not only unwanted cell populations and 
thus eradicates the gene therapy treatment.  
Several studies have reported the inclusion of chromatin insulators such as chicken β 
globulin 5’ DNase I hypersensitive site 4 (cHS4) into the U3 region of the LTR 
(Ramezani et al, 2008). RV and LV vectors are frequently subjected to position 
effects produced by host chromosomes (Ramezani et al, 2003). This often results in 
transcriptional silencing of transgenes.  Insulator sequences are genetic elements that 
are located close to chromatin domain boundaries (Emery et al, 2000). CHS4 
insulators can repress transcriptional activation generated by enhancers or reverse the 
silencing effects exhibited by heterochromatin regions (Li et al, 2009). These 
sequences can also act bi-directionally to suppress both promoter and enhancer 
activity and achieve high levels of titre production and transgene expression (Emery 
et al, 2000; Ramezani et al, 2003;2008; Nienhuis et al, 2006). Ultimately, the 
inclusion of chromatin insulators can reduce the rate of gammaRV/LV vector-
mediated genotoxicity and malignant transformation (Ryu et al, 2007; Li et al, 
2009).   
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Pseudotyping of viral vector constructs is another effective method of reducing the 
risk of IM and has been applied to genotoxicity models (Ramezani et al, 2008; 
Mátrai et al, 2010). Species-specific interaction between the viral envelope proteins 
and host cell receptor can restrict viral entry into specific target cells. Pseudotyping 
involves substitution of the wild type virus envelope glycoproteins for heterologous 
envelope sequences. This can greatly improve the range of host cells infected by 
RV/LV particles (tropism) (Kay et al, 2001; Cronin et al, 2005) and transduction 
efficiency. Wong et al, (2003) developed an EIAV based vector pseudotyped with 
the Rabies virus envelope glycoprotein. This study demonstrated that pseudotyped 
EIAV vectors were able to produce high titre vectors and successfully transduce 
striatum cells within the central nervous system. 
Other modifications include the use of ubiquitous and eukaryotic tissue specific 
promoters that are used to replace viral promoters to drive transgene expression and 
improve transduction efficiency (Sivalingham and Kon, 2011). These promoters 
prevent the expression of genes that could be harmful to certain cell types. Hence, 
expression of cytokines can be restricted to cells of the immune system rather than to 
the liver and therefore not cause unwanted hepatocyte proliferation. 
 
1.1.9   Hypothesis 
Lentiviral vector constructs were administered to foetal mice (MF-1 strain) in utero 
at 16 days gestation. The first objective of this study is to test the hypothesis that 
cancer development occurred as a result of non-primate LV integration into the host 
genome.  
We previously demonstrated a correlation between the insertion patterns of EIAV 
and FIV vectors and the development of HCC in foetal models (Themis et al, 2005). 
Therefore in this study it is hypothesised that EIAV and FIV vectors would integrate 
into RefSeq genes associated with cancer and yield consistent vector copy number in 
samples infected at the same dose.  
This current study also tested the hypothesis that host intrinsic factors such as gene 
transcription activity, integration site and vector copy number can influence clonal 
dominance and the development of oncogenesis in foetal mouse models. 
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It was predicted that integration sites retrieved from these foetal models would be 
useful for constructing gene expression profiles and oncogeneic networks associated 
with LV integration.  
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2.1    MATERIALS 
 
The materials used in these experiments are listed below, along with details of the 
suppliers from which they were purchased. 
2.1.1  General chemicals  
Chemical/reagent Company name 
Agarose Fisher Scientific (Loughborough, UK) 
BSA (Bovine Serum Albumin) Sigma Aldrich (Dorset, UK)  
Chloroform Fisher Scientific 
EDTA (ethylene diamine tetraacetic acid) 
Double distilled water (ddH₂O) Autoclaved Purite water¹ 
DMSO (dimethyl sulfoxide) Sigma-Aldrich 
Ethanol Hayman LTD (Essex, UK) 
Ethidium bromide Fisher Scientific 
 Glycerol 
IMS (industrial methylated spirit) Hayman LTD  
Isopropanol Fisher Scientific 
Phenol Sigma-Aldrich 
Potassium chloride Fisher Scientific 
SOC medium Qiagen (West Sussex, UK) 
Sodium chloride Fisher 
Sodium citrate Sigma Aldrich 
Sodium hydroxide BDH 
Tris Borate Acid (TBE) Fisher Scientific 
Table 4. General chemicals and reagents used in experiments ¹ represents ddH₂O. 
2.1.2  Transformation reagents 
 
Chemical/reagent Company name 
ddH₂O Qiagen 
 pDrive cloning vector (50 ng/µl) 
2X Ligation master mix 
QIAGEN EZ Competent Cells 
SOC medium 
Tryptone Fisher Scientific 
Yeast extract Fisher Scientific 
 Sodium Chloride 
Agar 
Ampicillin 
X-gal (5-bromo-4-chloro-3-indolyl β-D-
galactoside) 
IPTG (Isopropyl β-D-1-
thiogalactopyranoside) 
Table 5. Summary of reagents required for transformation protocols.  
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2.1.3 Ligation amplification mediated (LAM PCR) reagents 
 
Chemical/reagent Company name 
Linear PCR/First and second round PCR  
ddH₂O ¹ 
10X PCR buffer containing magnesium  Kappabiosystems (Woburn, MA, USA) 
dNTP mix (deoxyribonucleotide 
triphosphates) 
Invitrogen (Paisley, UK) 
Kapa Taq DNA Polymerase 
(Kappabiosystems) 
KapaBiosystems 
DNA capture of magnetic beads  
Dynal beads Invitrogen 
Washing solution containing 1X PBS^ & 
0.1% BSA 
Sigma Aldrich (PBS) & Fisher (BSA)  
Binding solution Invitrogen 
Second strand synthesis  
Klenow (Large Fragment DNA Polymerase I Invitrogen 
 Klenow dilution buffer 
dNTP’s  
10x React2Buffer 
10x Hexanucleotide mix Roche (West Sussex, UK) 
Restriction digest of the double stranded 
DNA with Tsp509I 
 
ddH₂O ¹ 
10x NEB buffer New England Biolabs (Herts, UK) 
 Tsp509I  
Ligation of linker cassette  
Ligation casette Sigma Aldrich 
10mM ATP Epicentre Biotechnologies (Post Rd, 
Madison, USA) 10X Fast Link ligation buffer 
2U/µL Ligase 
Agarose gel electrophoresis of LAM 
PCR products 
 
3% agarose gel  
6X Agarose gel loading dye  Fisher Scientific 
TrackIt™1Kb DNA ladder Invitrogen 
1Kb Plus DNA ladder 
Table 6.  Summary of reagents used in LAM PCR analysis. ¹ is used to denote ddH₂O that was 
prepared from autoclaved water. 
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2.1.4  Oligonucleotides used for LAM PCR analysis 
 
Gene name Annealing  
Temperatur
e  
Sequence 
Biotinylate
d linear 
PCR 
  
EIAV 60ºC GGCCAGGAACACCTCCAG  
EIAV 60ºC GCTGTCCCGGGGATCCTACG  
FIV-LTR-
5A 
60ºC GTTCTCGGCCCGGATTCC 
FIV-LTR-
5B 
60ºC CCCGGATTCCGAGACCTC 
3LTR 
Linear HIV 
A 
60ºC GAGCTCTCTGGCTAACTAGG 
3LTR 
Linear HIV 
B 
60ºC GAACCCACTGCTTAAGCCTCA 
Linker 
sequences 
  
LC1  GACCCGGGAGATCTGAATTCAGTGGCACAGCAGTTA
GG 
LC3  AATTCCTAACTGCTGTGCCACTGAATTCAGATC 
First round 
PCR 
  
EIAV-LTR-
5C 
60ºC GCGCCCCTCTCAGGTCCC  
EIAV LC-1 60ºC GACCCGGGAGATCTGAATTC 
FIV-LTR-
5C 
60ºC CTCGACAGGGTTCAATCTC 
FIV LC-1 60ºC GACCCGGGAGATCTGAATTC 
HIV-LTR-
5C 
60ºC AGCTTGCCTTGAGTGCTTCA 
HIV LC-1 60ºC GACCCGGGAGATCTGAATTC 
Second 
round PCR 
  
EIAV-LTR-
5D 
60ºC CCCTGTTCGGGCGCCAAC  
EIAV-
LCIII 
60ºC AGTGGCACAGCAGTTAGG 
FIV-5LTR-
5D 
60ºC CTCAAAAGTCCTCAACAAAG 
FIV LCIII 60ºC AGTGGCACAGCAGTTAGG 
HIV-3LTR-
5D 
60ºC AGTAGTGTGTGCCCGTCTGT 
HIV LCIII 60ºC AGTGGCACAGCAGTTAGG 
Table 7.  List of primers used for LAM PCR analysis. 
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2.1.5  RNA extraction for RT PCR and QPCR analysis  
 
Chemical/reagent Company name 
TRI® reagent Sigma-Aldrich 
Chloroform Fisher 
2-propan-1-ol (isopropanol) Sigma-Aldrich 
75% ice cold ethanol See 1.1.22 
Table 8. Reagents used for isolation of total RNA from tissue samples. 
 
2.1.6  Reagents for DNase I  treatment 
 
Chemical/reagent Company name 
10X reaction buffer Sigma-Aldrich 
 Amplification Grade DNase I (1,000 units) 
Stop Solution 
70% ethanol See 2.2.21 
Table 9. General reagents used for DNase I treatment. 
 
2.1.7  Reagents: CDNA synthesis for RT (Reverse Transcriptase) 
           - PCR analysis 
 
Chemical/reagent Company name 
Oligo (dT) 20 primer Invitrogen 
 dNTP mix 
DEPC-treated water 
10X RT buffer 
MgCl2 
0.1 M DTT 
RNaseOUT. (40 U/μl) 
SuperScript. III RT (200 U/μl) 
RNase H 
Table 10. General reagents used for CDNA synthesis of samples used for RT PCR. 
 
 2.1.8  RT PCR reagents  
 
Chemical/reagent Company name 
10x PCR buffer Invitrogen 
 50mM Mgcl2 
10mM dNTP’s mix 
2.5U Platinium Taq DNA polymerase 
Table 11. General reagents used for RT PCR. 
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2.1.9  Oligonucleotides for RT-PCR analysis 
 
Gene 
name 
Annealing  
temperature  
Sequence 
GAPDH 59ºC Forward - GGCCTTGACTGTGCCCGTTGAATTT 
Reverse  - ACAGCCGCATCTTCTTGTGCAGTG 
Coro7 
 
59ºC Forward - AGGCATGTGACCTACCTTGG 
Reverse  - CCGAAGCTGCTTGTCCTTAC 
Nek9 63ºC Forward - CAGGTGGAGGTTGACAGGTT 
Reverse  - CTCTTCAAGGTGGCTCAG 
Cx39 63ºC Forward - TGCTAGTGAGGCCACTTCCT 
Reverse  - CATGTCATTCCACCCCTACC 
Sac 63ºC Forward - CCTCCTGGTGAAAAAGCAG 
Reverse  - TTCTCTGTCTCCAGGCGTT 
Pcd1lg2 63ºC Forward - TGTGCTGCCTTTTCTGTGTC 
Reverse  - GCCAGGACACTTCTGCTAGG 
Tnfrsf19 63ºC Forward - CGCTGCCATTCTCTTCCTAC 
Reverse  - GGTCAAAGCATGACAGCTCA 
Similar to 
cyclin fold 
protein 1 
63ºC Forward - TATCTGCACCTGAGCACCAG 
Reverse  - CCTCTTTGCCTCTTCCACAG 
Table 12. Oligonucleotides used RT PCR amplifications. 
 
2.1.10 RNA purification for Real -Time Quantitative (Q) – PCR      
reagents 
 
Chemical/reagent Company name 
10X reaction buffer Sigma-Aldrich 
 Amplification Grade DNase I (1,000 units) 
Stop Solution 
70% ethanol See 1.1.22 
β-ME (2-Mercaptoethanol) Agilent technologies, Stratagene 
(Edinburgh, UK) Lysis solution 
1x low salt wash solution 
Elution buffer 
Table 13. General reagents/chemicals used for QPCR reactions. 
 
2.1.11  CDNA synthesis for Real -Time Quantitative (Q) - PCR 
reagents 
 
Chemical/reagent Company name 
ddH₂O ¹ 
10X RT Buffer Applied Biosystems 
 10X RT Random Primers 
25X dNTP mix (100mM) 
MultiScribe™, Reverse Transcriptase, 50 
U/µL 
RNase Inhibitor  
Table 14. General reagents/chemicals used for CDNA synthesis of total RNA for QPCR reactions 
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2.1.12  Q-PCR reagents for gene expression analysis and vector copy 
number (VCN)  
 
Chemical/reagent Company name 
ddH₂O ¹ 
2x TaqMan Universal PCR Master Mix 
containing AmpliTaq Gold®DNA 
polymerase, Amperase UNG, dNTP's and 
dUTP 
Applied Biosystems 
20x TaqMan gene expression assay 
Table 15. General reagents/chemicals used for TaqMan PCR reactions.  
 
 
2.1.13  Q-PCR  primer probe sets for VCN analysis 
 
Chemical/reagent Company name 
GAPDH - mouse (assay ID: Mm99999915_g1) 
 
GAPDH - human (assay ID: Hs0275858991_91) 
 
EIAV packaging signal (psi) 
Forward sequence:   
ATTGGGAGACCCTTTGACATTG 
Probe: 
AGCAAGGCGCTCAAGAAGTTAGAGAAGGTG 
Reverse sequence: 
ACCAGTAGTTAATTTCTGAGACCCTTGTA 
 
WPRE 
Forward sequence:   
TTCTCCTCCTTGTATAAATCCTGGTT 
Probe: 
CTGTCTCTTTATGAGGAGTTGTGG 
Reverse sequence: 
CCACGCCACGTTGCCTGACAACGG 
 
Applied Biosystems 
Table 16.  TaqMan primer probe sets used for VCN studies.  
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2.1.14   Pre designed and custom made TaqMan probes for gene 
expression analysis – Applied Biosystems   
  
Gene name Assay ID Exons 
amplified 
Amplificon 
product size 
18sRNA 4310893E N/A 187 
GAPDH Mm99999915_g1 2 – 3 107 
Pah Mm01224032_m1 2 – 3 68 
Acvr2a Mm01331093_m1 1 – 2 64 
Setd5 Mm01184707_m1 1 – 2 118 
Mrp1 Mm01208141_m1 1 – 2 74 
Park7 Mm00498538_m1 3 – 4 92 
Uvrag Mm00724367_m1 3 – 4 132 
Mrpl23 Mm01158967_m1 1 – 2 127 
Rabgef1 Mm00727426_s1 8-9 66 
Coro7 Mm00504152_m1 9 – 10 103 
Nek9 Mm01307401_m1 21 – 22 70 
Pscd3/Cyth3 Mm00441015_m1 1 – 2 90 
Tnfrsf19 Mm00443506_m1 4 – 5 96 
CX39/Gjd4 Mm00462088_m1 1 – 2 72 
Pcd1lg2 Mm00451734_m1 4 – 5 95 
Foxa2 Mm00839704_Mh 2 – 3 64 
Hnf1A Mm00493434_m1 1 – 2 134 
Hnf4A Mm00433964_m1 8 – 9 114 
Table 17.  TaqMan probes and unlabelled oligonucleotide sequences used for TaqMan analysis 
of lentivirus insertion genes. 
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2.1.15  Tissue culture reagents 
 
Chemical/reagent Company name 
DMEM (Dulbecco’s modified Eagle’s 
medium) containing GlutaMax™, 1000 mg/L 
and sodium pyruvate 
Fisher Scientific 
Fetal bovine serum  
Pen/strep (penicillin/streptomycin)   
10X Trypsin-EDTA (containing 0.5% trypsin 
in 5.3mM EDTA) 
 
DMSO (dimethyl sulfoxide) Sigma-Aldrich 
 1X PBS^ 
Trypan blue GIBCO™ Invitrogen 
Virkon disinfectant Fisher Scientific 
Table 18. General reagents used for tissue culture. 
 
2.1.16  Reagents for DNA extraction from frozen tissue samples and 
cultured cells 
 
Chemical/reagent Company name 
Phenol Sigma-Aldrich 
Chloroform Fisher Scientific 
Extraction buffer See 1.1.22 
Proteinase K Fisher Scientific 
RNase A Fisher Scientific 
Ethanol Hayman LTD 
70% ethanol See 2.2.21 
Liquid nitrogen  
Table 19. Reagents used for DNA extraction of frozen tissue and cultured HepG2 cells lines. 
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2.1.17  Reagents for Global methylation assay using Imprint ® 
Methylated DNA quantification kit 
 
Chemical/reagent Company name 
10x Wash Buffer Sigma-Aldrich 
DNA Binding Solution 
Methylated Control DNA (50 ng/μL) 
Block Solution 
Capture Antibody 
Detection Antibody 
Developing Solution 
Stop Solution 
Table 20. General reagents used for global methylations assays. 
2.1.18  Reagents for Quantification of DNA methyltransferase 
activity using QPCR 
 
Gene 
name 
Assay ID Exons 
amplified 
Amplificon 
product size 
18sRNA 4310893E * * 
Dnmt1 Mm00599763_m1 1-2 68 
Dnmt3a Mm00432870_m1 6-7 75 
Dnmt3b Mm00599800_m1 1-2 61 
Table 21. TaqMan gene expression assays used to quantify DNA methyltransferase activity
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2.1.19  Human cancer cell line 
 
HepG2 (Human hepatocellular carcinoma cell line) was used for mammalian tissue 
culture. These cells were kindly provided by Dr Amanda Harvey (Brunel University, 
Uxbridge, UK).  
HepG2 cells have been isolated from human liver cancer patients. These cells are 
frequently used in Genotoxicity studies and identification of reactive components 
(Knasmuller et al, 2004).  
 
2.1.20  EIAV, FIV and HIV vectors 
 
The SMART2Z, SMART2ZWΔ, SMART2hFIX, pLIONhAATGFP and HR’SIN-
cPPT-S-FIX- vectors used in this study were originally provided by Dr Themis. 
These vectors were used to inject fetal mice (via the fetal yolk sac) at 16 days of 
gestation. Observations showed the development of lentiviral associated oncogenesis 
following transduction with EIAV vectors. The effect of FIV infection was also 
explored in this study using FIV based vectors produced using methods described by 
Condiotti et al (2004). 
2.1.21  Compositions of buffers and solutions  
 
General buffers & solutions 
DNA extraction buffer 
50 mM Tris pH 8.0 
100 mM EDTA pH 8.0 
100 mM NaCl 
0.1% SDS 
5X TBE (tris-borate EDTA) buffer 
500ml ddH₂O 
27g Tris base 
137.5g boric acid 
10ml 0.5M EDTA pH 8.0 
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1X TBE 
700ml ddH₂O 
300ml of 5XTBE solution 
 
75% Ethanol 
750ml ddH₂O 
250ml of Absolute ethanol solution 
 
70% Ethanol 
700ml ddH₂O 
300ml of Absolute ethanol solution 
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2.2  METHODS 
 
2.2.1  Quantification of nucleic acids  
 
Nucleic acids (dsDNA, cDNA and RNA) were quantified and absorbance values 
measured at several wavelengths (260, 280 and 260:280) using the Nanodrop 
spectrophotometer. The 260 absorbance reading was used to determine the 
concentration of nucleic acids present in uninfected, normal and tumour mouse 
samples. The 280 absorbance reading was used to detect protein contamination in 
mouse samples. ddH₂O/TE nucleic acids buffer was used as a reference sample. 1µl 
of this reference sample was applied to the Nanadrop using a sterile pipette and this 
was used to read a zero absorbance for the ‘blank’. 1µl of DNA, plasmid DNA, 
cDNA and RNA samples were then measured using the Nanadrop.  For pure DNA 
and RNA samples the 260/280 ratio given were approximately 1.8 and 2.0 
respectively.  
2.2.2  Agarose gel electrophoresis 
 
Agarose gel electrophoresis allows negatively charged nucleic acids (DNA and 
RNA) to be separated according to size. An electrical current is passed through the 
agarose gel allowing the movement of small molecules. Agarose gel electrophoresis 
was used to determine the purity and integrity of nucleic acids. A 60ml agarose gel 
was prepared by dissolving agarose powder in 60ml of 1X TBE solution. The 
percentage of agarose powder used varied according to the expected size of products 
being separated. The solution was heated in a microwave for 2 minutes to dissolve 
the agarose and yield a clear viscous solution. The solution was gently swirled to 
mix and allowed to cool to approximately 50ºC. 6µl ethidium bromide (10mg/ml 
stock) was added to the 60ml heated agarose solution before pouring into a casting 
tray containing a well-forming comb. The ethidium bromide was used to allow 
flourescent visualisation of nucleic acids under UV light. Once set the comb was 
removed and the gel immersed (~5mm above the gel) in 1X TBE solution.  Loading 
buffer (Fisher Scientific Cat # BPE633-5) was added and mixed with samples on a 
parafilm sheet or sterile tubes before loaded into wells on the gel. A separate well 
was used to load a standard DNA marker (Invitrogen Cat # 10787-018 & 10488-072) 
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or (Fisher Scientific Cat # F-303SD). This well was used to measure  the size of  
DNA, RNA and cDNA fragments ranging from +/- 100 to  12,000 base pairs. A 
power pack was attached to the gel tank using a positive (anode) and negative 
(cathode) electrode. The power was switched on to allow separation of nucleic acids. 
A typical gel was allowed to run at 50V for aproximately 1 hour. However, this time 
varied according to the experiments required to allow clear seperation of nucleic 
acids. To view results the power pack was switched off  and the 1XTBE solution 
decanted into a destaining bag. DNA, RNA and cDNA fragments were visualised 
using ultraviolet illumination of the gel. Gel images were captured and printed on to 
thermal paper using the Alpha Imager 2200 device (Alpha Innotech Corporation).  
 
2.2.3  Preparation of LB agar plates and LB medium 
 
Bacterial cell including transformed competent cells were grown on plates enriched 
in LB agar. LB agar was prepared in a sterile bottle using the reagents and quantities 
listed in Table 22.  
Chemical/reagent Quantities/volume LB agar LB medium 
Tryptone 5g      
Yeast Extract 2.5g     
Sodium Chloride 2.5g     
Agar 7.5g     
Distilled water 100ml     
Table 22. Reagents /chemicals required for preparation of LB agar plates and LB medium.  
 
The LB mixture was autoclaved and the solution cooled down in a 50ºC water bath. 
All reagents were transferred to a sterile air flow hood. 250µl of ampicillin 
(100µg/L) was added to 500ml of LB agar solution. The solution was mixed by 
swirling and the solution poured into sterile plates making sure to avoid air bubbles. 
LB agar was left to solidify then stored in a 37ºC incubator until ready to use. 40µl 
of X-gal (40mg/ml) and 40µl (100mM) of IPTG was aliquoted and spread on to each 
LB agar plate using a sterile glass spreader immersed in IMS. LB agar plates were 
then left to dry at 37ºC until ready for use.  
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2.2.4  Transformation of PCR products 
 
PCR products were cloned into the pDrive cloning vector (Qiagen, Cat # 231122; 
Figure 4). A ligation master mix was prepared and placed on ice. The volumes 
required for one reaction consisted of 1µl of pDrive Cloning Vector, 2µl of LAM 
PCR product, 2µl of distilled water and 5µl of ligation master mix. Each reaction 
mixture was mixed by reverse pipetting and incubated in ice for 2 hours. Tubes 
containing Qiagen EZ competent cells (Qiagen Cat # 231222) were briefly thawed 
on ice. 2µl of ligation-PCR master mix was then added to competent cells and mixed 
by gently flicking the tube. The transformation mixture was incubated in ice for 5 
minutes then placed in a 42ºC water bath for 30 seconds. Transformation mixtures 
were then transferred to ice and incubated for 2 minutes. After incubation 250µl 
SOC medium was thawed at room temperature then added to each transformation 
mixture. 100µl of reaction mixtures were transferred to freshly prepared LB agar 
plates (Table 22) using a pipette and evenly spread using a sterile glass spreader. 
Samples were left on the plates for 10min before being stored in a 37ºC incubator 
overnight.  
 
 
Figure 11. Schematic representation of the pDRIVE vector used to clone PCR products and 
transform bacterial cells prior to DNA sequencing. The cloned plasmids were purified. 200-
300ng of sample was sent to the Dundee DNA Sequencing service (MRCPPU, College of Life 
Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) to determine the nucleotide 
sequences of PCR products. Image taken from Qiagen® PCR Cloning Handbook (2001). 
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2.2.5  Selection of transformed clones using ‘blue/white screening’ 
The LB plates were stored in the fridge for approximately 3 hours (4ºC) to allow the 
formation of blue/white screening of colonies. Blue/white screening is used to 
differentiate between transformed and untransformed bacteria cells and identify 
desired clones. Untransformed bacteria are unable to grow on LB agar plates 
containing ampicilin as they lack the antibiotic resistance gene present in the 
pDRIVE vector. Recombinant plasmids confer antibiotic resistance and are able to 
grow on ampicilin plates. Transformed clones were also selected through the use of 
blue white screening. The pDRIVE vector carries the LacZ gene which catalyses the 
breakdown of X-gal. The addition of IPTG to LB plates helped promote LacZ 
expression. The ligation of a PCR product into the LacZ coding region disrupts LacZ 
activity and turns colonies white or pale blue on LB plates. Untransformed clones 
that lack inserted sequences were observed as dark blue colonies on LB plates.   
 
2.2.6  Growth of transformed plasmids in LB medium 
 
Fresh LB medium was prepared using the reagents and quantities listed in Table 24. 
100µl of ampicillin (50µg/ml) was added to 100ml of LB medium under sterile 
conditions. The LB medium was then mixed by swirling. 5ml of LB medium was 
added to 50ml Falcon tubes. Single transformed colonies were picked from the plate 
using sterile picks and transferred to respective 50ml Falcon tubes. Tubes were then 
incubated in a 37ºC shaker overnight. 
 
2.2.7  Storage and recovery of bacterial cells for sequencing analysis 
 
250µl of incubated bacterial culture was added to 250µl of 20% glycerol solution 
and the mixture vortexed to mix. Reaction tubes were stored in a -80ºC freezer 
overnight. Frozen glycerol stocks were extracted using a sterile rod and transferred 
to 50ml tubes containing 5ml of fresh LB medium and ampicilin (Table 22). The LB 
medium was incubated in a 37ºC shaker overnight. This bacterial culture was used to 
prepare plasmid DNA for sequence analysis.  
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2.2.8  Plasmid DNA purification 
 
The QIAprep Spin Miniprep Kit (Qiagen Cat # 27106) was used to purify plasmid 
DNA. 
LB broth containing bacterial cultures were spun down in a centrifuge for 5 minutes. 
Pellets (competent cells) were re-suspended in 250µl of re-suspension buffer (P1) 
containing RNaseA. The reaction mixture was mixed thoroughly by reverse pipetting 
followed by vortexing then transferred to a 1.5ml centrifuge tube. 250µl of Lysis 
buffer (P2) was added to each reaction and mixed by inverting tubes 6 times until a 
clear viscous solution was formed. 350µl of Neutralising buffer (P3) was added to 
each tube and the reaction mixture quickly mixed by inverting the tube 10 times. The 
cloudy solution was centrifuged at 13,000rpm for 10 minutes to yield a white pellet. 
The supernatant was transferred to QIA prep spin column using a pipette. The 
reaction mixture was re-centrifuged for 1 minute and the flow through solution 
removed using a pipette. 0.5ml of Binding buffer (PB) was added to each spin 
column and the tubes were re-centrifuged for 1 minute. The flow through was 
removed and 0.75ml of wash buffer (PE) added to each column. Centrifugation (1 
minute) and removal of flow through solution was repeated twice to remove traces of 
ethanol derived from PE buffer. The QIA prep column was then transferred to a 
sterile 1.5ml centrifuge tube. 50µl of Elution buffer (EB) containing 10Mm of Tris-
CL (pH 8.5) was added to the centre of each spin column and left to incubate at room 
temperature for 1 minute. The purified plasmid DNA was eluted from reaction tubes 
by centrifugation at 13,000rpm for 1 minute using a bench top centrifuge.  
2.2.9  Restriction digestion of purified plasmid DNA 
 
The pDrive vector was digested using the restriction enzyme EcoRI.  EcoRI 
restriction sites were located between 306-317 bp and 318-322bp of the pDrive 
vector. A restriction digestion master mix was prepared using the reagents and 
quantities listed in Table 23.  Control reaction mixtures consisted of undigested 
plasmid DNA. 
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Reagents Volumes x1 (µl) 
ddH₂O 17.5 
10x NEB buffer 4 2 
EcoRI 0.5 
DNA (purified plasmid) 2 
Total 20 
Table 23. Reagents used for restriction digestion of plasmid DNA using EcoRI. 
 
The reaction mixture was mixed by reverse pipetting followed by brief 
centrifugation at 13,000rpm. Restriction digestion reactions were incubated for 1 
hour at 65ºC to ensure complete digestion of plasmid DNA. Restriction digested and 
control reaction samples were loaded and run on a 1% agarose gel. 
2.2.10  Colony PCR 
 
Colony PCR was used to screen for plasmid inserts. A PCR was performed using 
primers specific to the SP6 promoter and M13 regions present in the pDrive cloning 
vector (Figure 11). A PCR master mix was prepared using the reagents and 
quantities listed in Table 24. 
 
Chemical/reagent Working volumes x1 (µl) 
ddH₂O 7.6 
10X PCR buffer containing Mg2+ 
(KappaBiosystems) 
1 
10mM dNTP  0.2 
SP6 forward primer 0.1 
M13 reverse primer 0.1 
Taq polymerase (1:20 dilution) 1 
Table 24.  Reagents and volumes required to prepare a one times reaction mixture for colony 
PCR. 
 
A 1 in 100 dilution was made of the LB medium containing transformed cells (LB 
broth). 10µl of PCR master mix was added to a 0.5µl of diluted LB broth mixture in 
a 0.5ml centrifuge tube. A few drops of mineral oil were added to the top of the 
reaction mixtures to prevent sample evaporation.  
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The PCR reaction tubes were then transferred to a thermal cycler (Hybaid 
Ominigene thermal cycler) and the colonies amplified using the parameters listed in 
Table 25.  
 
Step Temperature Time No. cycles 
Denaturation 95ºC 5 minutes 1 
Denaturation 95ºC 1 minutes  
Annealing 54ºC 1.5 minute  
Extension 72ºC 90 seconds  
Extension 72ºC 5 minutes 1 
Table 25. PCR parameters used for colony PCR.  
 
The amplified PCR products were loaded onto a 1% agarose gel and ran at 60V for 
45 minutes. The presence of bands confirmed the presence of transformed competent 
cells containing PCR products. 
2.2.11  DNA sequencing 
 
The Nanodrop was used to measure the absorbance values of purified plasmids. 
Mean absorbance values were calculated and samples diluted with water to 300ng in 
a total volume of 30µl. The labeled samples were delivered to Dundee Sequencing 
Service for sequence analysis. DNA sequencing was carried out by DNA Sequencing 
& Services (MRCPPU, College of Life Sciences, University of Dundee, Scotland, 
www.dnaseq.co.uk) using Applied Biosystems Big Dye Ver 3.1 Chemistry on an 
automated capillary DNA sequencer (Applied Biosystems DNA analyser Model # 
3730).  
 
 
 
 
 
 
 
 
 
 
 
 
 
40 x 
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2.2.12  LAM PCR  
 
 
 
Figure 12.  A schematic overview of the steps required for LAM PCR. The proviral-genomic DNA 
junction is first amplified using biotinylated – LTR specific primers. This generates a linear PCR 
product complementary to the provirus insertion site starting from the LTR region into the 
neigbouring host DNA. Streptavidin Dynabeads are added to a sterile tube containing linear 
(biotinylated) PCR products. This results in streptoavidin-biotin binding. Streptoavidin-biotin 
complexes are isolated using magnetic capture. Klenow fragment (DNA polymerase 1) is used 
to synthesise a strand complementary to linear PCR products containing proviral and flanking 
mouse genomic sequences. This is followed by magnetic capture. Tsp509I (a 4 cutter enzyme) 
was used to digest double stranded provirus junction at 5’- AATT – 3’ restriction sites followed 
by magnetic capture of the resulting products. A known linker cassette sequence was ligated 
onto the end of isolated products. PCR and nested PCR amplification was then used to amplify 
the linker-genomic DNA-provirus complex using virus and linker specific primers. 
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Linear PCR 
 
Linear amplification reactions were conducted on FIV infected and uninfected tissue 
samples using biotinylated primers that hybridise to the LTR sequence of the FIV 
lentiviral constructs (Table 7; Figure 12). A PCR master mix (Table 26) was 
prepared in a 1.5ml centrifuge tube and placed on ice. The PCR master mix was 
briefly centrifuged at 13,000 rpm (17,900 x g) using a table-top centrifuge and 
aliquoted into 0.2ml centrifuge tubes for each reaction. 2μl of DNA was then added 
to each respective tube.  
 
Chemical/reagent Final concentration Working volume x1(μl) 
Distilled water - 42.5 
PCR buffer + magnesium mix  x1 5 
dNTP solution  0.2mM 1 
FIV-LTR-5A primer 
 
2.5nM 0.5 
FIV-LTR-5B primer 
 
2.5nM 0.5 
KAPA Taq DNA Polymerase 2.5U 0.5 
DNA template (liver tissue) 50ng/μl 2 
Total Volume  50 
Table 26. Reagents and volumes required to make a linear PCR master mix for one reaction. 
 
 
The PCR sample tubes were transferred to a thermal cycler (MJ Research PT-225 Tetrad 
Therma cycler) and amplified for 3 hours and 58 seconds. The PCR parameters are listed in 
Table 27. 
 
Step Temperature Time No. cycles 
Denaturation 95ºC 5min 1x 
Denaturation 95ºC 1 min  
Annealing 60ºC 45 sec  
Extension 72ºC 90 sec  
Extension 72ºC 10 min 1x 
Pause 4ºC - - 
Table 27.  PCR parameters required for linear PCR of lentiviral infected samples. 
 
Once the linear PCR amplifications were completed 0.5μl of Platinum Taq 
polymerase was added to each PCR reaction tube. PCR tubes were then re-amplified 
50 x 
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using the same parameters listed in Table 27 in order to increase the number of 
biotinylated products containing provirus insertions sites. PCR products were then 
stored at 4ºC overnight. 
Preparation of the linker cassette  
 
The linker cassette contains short sequences (5’-AATT-3’) with a Tsp509I  
restriction enzyme site. This synthetic linker cassette sequence was prepared using 
LC1 and LC3 oligo sequences (Table 7). A linker cassette master mix was prepared 
using 40μl of LC1 (final concentration of 20µM), 40μl of LC3 (final concentration 
of 20µM), 55μl of Tris pH 7.5 (137.5mM) and 20µl of MgCl2 (5mM) and heated in a 
hot block (95˚C) for 5 minutes. The master mix was then left to cool slowly for 
several hours.  
 
DNA capture of magnetic beads 
 
Biotin binds to streptoavidin with an extremely high affinity. This was exploited 
using the Dynal® kilobaseBINDER™ Kit (Invitrogen Cat # 601-01). Streptoavidin 
Dynabeads were vortexed to re-suspend the beads. 20μl of the beads were added to 
sterile centrifuge tubes and placed in a magnetic rack to immobilise beads. The 
supernatant was removed with a pipette and the brown pellet of beads mixed with 
20μl of fresh washing solution (0.1% BSA dissolved in 1X PBS^) by flicking the 
tube. Tubes were then transferred to a magnetic rack. This step was repeated once. 
Beads were then gently re-suspended by flicking in 20μl of binding solution making 
sure to avoid foaming. The beads were again immobilised in a magnetic rack, 
supernatant removed and re-suspended in 50μl of binding solution. Beads were then 
immobilised and the supernatant removed before conducting a final re-suspension 
step. The magnetic beads were then re-suspended in 50μl of linear PCR products. 
Reaction mixtures were incubated for one hour at room temperature to allow the 
formation of streptoavidin-biotin complexes. Reaction mixtures were kept re-
suspended by gently flicking the tubes every 15 minutes. 
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Second strand synthesis 
 
Second strand synthesis was prepared using the DNA synthesising enzyme klenow 
(DNA polymerase I fragment) and a hexanucleotide mix. A second strand synthesis 
master mix was prepared in a sterile 1.5ml centrifuge tube on ice and briefly mixed 
at 13,000rpm. The volumes of the reagents used are shown in Table 28. 
 
Chemical/reagent Final concentration Working volume x1 (μl) 
Distilled water - 14.5 
 diluted Klenow  2U/μl 1 
dNTP  2.5µM 0.5 
React2Buffer  1x 2 
Hexanucleotide mix  1x 2 
Total  20 
Table 28. Reagents and volumes required to make for one reaction for second strand 
synthesis. 
 
Klenow (Large Fragment DNA Polymerase I) was used to dilute to Klenow dilution 
buffer and placed solution on ice. Incubated linear PCR products were washed with 
100μl of double distilled water and immobilised in a magnetic rack. The supernatant 
was removed and beads re-suspended with 20µl of second strand synthesis master 
mix. All reactions were incubated in a 37˚C water bath for one hour. Samples were 
kept re-suspended by gently flicking tubes every 15 minutes. 
Restriction Digest of the double stranded DNA with Tsp509I 
 
TSP509I was used to digest the double stranded DNA prior to the ligation of the 
linker cassette sequence. A restriction digestion master mix was prepared using the 
reagents and quantities in Table 29 and placed on ice. 
 
Stock solutions Final concentration Working volume x1 (μl) 
Distilled water - 17 
 10x NEB buffer  1x 2 
4000μg/ml Tsp509I  
 
200µg/ml 1 
Total  20 
Table 29. Reagents and volumes required to make for one reaction for restriction digestion 
using Tsp509I. 
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Second strand synthesis samples were removed from the water bath and placed in a 
magnetic rack. The supernatant was removed from each sample. Washing, 
immobilisation and supernatant removal steps were performed firstly with 80μl and 
repeated with 100μl of ddH₂O. 20μl of reaction digest master mix was added to the 
concentrated pellet in each reaction tube. All samples were incubated in a 65˚C water 
bath for one hour. Samples were kept re-suspended by gently flicking every 15 
minutes. 
Concentration of the linker cassette with a Micron-YM30 concentrator. 
 
The linker cassette master mix was concentrated from 200 to 80μl. The 200μl linker 
cassette solution was added to the column membrane of the Micron-YM30 
concentrator (Millpore, Cat # 42409) and the tube spun in a desktop centrifuge at 
13,000rpm for 8 minutes. 20μl of ddH₂O was added to the column membrane then 
spun at 13,000 rpm for 1 minute in a desktop centrifuge. The column was then 
turned upside down and placed in a sterile 1.5ml eppendorf tube. Centrifugation at 
13,000rpm was repeated for approximately 2 minutes. 60μl of ddH₂O was then 
added to the concentrated linker cassette volume and the sample tube placed on ice. 
Ligation of the linker cassette 
 
A ligation master mix was prepared using the reagents and quantities listed in Table 
30. 
Chemical/reagent Final concentration Working volume x1(μl) 
dH₂O  - 4 
 Ligation casette  - 2 
ATP  1mM 1 
Ligation buffer 1x 1 
Ligase 0.4U/µl 2 
Total  10 
Table 30.  Reagents and volumes required to make for one reaction for ligation the linker 
cassette using the ligase enzyme. 
 
The restriction digest samples were removed from the water bath and placed on ice. 
80μl of ddH₂O was added to each tube and mixed by flicking. The samples were 
placed in magnetic rack and the pellets re-suspended in 100µl of ddH₂0. Sample 
tubes were immobilised in a magnetic rack and the supernatant removed.  
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The concentrated samples were then re-suspend with 10μl of ligation master mix and 
incubated at room temperature for 30 minutes. Restriction reactions were kept re-
suspended by gently flicking every 10 minutes. 
First round PCR 
 
A PCR master mix was prepared using the reagents and quantities in Table 31 then 
placed on ice. 
Chemical/reagent Final concentration Working volume x1 (μl) 
Distilled water - 31 
PCR buffer + magnesium mix  1x 5 
dNTP solution  0.2mM 1 
FIV-LTR-5C primer 0.5μM 5 
LC-1 primer 
 
0.5μM 5 
Taq polymerase 
 
0.1U/µl 1 
DNA template (ligation product) - (2) 
Total  50 
Table 31. First round PCR: Reagents and volumes required to make a PCR master mix for one 
reaction. 
 
Primers used were specific to both the 5LTR (FIV-LTR-5C) and the LC-1 linker 
sequences (Table 7). Ligated linker samples were re-suspended and washed with 
90μl of ddH₂O then placed in a magnetic rack. The supernatant was discarded with a 
pipette. DNA was denatured by adding 5μl of NaOH (0.1M) to each pellet. Reaction 
mixtures were then incubated at room temperature for 10 minutes. 48µl of master 
mix and 2µl of denatured DNA was added to respective PCR centrifuge tubes and 
placed on ice. The reaction mixture was briefly mixed in a centrifuge then placed on 
ice. Tubes were transferred to a pre-set thermal cycler using the PCR parameters in 
Table 32. 
 
Step Temperature Time No. cycles 
Denaturation 95ºC 5min 1x 
Denaturation 95ºC 1 min  
Annealing 60ºC 45 sec  
Extension 72ºC 90 sec  
Extension 72ºC 10 min 1x 
Pause 4ºC - - 
Table 32. PCR parameters required for first round PCR. 
30 x 
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Second Round PCR  
 
Nested primer sequences were used to amplify the products generated by first round 
PCR. This step used vector-specific (FIV-5LTR-5D) 
5’CTCAAAAGTCCTCAACAAAG 3’ and linker specific (LC3) 
5’AGTGGCACAGCAGTTAGG 3’ primers respectively. A master mix for the 
second round PCR was prepared using the reagents and quantities in Table 33 then 
placed on ice. 
 
Chemical/reagents Final concentration Working volume x1 (μl) 
Distilled water - 32 
PCR buffer + magnesium mix  1x 5 
dNTP solution  0.2mM 1 
FIV-LTR-5D primer 
 
0.5μM 5 
LC-3 primer 
 
0.5μM 5 
KAPA Taq polymerase 
 
0.1U/µl 1 
DNA template (First round PCR) - 1 
Total  50 
Table 33. Reagents and volumes required to make a second round PCR master mix for one 
reaction.  
 
49μl of second round PCR master mix and 1μl of DNA template was added to sterile 
PCR tubes. The reaction mixture was briefly mixed in a centrifuge then placed on 
ice. PCR reaction tubes were transferred to a thermal cycler for amplifications using 
the pre-set parameters (Table 32). A 3% agarose gel (1.8g of agarose) was prepared 
and used to separate LAM-PCR amplified products. 15µl of  LAM PCR products 
was mixed with 3.5µl of loading buffer  (Fisher Scientific Cat # BPE633-5) and 
loaded onto the gel.  The gel was run at 50 V for approximately 1 hr. 
 
2.2.13  454 sequencing  
100-300ng of sample genomic DNA was subjected to deep parallel 454 
pyrosequencing by Dr Manfred Schmidt (National Center for Tumor Diseases and 
German Cancer Research Center, Heidelberg, Germany) using the Roche GS FLX  
system.  
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2.2.14  RNA extraction, purification and cDNA synthesis for RT 
(reverse transcriptase) and QPCR (Real -Time Quantitative (Q) 
– PCR) analysis  
 
RNA extraction for QPCR and RT PCR analysis. 
 
Frozen liver tissue (-80ºC) was transferred to a mortar containing liquid nitrogen. 
Tissue was coarsely crushed using a pestle. Crushed tissue was extracted from the 
mortar using sterile forceps and transferred to a sterile 1.5ml centrifuge tube. 250µl 
of Tri Reagent was added to the sample and the tissue was homogenised using a 
sterile plastic rod. 500µl of Tri Reagent was added to the homogenised tissue. 200µl 
of chloroform was then added to the reaction mixture. The sample tube was mixed 
by inverting 5 times and left to incubate at room temperature for 15 minutes. 
Reaction mixtures were centrifuged at 12,000 g for 15 minutes at 4ºC in a Sigma 
centrifuge (model GK10). Following centrifugation the reaction mixture was 
separated into 3 layers representing RNA solution (clear aqueous phase), proteins 
(white phase) and DNA (pink phase) respectively. The clear upper fluid was 
transferred to a sterile 1.5ml centrifuge tube and 500µl of isopropanol (2-propan-1-
ol) added. The reaction mixture was mixed by inverting tube several times and left to 
incubate at room temperature for 10 minutes. The reaction tubes were re-centrifuged 
for 10 minutes. The supernatant was removed using a pipette and the pellet re-
suspended in 1ml of 75% ice cold ethanol to wash. The reaction mixture was 
vortexed followed by centrifugation at 12,000 g for 5 minutes (4ºC). This washing 
step was repeated once. The supernatant was removed and the tubes left to air dry for 
15 minutes. The RNA pellet was then re-suspended in 50µl of DEPC water.  
DNase I treatment  
 
 A DNaseI reaction mixture was prepared using the reagents and quantities listed in 
Table 34. 
 
Reagent Final concentration Working volume x1 (µl) 
RNA sample - 50 
Reaction buffer 1x 5 
Amplification Grade DNaseI 1U/µL 5 
Table 34. Preparation of a one reaction mixture for DNase I treatment.  
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DNase I was used to digest DNA present in RNA samples into oligo and 
mononucleotides prior to cDNA synthesis. The reaction mixture was left to incubate 
at room temperature for 15 minutes. 5µl of Stop DNAse I (50mM EDTA) solution 
was added to the reaction mixture and the solution mixed by brief centrifugation. 
Reaction tubes were transferred to a 70ºC heating block for 10 minutes. The reaction 
tubes were cooled in ice. 
 
RNA purification for Real -Time Quantitative (Q) - PCR  
 
Total RNA and mRNA samples were extracted and RNA was purified using the 
Absolute Total RNA & mRNA Purification Kit (Agilent technologies, Stratagene 
Cat # 400806). 1.75µl of β-ME was added to total RNA samples. 250µl of lysis 
buffer and 250µl of 70% ethanol was added to each reaction mixture and mixed by 
centrifugation 12,000 x g. The reaction mixture was transferred to an RNA binding 
spin cup and seated in a 2ml receptacle tube. The reaction mixture was mixed by 
centrifugation for 1 min. The flow through was discarded and 500µl of 1x low salt 
wash buffer added to the spin cup. The tube was re-centrifuged for 1 min and the 
flow through discarded. The addition of wash buffer followed by centrifugation and 
removal of flow through was repeated once with 500µl and again 300µl of wash 
buffer. The reaction mixture was re-centrifuged for 2 minutes. The spin cup was 
transferred to a sterile 1.5ml micro-centrifuge tube and 50µl of elution buffer added. 
The reaction mixture was incubated at room temperature for 2 min then re-
centrifuged. The elution, incubation and centrifugation step was repeated once. 
Purified RNA samples were placed in ice and prepared for immediate cDNA 
synthesis.  
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2.2.15  CDNA synthesis for RT PCR 
 
The absorbance values of purified RNA samples were found using the Nanodrop 
spectrophotometer.  Second strand synthesis was performed in two steps RNA 
primer and cDNA synthesis using Superscript III First Strand Synthesis System 
(Invitrogen Cat # 18080-051). RNA primer master mix was prepared using the 
reagents and quantities listed in Table 37.  
Reagent 1x working volume (µl) 
5µg of total RNA  8 
50µM Oligo (dT)₂o primer 1 
10mM dNTP mix 1 
ddH₂O 10 
Table 35. Preparation of a RNA primer master mix for one reaction mixture.  
 
 
The reaction mixture was incubated in a 65ºC water bath for 5 minutes then placed 
in ice for 1 minute. A cDNA synthesis master mix was prepared using the reagents 
and quantities listed in Table 35 and placed on ice. 
 
Reagent 1x working volume (µl) 
10x RT buffer 2 
25Mm Mgcl2 4 
0.1M DTT 2 
40U/µl RNaseOUT 1 
200U/µl Superscript III RT 1 
Table 36. Preparation of a cDNA synthesis master mix for one reaction mixture.  
 
10µl of this master mix was added to the RNA primers reaction mixture then mixed 
by centrifugation for 30 seconds. The reactions were terminated using heat 
inactivation  by incubating tubes in a 85ºC heating block for 5 minutes then 
transferred to ice for 1minute. Reaction mixtures were briefly re-centrifuged 
followed by the addition RNaseH (1µl) to each tube. Reaction tubes were incubated 
in a 37ºc heating block for 20 minutes then stored at -20ºC until ready for use.  
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2.2.16  RT PCR amplification reagents  
 
Primers were designed for mouse genomic sequences identified by sequencing. The 
expression of these genomic sequences was examined using RT PCR analysis.  
A RT PCR master mix was prepared using the reagents and quantities listed in Table 
37. 19µl of master mix was added to1µl of FIV infected cDNA samples (236ng/µl).  
Control reactions included gender matched normal livers and tumours without FIV 
insertions and blank negative controls. 
 
Chemicals/Reagents Final concentration Volume x1 (µl) 
ddH₂O - 11 
PCR buffer 1x 2 
Mgcl2 2.5mM 1 
dNTP 0.4mM 2 
Forward primer Variable dependant on reaction 1 
Reverse primer  1 
Taq DNA polymerase  0.2U/µL 1 
Total  19 
Table 37. Preparation of RT PCR master mix for one reaction mixture. 
 
 
2.2.17  cDNA synthesis for QPCR 
 
 
cDNA was prepared from purified total RNA samples isolated from liver and gonad 
liver tissue. All RNA samples were quantified using the Nandrop spectrophotometer. 
For control experiments a standard curve was designed to optimise the PCR 
amplification. The starting amount of RNA was 1µg in a total volume of 10µl. 
Following this a two-fold dilution of the RNA samples was made using ddH₂O to 
yield a series of RNA templates with different concentrations. 6 dilutions were made 
per sample to yield a final sample containing 15.6ng in 10µl. The optimised input of 
RNA template was 125ng in 10µl of RNA. All reverse transcription reactions were 
performed on ice each RNA sample using the reagents and quantities listed in Table 
38. 
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Reagents Working volumes x1 (µl) 
ddH₂O 3.2 
10X RT Buffer 2 
10X RT Random Primers 2 
25X dNTP mix (100mM) 0.8 
MultiScribe™, Reverse Transcriptase, 50 
U/µL 
1 
RNase Inhibitor 1 
Table 38. General reagents/chemicals used for CDNA synthesis of total RNA for QPCR 
reactions. 
 
  
10µl of RNA sample was added to each reverse transcription reaction and mixed 
briefly centrifugation. The reaction mixtures were transferred to thermal cycler and 
reverse transcription performed using the parameters listed in Table 39. 
 
Step Temperature Time 
Primer extension 25ºC 10 min 
cDNA synthesis 37ºC 120 min 
Reaction 
termination 
85ºC 5 min 
Pause 4ºC - 
Table 39. PCR parameters used for cDNA synthesis using MultiScribe reaction kit. 
 
2.2.18  Q-PCR for gene expression analysis and VCN analysis 
 
A real time PCR reaction master mix was prepared on ice using the reagents and 
quantities listed in Table 40. The reaction mixtures were aliquoted into a 96 well 
plate. 2µl of cDNA was added to each reaction master mix. The amount of DNA 
required for gene expression analysis of FIV insertion genes was 125ng of cDNA. 
For VCN experiments 2µl (15.63ng/µl) of genomic DNA was added to each real 
time reaction master mix. The reaction plates were sealed with a MicroAmp® 96 
Optical adhesive film (Applied Biosystems Cat # 4311971) to prevent evaporation & 
loss of samples during PCR reactions. 
 
Reagent Working volume x 1 (µl) 
ddH₂O 7 
2x TaqMan Universal PCR Master Mix 10 
20x TaqMan gene expression assay 1 
Table 40. Reagents/chemicals used for preparation of TaqMan PCR mastermix for 
amplifications.  
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The reaction mixtures were transferred to a 7900HT real time PCR thermal cycler 
(Applied Biosystems). PCR amplifications were run in the absolute quantification 
blank template format. The parameters for all amplification reactions are listed in 
Table 41. 
 
Step Temperature Time No. cycles 
.... 50ºC 2 minutes 1x 
Denaturation 95ºC 10 minutes ... 
Denaturation 95ºC 15 seconds  
Annealing 60ºC 1 minute  
Extension 72ºC 90 seconds  
Table 41.  PCR parameters used for TaqMan amplification reactions.  
 
 
Validation experiments for PCR efficiency and optimal template concentration 
required were calculated quantitatively using a standard curve. An R² value of 1 
indicated the ability to predict template amount with the Threshold Cycle (CT) 
value.  Raw data for each reaction plate consisted of CT values. CT values were 
manually transferred from the thermal cycler to a CD for data analysis.  
 
Q-PCR for gene expression analysis: 
 
All reactions were performed in quadruplets and the reactions repeated on two 
occasions. All genes were normalised using the house keeping gene (18sRNA) and 
normal liver samples. A gender matched normal liver sample was used as the 
reference sample in each experiment. The relative expression level of each gene was 
manually calculated from CT values using the delta delta CT (ΔΔCT) method. 
 
1. The average CT for each gene was subtracted from the average housekeeping 
CT value to produce a ΔCT value. 
2. ΔCT values from each sample was subtracted from the reference sample to 
yield a ΔΔCT value (ΔΔCT = ΔCTsample – ΔCTnormal liver). 
3. Relative gene expression values 2(-log fold values) were calculated using the 
following equation - 2
-ΔΔCT
. 
 
40 x 
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Statistical analysis including  95% confidence intervals, standard error of the mean 
(SEM) and student T testing was performed on CT values to validate gene 
expression data between normal and tumour samples.    
 
Q-PCR for determination of vector copy number (VCN) 
 
For VCN analysis raw CT values for vector specific sequences and housekeeping 
genes were converted into VCN values. A standard curve was obtained from a serial 
dilution of a tumour control sample with a known copy number of 1.  A standard 
curve was constructed by plotting Log10 genome values (x axis) against CT values 
(Y axis).VCN values were calculated using a template excel spreadsheet containing 
all relevant calculations. The linear regression equation (y = mx+c) where m = slope 
and c = intercept was obtained from the standard curve. This equation was used to 
interpolate the VCN for all samples with unknown copy numbers and compare to 
tumour samples with known VCN (see Appendix 7 - Southern blotting).  
 
1. For each sample the numbers of sequence copies were calculated by 
subtracting the average GAPDH CT from the intercept value (standard curve 
- GAPDH probe). This value was then divided by the slope value obtained 
from the standard curve.  
2. Step 1 was repeated using values obtained with WPRE/EIAV psi data. 
3.  To calculate the copy number per haploid genome the total number of virus 
specific sequences detected were divided by the calculated total number of 
GAPDH.  
 
Copies of virus specific sequences (WPRE/EIAV psi)     =  Copy number per haploid                                            
.                                     genome 
                                         
                              Copies of GAPDH 
 
4. Calculated haploid copy numbers were multiplied by 2 to obtain copy 
number per diploid genome (VCN). 
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2.2.19  Microarray analysis for gene expression of murine cellular 
genes retrieved by LAMPCR and 454 sequencing and known E2F 
targets 
 
Preparation of  RNA and collation of raw data for Microarray was conducted by Dr 
Manfred Schmidt (National Center for Tumor Diseases and German Cancer 
Research Center, Heidelberg, Germany). All microarray data was adjusted and 
classified according to individual p-values to create comprehensive lists of 
differentially expressed genes. This was done in collaboration Dr Rob Andrews at 
the Welcome Trust Sanger Centre, Cambridge, UK. 
2.2.20  Bioinformatics – STRING analysis 
 
Computational analysis was used to find genes related to genes found flanking the 
provirus insertion site. This enabled the analysis of the microarray data and to 
determine potential pathways associated with HCC. Suggested genes were entered 
into the STRING (Search Tool for the Retrieval of Interacting Genes/Proteins) 
database (http://string-db.org/). This database contains a combination of known and 
predicted proteins. For analysis of protein-protein interaction raw network data is 
scored for all interaction partners with values listed in descending order. Each 
network is then categorised and clustered to reveal tightly connected functional 
partners and direct and physical associations.  
 
2.2.21  Tissue culture  
 
All tissue protocols were performed under a laminar class II cell culture hood 
(Heraeus). HepG2 cells were cultured in culture dishes (Fisher Scientific) containing 
10ml of complete DMEM medium containing pen/strep and FBS.   
To make 50ml of complete medium at 15% FBS the following reagents were added 
to a falcon tube: 42ml DMEM (Fisher, VX21885025), 7.5ml FBS (Fisher, 
VX10270106) and 495µl pen/strep (Fisher, VX15400054). 
The culture dishes were transferred to a 37ºC incubator in a humidified atmosphere 
(5% CO2). The cultures were allowed to grow until 70% confluent before proceeding 
to passaging steps. The culture medium (10ml) containing cells were transferred to a 
50ml falcon tube. 10ml of sterile 1x PBS was used to wash the cells (by swirling) 
and the solution placed in a 50ml falcon tube (containing complete medium). 
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Confluent cells were detached from culture dishes using 1ml of 1x trypsin.  The 
culture dishes were then incubated at 37°C for 5 minutes. 10ml of complete medium 
was added to each dish and gently mixed by pipetting up and down. The neutralised 
cell suspension was centrifuged at 1000rpm for 5 minutes. The clear supernatant 
formed was discarded. The pellet was re-suspended in 1ml of fresh (complete) 
medium and mixed by pipetting using a p1000 Gilson pipette. 1ml of cells 
suspension was added to 29ml of fresh (complete) medium and pipette up and down. 
10ml of each cell suspension was transferred to a three sterile culture dishes and 
transferred to a 37°C incubator for growth. 
2.2.22  Storage of cells derived from tissue culture  
 
Cells were frozen in liquid nitrogen (-196°C) for long term storage or preparation for 
tissue extraction. Cells pellets obtained from centrifugation during passaging were 
re-suspended in freezing medium containing 1ml of culture medium & 10% DMSO 
The cell suspension solution was cooled at -80°C then transferred to a dewar 
containing liquid nitrogen. 
2.2.23  DNA extraction from frozen tissue samples and cultured cells 
 
All surfaces and equipment (forceps, pestle and mortar) were wiped own with 2% 
trigene and 70% ethanol. Frozen tissue samples were crushed to a fine powder in 
liquid nitrogen using a sterile pestle and mortar. Homogenised tissue samples were 
diluted with 2-3ml of extraction buffer and mixed by stirring with sterile pipette until 
a thick gluppy solution was generated. The reaction mixture was transferred to a 
sterile 50ml centrifuge tube using a pipette. Proteinase K at a concentration of 
100µg/ml and RNAse was added to the reaction tubes and incubated at 55°C for 2 
hours. An equal amount (2-3ml) of phenol was then added to the reaction mixture 
and mixed by gently inverting tube sideways until a white solution was formed. The 
reaction mixture was spun in a centrifuge at 6,000 rpm for 10 min at 4°C. The 
reaction mixture yielded 2 phases separating DNA and protein between the phenol 
and TE solutions. The top layer was DNA in aqueous solution. The aqueous DNA 
solution was transferred to a sterile centrifuge tube and an equal volume of 
chloroform was added. The solution was then mixed carefully by inversion. The 
reaction mixture was spun down at 6,000 rpm for 5 min at 4°C. The supernatant was 
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removed and transferred to a sterile centrifuge tube. 2-3ml of ice cold 100% ethanol 
was added to wash the reaction mixture and the tube gently mixed by tilting until a 
clear solution with DNA precipitate was formed. The solution containing DNA 
precipitate was spun down to form a pellet. The ethanol solution was poured off by 
tilting the tube in the opposite direction of the DNA pellet. DNA pellets were 
transferred to separate bijou tubes using a sterile pipette. The DNA pellets were 
washed in 70% ethanol to remove excess salt.  The tubes were air dried in a sterile 
hood and the pellets re-suspended in 3ml of double distilled water. The reactions 
mixtures were left to dissolve at 4°C overnight.    
2.2.24  Global methylation assay using Imprint® Methylated DNA 
quantification kit 
 
DNA samples that were extracted from lentiviral (EIAV, FIV & HIV) infected liver 
and gonad tissues were quantified using a spectrophotometer.  DNA samples were 
diluted with DNA binding solution (Sigma-Aldrich Cat # MDQ1) to yield a 
concentration of 50ng in 30µl. Standard control samples consisted of a negative 
blank and a positive DNA sample (uninfected and standard methylated DNA 
samples). The negative controls and methylated DNA (Sigma-Aldrich Cat # MDQ1) 
were also diluted in DNA binding solution. All dilutions were mixed by brief 
centrifugation at 12,000 x g and 30µl of each sample was added to an ELISA plate. 
To ensure that each well was coated the plate was gently tilted from side to side. The 
plate was covered with optical adhesive film (Applied Biosystems Cat # 4311971) 
and incubated at 37°C for 1hr. 10x wash buffer was thawed on ice. Following 
incubation 150µl of blocking buffer solution was added directly to each well to coat 
samples and reduce non-specific DNA binding. The plate wells were covered and 
incubated at 37°C for 30 minutes. The reaction mixtures were removed from each 
well by inverting plate. Each well was washed by adding 150µl of 1x wash buffer 
followed by inversion of the plate to remove the contents. This step was repeated 3 
times. Methylated DNA capture involved the use of a capture antibody specific to 
methylated CpG dinucleotides.  A 1X wash buffer was prepared in a sterile bottle 
using 11ml of 10x wash buffer (Sigma Aldrich Cat # MDQ1) and 99ml of ddH₂O. 
Capture antibody was diluted in a 1:1000 ratio using 1x wash buffer. 50µL of diluted 
Capture antibody was then added to each well. The plate was then covered and 
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incubated at room temperature for 1hr. The capture antibody was removed from each 
well by inverting the plate. Each well was washed 4 times with 150µl of 1x wash 
buffer. The detection antibody was diluted to a 1 in 1000 ratio using 1x wash buffer. 
50µl of diluted detection antibody was added to each well. The plate was covered 
and incubated at room temperature for 30 minutes. The detection antibody was 
removed from each well and the reaction wells were washed 5 times with 150µl of 
1x wash buffer. For the detection of methylated DNA 100µl of developing solution 
was added to each well. The plate was covered and incubated at room temperature 
away from light for 1-10 minutes. The reaction mixtures were monitored for colour 
change to ensure the formation of a blue solution. 50µl of stop solution was added to 
each well which yielded a yellow solution. The absorbance values correspond to the 
level of CpG methylation. Absorbance (Abs) values were measured at 450nm on a 
plate reader (Biotex Instruments). To calculate the relative methylation levels for 
each DNA sample.  Firstly replicate absorbance values for all DNA and blank 
samples were averaged. The average blank value was then subtracted from the 
average absorbance values for each DNA sample to give value A. Next the average 
blank value was subtracted from the average absorbance value taken from the 
positive control sample to give value B. Value A was divided by value B and 
multiplied by 100. This calculated percentage value represents a global methylation 
level that is a percentage of the positive control DNA sample. 
 
Calculation for global methylation:               (Abs 450 sample - Abs 450 Blank) 
                                                       (Abs 450 Methylation Control DNA - Abs 450 Blank)    
 
 
 
 
 
 
 
 
 
 
 
 
 
X 100 
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2.2.25  Quantification of DNA methyltransferase activity using QPCR 
 
Several gene expression assays were used to assess the expression of DNA 
methyltransferases in lentiviral infected samples. These results were compared to the 
expression of Dnmt’s in uninfected cDNA samples. 18sRNA was used as the 
housekeeping gene to normalise gene expression. The reagents for the real time PCR 
were prepared on ice. A single PCR master mix was prepared using the reagents and 
quantities listed in Table 40. 2µl of cDNA was then added to 18µl of PCR master 
mix in 96 well reaction plates. The raw data (CT) values were analysed via ΔΔCT 
analysis (see section 2.2.18). 
2.2.26  Bisulphite modification, methyl sensitive PCR and DNA 
sequencing  
 
Bisulphite modification, PCR and sequencing analysis was done in collaboration Dr 
Rob Andrews at the Welcome Trust Sanger Centre, Cambridge.
 
2.2.26  Brief on statistical methods used 
 
All QPCR reactions were performed in quadruplicates for each sample. Each 
reaction was then repeated again (x4) on another occasion. An n value of 8 was used 
for T-test analysis. For microarray analysis fold changes in gene expression (logFC) 
were calculated and statistical analysis performed on raw data.  For IPA analysis the 
Fisher’s exact test was used to determine the statistical significance of genes 
enriched within a given GO category and validate genes overrepresented in data sets. 
P-values<10
−20
 or lower were used to select highly significant overrepresentation 
after Benjamini Hotchberg correction. 
 
 
 
 
 
 
RESULTS CHAPTER 3 
 
78 
 
3.1  Investigation of vector associated geneotoxicity in mice 
following in utero delivery of EIAV, FIV and HIV vectors. 
 
3.1.1  Detection of viral vectors (EIAV, FIV and HIV) in infected mouse 
normal and tumour tissue 
In 2005 the Gene Therapy Research group at Imperial College London under the 
supervision of Dr Michael Themis reported that 80% of haemophiliac and MF-1 
mice treated with SMART EIAV based vectors in utero at day 16 gestation 
developed HCCs that were clonal in origin. Conversely, no HCCs were observed 
when the HIV vector HR’SIN-cPPT-S-FIX-W was used. The virus copy numbers 
(VCNs) found in these tumours varied between 1 and 10 for EIAV SMART vectors 
and in normal livers mean VCN’s were 0.9 (+/-0.09) and 0.8 (+/-0.29) for the EIAV 
and HIV vectors, respectively. As insertional mutagenesis was suspected to be the 
cause of oncogenesis provirus integration sites were investigated. To do this LAM 
PCR was used to obtain 26 provirus integration sites from liver and gonad tissue. Of 
these, 20 were matched to RefSeq genes that were either cancer genes or cancer 
associated. This suggested that lentiviral transduction could have caused the 
oncogenesis in the fetally treated adult mice. During this investigation the WPRE 
was suspected also to be involved in tumour development. The was because the 
EIAV vector carries the woodchuck post translation regulatory element (WPRE) 
which contains the X gene which in the wild-type 140 amino acid form is known to 
be involved in HCC formation (Zufferey et al, 1999; Kingsman et al, 2005; 
Higashimoto et al, 2007; Schambach et al, 2007). In the EIAV and HIV vectors the 
sequences for a truncated form of the X gene was included but only in the EIAV 
vector is the start codon and X promoter (native form), that could allow X gene 
expression in contrast to the HIV vector sequences mutated to prevent X gene 
expression. Hence it was important that the role of the X gene was investigated as a 
possible factor leading to oncogenesis.  
Following the original work carried out by the Themis group, a modified EIAV 
vector SMART2 and a feline immuno-deficiency virus FIV pLIONhAATGFP that 
has been shown to effectively transduce fetal mice (Condiotti et al, 2004) was used 
alongside the original SMART2 vector and the HR’SIN-cPPT-S-FIX-W HIV vector 
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that did not cause oncogenesis in fetal mice. This study was used to test the WPRE 
in EIAV and FIV and to determine whether the observed oncogenesis was restricted 
to EIAV vectors only. Mice treated with these vectors developed tumours at a 
frequency of 4/6 (SMART2 unmodified), 4/10 (SMART2 modified vector) and 4/8 
(pLIONhAATGFP). The vectors used for this work are shown in Figure 13. 
The research work described in this thesis began by investigating integration sites of 
the FIV vector in the mouse genome in order to identify common insertion sites 
(CIS) that could give clues on a particular gene which, if mutated, could be 
responsible for HCC following virus integration. The vectors and tissue samples 
obtained following in utero gene transfer to fetal mice were provided by Dr Themis 
following the genotoxicity studies described above (not previously published) and 
those previously described by the Themis research group (Themis et al, 2005).  
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3.1.1.1  Sequence comparison of vector sequences in vivo 
 
 
Figure 13. Schematic representation of the genomic organisation of vector constructs used to 
treat MF-1 mice in utero. Vector constructs used were pLIONhAATGFP, SMART2hFIX, 
SMART2Z, SMART2hFIX WΔ, SMART2ZWΔ and HR’SIN-cPPT-S-FIX-W respectively. All lentiviral 
constructs included SIN LTR sequences which contain a mutation in the U3 region of the 3 LTR. 
a) PLIONhAATGFP contains an antitrypsin (a1AT) promoter and enhanced green fluorescent 
protein (eGFP) reporter gene. b) All SMART2 vectors were driven by a CMV promoter. However 
each vector contained either a Factor IX (SMART2hFIX) or a LACZ transgene (SMART2Z). 
Modified SMART vectors (SMART2hFIX WΔ and SMART2ZWΔ) contained a mutated WPRE 
sequence (WΔ). d) The HR’SIN-cPPT-S-FIX-W construct used a SFFV (Spleen Focus-Forming 
Virus) to drive transcription. HIV vectors used in this study included either eGFP or Factor IX 
transgenes. 
Δ 
a 
c 
d 
b 
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3.1.1.2  Comparison between VCN data obtained from Southern 
blotting and QPCR 
 
Montini et al (2009) showed that VCN can contribute to vector mediated 
oncogenesis using a mouse model predisposed to oncogenesis with mutations 
effecting both p53 and Rb pathways.  
VCN was established in EIAV, FIV and HIV infected liver tissues from the mice and 
shown in Table 42. Standards for VCNs were obtained from Southern blot analysis 
of clonal mouse tumours infected by EIAV vectors (see Appendix 7) carried out 
prior to the work presented here. These Southern blots showed clear bands of 
provirus insertions with each band representing a single proviral integration site. 
Based on these VCNs QPCR was used to establish VCN in infected tissues. QPCR 
failed to detect provirus insertions in uninfected tissues as expected but identified 
insertions in the known clonal tumour samples. QPCR results of animal samples are 
shown in Table 42.  
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Table 42. Vector copy number in infected livers and tumours 
 
 
Vector Mouse name  
 
Gender Age of mouse Normal liver 
VCN (+/- SEM) 
Tumour  
VCN (+/- SEM) 
- Uninfected  Male 578 Uninfected - 0 (0) 0 
 Angus Male 573 9.80 (0.62) 5.78 (0.42) 
SMART2Z Agnus Female 487 18.69 (0.08) 8.61 (0.18) 
 Archie  Male 531 2.07 (0.14) 2.09 (0.02) 
 Adame Female 644 4.23 (0.09) 2.89 (0.67) 
 Gina Male 127 4.81 (0.11) 8.05 (0.56) 
 Gerty  Female 162 
 
0.004 (0.01) NI 
 Golliath Male 537 5.74 (0.00) 4.34 (0.22) 
SMART2ZWΔ Gladys Female 369 2.61 (0.04) 6.47 (0.14) 
 Gerry Male 279 45.16 (0.09) T(1) 86.34 (0.10) 
T(2) 202.13 (0.03) 
 Gonzo Male 640 0.01 (1.12) Bone mass 0.07 (0.79) 
SMART2 hFIX 
 
Jonas Male 348 
 
26.38 (0.14) 43.99 (0.09) 
SMART2lacZ LCMV Monika Male 229 
 
NI 2.28 (0.34) 
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SMART2lacZ rabies Rachel liver tumour Female 192 NI 1.33 (0.25) 
SMARTZ Ebola Mike Male 359 NI 1.46 (0.35) 
 Flora  Female 715 Flora N -  (OC)0.03 (0.08) 
 Frank  Male 433 0.47 (0.78) T(1)2.12 (1.43) 
T(2)5.84 (0.26) 
pLIONhAATGFP 
 
Fanny  Female 484 1.53 (0.03) T(1)2.30 (0.26) 
  T(2)12.75 (0.05) 
 
 Fiona  
 
Female 273 14.61 (0.14) 
 
T(1)3.28 (0.34) 
T(2)5.15 (0.37) 
 Topsy  Female 657 0.73 (0.40) (adrenal mass)None 
 Tilley liver  Female 694 2.70 (0.00) liver mass 0.32 (0.09) 
HR’SIN-cPPT-S-FIX-W Kostas liver Male  0.19 (0.10) None 
 Bruce liver Female  0.21 (0.04) None 
 Pierre liver Male  0.21 (0.10) None 
 
Table 42. Animal tissues subjected to QPCR to determine VCN using primer/probes that recognised EIAV Packaging Signal (PSI) of the EIAV SMART 
vectors and the WPRE sequence present in the HIV and FIV vectors found inserted in mouse (MF-1 strain) genomic DNA. Values obtained from samples 
with known copy number found by Southern analysis were used to calculate VCNs in infected livers and tumours. VCNs varied widely regardless of the 
dose of vector used for infection (Appendix 1). Hence, it is difficult to control VCNs in treated mice.  Interestingly, VCNs in HIV infected samples were all 
below 3 in contrast to those found in EIAV and FIV tissues. These low VCNs may be the reason why no tumours were identified in HIV treated mice. NI 
represents samples not investigated in this study due to the absence of tissues. Samples with results of ‘’none’’ failed to develop liver tumours. LCMV = 
lymphocytic choriomeningitis virus envelope, Ebola = Ebola Zaire envelope, Rabies = rabies envelope. OC = Ovarian cyst.
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The mean VCNs in normal mice treated with SMART2Z and SMART2ZΔ were 
found to be 8.7 (SEM – 3.7) and 11.7 (8.4), respectively. Student T-test analysis 
failed to find any significant differences between VCN values obtained from normal 
mice treated with SMART modified and unmodified vector constructs. The VCN 
values obtained from mouse tumour samples infected with SMART 2Z and 
SMART2ZΔ were 4 (SEM - 1.5) and 36.3 (SEM - 22.7), respectively. Again T test 
analysis failed to identify any significance between the VCN values obtained from 
tumour samples of these groups. Interestingly Gerry T1 and T2 samples yielded high 
VCN values of 86.397 (0.10) and 202.314 (0.03), respectively.  These samples 
contributed to the large range of VCN values represented by the SMART2ZΔ group. 
VCN values obtained from SMART2 vectors showed that VCN varied greatly 
between mice that received the same dose of vector (Table 42).  The VCN results 
taken from normal FIV infected mice ranged from 0.474 (SEM - 0.8) to 14.606 
(SEM - 0.1) in normal samples. In comparison VCN values obtained from FIV 
treated tumour tissue ranged from 0.026 to 12.752. Similarities between the VCN 
data obtained from normal and tumour FIV infected samples yielded P values that 
were not significant (>0.05). However, this range of VCN values seen in FIV treated 
mice show once again the large variation in VCNs in mice receiving the same vector 
dose. HIV VCN results were significantly lower than those collected from FIV 
tumour samples (p<0.05). Mice infected with HR’SIN-cPPT-S-FIX-W had a mean 
VCN value of 0.573 (SEM - 0.31). The low VCN values found in HIV infected 
samples suggest the absence of tumour development in HIV infected mice may be 
due low vector copies. However, Flora ovarian cyst produced a VCN value of less 
than 1 (0.03). This suggests that other factors apart from VCN may play a role in 
oncogenesis.   
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We determined whether the VCN obtained from QPCR analysis correlated with the 
Southern blot VCNs previously obtained (Table 43). These results were then 
compared to the diploid VCN per genome values found using QPCR. The QPCR 
VCNs closely agreed with those found by Southern analysis of Angus T, Adame T1, 
Gina T, Rachel and Fiona T2 tumour samples and confirmed a wide variation of 
vector copies between infected tissues. Certain tumour samples that had broad bands 
following hybridisations on Southern blot membranes prevented accurate calculation 
of provirus copies. Examples of these include those found in Gerry T1 and T2 
samples. 
 
Table 43. Comparison between VCN data obtained from Southern blotting and QPCR. 
Tumour samples QPCR 
VCN 
Southern blot VCN 
Uninfected 0 0 
Angus T  5.78 9 
Agnus T 8.61 10 
Archie T 2.09 3 
Adame T1 2.89 3 
Gina T 8.05 8 
Goliath T1 4.34 2+ smear 
Gladys T 6.47 2 + smear 
Gerry T1 
Gerry T2 
86.34 
202.13 
Thick smear difficult to identify specific 
bands 
6 + thick smear 
Gonzo BM 0.01 0 
Jonas LT 43.99 
 
5 
Monika 2.28 1 
Rachel 1.33 1 
Mike 1.46 Smear 
Flora Ovarian Cyst 
(FOC) 
0.03 1 
Frank T1 
 Frank T2 
2.12 
5.84 
Thick smear difficult to detect individual 
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 bands 
2 
Fanny T1 
Fanny T2 
2.3 
12.75 
 
6 thick merging bands possibly more 
5 thick merging bands possibly more 
Fiona T1 
Fiona T2 
3.28 
5.15 
 
5 
6 
Provirus copies between samples examined using Southern blotting and QPCR were in close 
agreement. Where thick bands were found suggestive of two or more provirus insertions, 
estimation of VCN is given. 
 
 
To determine any relationship between VCN and age of onset of oncogenesis, values 
for each parameter were plotted and examined. Figure 14 and 15 shows that no 
correlation between VCN and age of death exists following EIAV or FIV infection.  
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3.1.1.3  VCN measurements in EIAV infected mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. EIAV infected samples: Graphs a. and b. showing age at death versus VCN. Each 
dot represents a tissue sample derived from an EIAV infected mouse. The dose used for 
infections was 1.2x107 and the age of death varied between 127 and 644 days in treated mice. 
VCN did not correlate with age of death suggesting other factors may be associated with vector 
may mediate oncogenesis.  
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3.1.1.4  VCN measurements in FIV infected mice 
 
 
Mice treated with FIV vectors (3 normal and 7 tumours) were also examined to look 
for correlation between age of death and VCN. Again no correlation was found 
between age of death and VCN in FIV treated mice (Figure 15). 
 
 
Age at death (days) 
 
 
 
 
Figure 15. FIV infected samples: Graphs a. and b. of age at death versus VCN. Each dot 
represents tissue from an infected mouse. The dose used for infections was 1.0x107. Ages at 
death varied between 127 and 644 days in treated mice and VCN did not correlate with age of 
death.   
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3.2.2  Retrieval of proviral insertion sites and flanking genomic 
sequences by LAM PCR and BLAST analysis 
 
 
Previous gene therapy trials revealed that vector integration may produce unwanted 
side effects including clonal dominance and oncogenesis (Hacein-Bey-Abina, 2003; 
Ott et al, 2006; Schmidt, et al, 2007).  
LAM PCR is able to detect vector genome junctions in a sample and retrieve 
integrations from clones even at the single cell level (Smidth et al, 2002; 2007; 
2009). This has allowed for examination of integration site distribution and to study 
side effects of vector integration in the host genome. Several studies have utilised 
this method to retrieve retroviral integration sites (Schmidt
 
et al, 2003, Themis et al, 
2005; Hayakawa, et al, 2009).  
In the previous study conducted by Themis et al (2005) LAM PCR analysis was 
used to retrieve 26 unique lentiviral insertion sites but failed to identify any CIS in 
tumour samples (n = 8)  treated with SMART2 vectors. In this chapter vector 
integration sites were retrieved from FIV infected tissue samples to try to identify 
insertions that could be associated with oncogenesis. LAM PCR was performed on 
six liver tumours, one normal liver and one Ovarian Cyst sample. Unique integration 
sites were identified representing clonal insertions. In addition, 2 insertion sites were 
retrieved from non-clonal tissue. All LAM PCR products were run on agarose gels 
(Figure 17) and each band represents a single provirus insertion. Some normal 
samples gave the appearance of smears that are representative of multiple non-clonal 
insertions. LAM PCR did not detect proviral integration sites in uninfected control 
samples (Figure 17). Proviral insertions sites were also not identified in blank control 
samples (Lanes 1, 2 and 8).   In order to reveal the identity of mouse genomic 
sequences LAM PCR products were cloned and subjected to DNA sequencing using 
an automated capillary DNA sequencer (Dundee DNA Sequencing Services, UK). 
Integration sites were visualised as chromatogram sequences (Figure 18).  
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Basic Local Alignment Search Tool (BLAST) is a program that allows researchers to 
compare protein or nucleotide queries with bioinformatic databases for sequence 
similarities (Altschul et al, 1997; McGinnis and Madden, 2004). Each LAM PCR 
product was exported into the BLAST program to retrieve sequences which shared a 
close homology with mouse genomic sequences found flanking the provirus. 
The chromosome positions and names of well matched query sequences (>95%) 
were retrieved from the database. BLAST software was also used to annotate 
nucleotide sequences representing vector integration sites. Sequences annotated 
included the linker cassette, FIV LTR and pDRIVE cloning vector. A full list of 
known nucleotide sequences representing LAM PCR proviral insertions sites  
are provided in the Appendix 8. 
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LAM PCR revealed several unique insertion sites. 
 
 
 
 
 
Figure 16. Schematic image of FIV vector and oligo sequences used in LAM PCR analysis. Oligo sequences were designed to hybridise to FIV LTR sequences. 
Biotinylated primers (5A and 5B) were used to produce biotin labelled linear PCR products containing the FIV vector and flanking genomic sequences. These oligos 
were used to generate a linear product containing viral LTR sequences and flanking mouse genomic sequences. 5A and 5B oligos were positioned at 3498-3479bp 
and 3554-3536bp, respectively. First and second round PCR steps used linker and vector specific (5C and 5D) oligo sequences. 5C and 5D oligo sequences 
hybridised to sequences located at 3597-3580bp and 3605-3588bp in the pLIONhAATGFP vector construct. 
 
 
3605-3588 
3597-3580 
3554-3536 
3498-3479 
Host DNA Linker 
Names & positions 
of LAM PCR oligos in 
FIV vector sequence 
(see Appendix 2). 
 
5B 
5A 
5C 
5D 
5LTR 
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Figure 17. Proviral insertion sites retrieved from tumours: integrated provirus bands from each DNA 
sample was compared to two standard 1kb markers (* & □).  LAM PCR products were cloned into the 
pDRIVE plasmid and sequenced using automated capillary sequencing methodology.  
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Figure 18. Schematic diagram of a chromatogram sequence representing a LAM PCR retrieved 
integration site from an FIV vector. Coloured peaks represent fluorescently labelled nucleotide 
bases. Blue, red, black and green peaks represent cytosine (c), thymine (t), guanine and 
adenosine (a) nucleotides, respectively. Chromatagram files containing mouse genomic 
sequences were exported to a FASTA format and aligned to the mouse genome using the 
BLAST (Basic local alignment search tool) database http://blast.ncbi.nlm.nih.gov/Blast.cgi  
(accessed online 2008).   
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3.2.3  Analysis of the position and role of EIAV and FIV insertion 
genes - gene ontology 
 
The gene ontology (GO) of all provirus insertions was also identified using mouse 
genome databases including the MGI Mouse database 
http://www.informatics.jax.org/genes.shtml. 
EIAV integration sites in tumours derived from EIAV infected mice were also 
retrieved using 454 sequencing. 454 sequencing is a highly sensitive method that 
generates simultaneous sequencing data (‘reads’) (Margulies et al, 2005).  
25 FIV and 16 EIAV sequences were retrieved by LAM PCR and 454 sequencing. 
These sequences were examined to identify insertion sites within 100kb of known 
RefSeq genes. 
Genomic sequences obtained from BLAST analysis were imported into the RTCGD  
Database (http://rtcgd.abcc.ncifcrf.gov/) (Table 44). This database describes the 
genomic position and orientation of several retroviral integration sites (RIS) that 
have been cloned from mouse tumours (Akagi et al, 2004). A ‘hit’ was used to 
describe a gene that had been previously identified and associated with oncogenesis 
in mouse tumour models. Common insertion sites (CIS) describes genomic regions 
with insertions occurring in more than one tumour and more likely to encode a 
disease causing gene. This study recovered several unique insertion sites in EIAV 
and FIV infected tumour DNA samples. Analysis of these insertions suggests that 
the HCCs are heterogeneous nature as no CISs were found (Table 44). This has 
previously been described for solid tumours where oncogenesis is believed driven by 
the activation of several pathways (Avila et al, 2006). Interestingly, 67% and 33% of 
FIV tumour insertions were positioned in the positive and negative orientation, 
respectively, to the transcriptional direction of the inserted gene (Table 44). 
The distribution of proviral integration sites was also examined to identify any 
preferences for integration in the mouse genome.  A small proportion of insertions 
found in this study have been described as RIS insertions in the RTCGD Database. 4 
integrations (Smg6, Tmem68, Bre and Pah) from EIAV associated tumours were also 
RIS hits (Table 44). These insertion genes were obtained from Jonas and Adam 
tumour DNAs.   RIS ‘hits’ were also identified in Frank T2 (Coro7), Fiona T2 
(Pscd3) and Fanny T1 (NFI/B) tumour samples (Table 44). The RTCGD database 
also showed ‘hits’ for the Smg6 (9), Tmem68, (1) Bre (2) and Pah (1) genes, 
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respectively. Interestingly an RIS ‘hit’ was also identified for Clecd a provirus 
insertion site isolated from Frank normal hepatic tissue. Although no CIS’s were 
identified in this study, of the 24 insertions found 12.5 % and 16.5% were identified 
to be involved in signalling and cell cycle/cell division processes respectively. 
Interestingly 58% of FIV insertions are known to play a role in binding functions 
and mechanisms.  The failure to identify CIS may be due to small number of 
provirus insertions studied. High sequence counts retrieved from the EIAV study 
found 7 CIS’s. RefSeq genes and possible hotspots for provirus integration in Adame 
tumour tissue included Pah, LOC382044 and Acvr2a. 2 and 3 hotspots were 
retrieved from Gerry and Jonas tumour samples respectively (Table 44).  
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Table 44.  Vector integration sites in FIV and EIAV infected tumours: 
 
Mouse Number 
(Tumour) 
Chr Nearest' RefSeq 
Gene 
ORI 
vector
/gene 
Identity Molecular Function Ontology and Biological 
Process 
RTCGD 
CIS 
RTCGD 
RIS 
Relationship to Cancer 
EIAV 
SMART 2ZWD  
Jonas LT 
 
11 Int 10 of Smg6 + Telomerase subunit 
EST 1A 
DNA binding Telomerase-dependent 
telomere maintenance 
Yes 9 hits Associated with cancer 
5 Int 2 of Bre + Brain and 
reproductive organ-
expressed protein 
Tumour necrosis 
factor receptor 
binding 
DNA repair, apoptosis, 
response to DNA damage 
None 2 hits Oncogene 
3 5’ of Slc7a12 + solute carrier family 7 
(cationic amino acid) 
Amino acid 
transporter activity 
Amino acid transport; 
Transport 
No; 2 
other Slcs 
are CIS) 
None None 
12 Int 1 of Mark3 + MAP microtubule 
affinity-regulating 
kinase 3 
ATP binding; Protein 
serine/threonine 
kinase activity; 
Transferase activity 
Protein amino acid 
phosphorylation 
None None oncogene; Wnt-signaling 
activator 
10 Int 1 of Katna1 + Katanin p60 (ATPase-
containing) subunit 
A1 
Hydrolase, ATPase 
and Nucleoside-
triphosphatase 
activity; Nucleotide 
binding 
Cytokinesis; Protein 
localization; Mitosis; Cell 
cycle 
None None choriocarcinoma-related gene 
SMART2ZWD  
Jonas ST 
 
4 Int1 of Tmem68 
 
 
- Transmembrane 
protein 68 
Acyltransferase 
activity; Transferase 
activity 
Phospholipid biosynthesis No; 5 
other 
Tmems 
are CIS 
1 hit Associated with oncogenesis 
3 Int 1 of Foxo1 + Forkhead box O1a Transcription factor 
activity; DNA binding 
Insulin receptor signaling 
pathway; Regulation of 
proliferation/transcription  
No; 
Foxo3a; 1 
hit 
None TSG and oncogene associated 
9 Int 18 of Smarce1 + SWI/SNF related 
matrix associated 
DNA binding; 
Chromatin binding  
Regulation of transcription, 
chromatin and structure  
None None oncogene Brg1 associated factor 
8 3’ of Irs2 - insulin receptor 
substrate 2 
Receptor activity, 
protein kinase binding 
Cell proliferation, insulin 
receptor signaling, cell 
migration 
No; Irs4; 
1 hit 
None Ret oncogene co-factor 
19 3’ of Aldh1a7 - Aldehyde 
dehydrogenase family 
1 subfamily A7 
Aldehyde 
dehydrogenase 
(NAD) activity; 
Oxidoreductase 
activity 
Retinal metabolism; 
Metabolism 
No; 
Aldh1b1 1 
hit 
None TSG 
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Mouse Number 
(Tumour) 
Chr Nearest' RefSeq 
Gene 
ORI 
vector
/gene 
Identity Molecular Function Ontology and Biological 
Process 
RTCGD 
CIS 
RTCGD 
RIS 
Relationship to Cancer 
EIAV          
 9 3’ of Oxsr1 - Oxidative-stress 
responsive 1 
ATP binding; Protein 
serine/threonine 
kinase activity; 
Transferase activity 
Protein amino acid 
phosphorylation 
None None None 
SMART 2ZWD 
Gerry T1 
 
6 Int 1 of Setd5 + SET domain 
containing 5 
None None None None None 
5 5’ of Mrpl1 - Mitochondrial 
ribosomal protein 1 
RNA binding RNA processing, translation None None None 
SMART 2Z 
Adame T1 
 
10 Int 2 of Pah + Phenylalanine 
hydroxylase 
Amino acid binding, 
metal ion binding, 
monooxygenase and 
oxidoreductase 
activity 
Metabolic and oxidation 
reduction activity 
None 1 hit Reduced expression in cancer 
8 Int 2 of  
LOC382044 
- Predicted gene 5158 None None None None None 
2 5’ of Acvr2a + Activin receptor IIa Activin receptor 
activity, ATP, growth 
factor, metal ion,  
nucleotide binding, 
serine/threonine 
kinase activity and 
receptor activity 
Activin receptor regulation 
of BMP signalling and 
nitric-oxide synthase 
activity, development, 
protein/amino acid 
phosphorylation, cell 
proliferation; 
serine/threoinine kinase 
signalling receptor  
None None Associated with BMP in breast 
cancer 
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Mouse Number 
(Tumour) 
Chr Nearest' RefSeq 
Gene 
ORI 
vector
/gene 
Identity Molecular Function Ontology and Biological 
Process 
RTCGD 
CIS 
RTCGD 
RIS 
Relationship to Cancer 
FIV          
pLIONhAATGFP 
Fanny T1 
6 Int 10 of Sgce + Sarcoglycan epsilon  Calcim ion and 
protein binding; 
membrane 
stabilization 
None    None None         Associated with HCC.  
 6 3' of Peg10 + Paternally expressed 
10 
DNA and metal ion 
binding 
Differentiation, placental 
development and apoptosis;  
None None Associated with HCC 
 6 5' of Casd1 - CAS1 domain 
containing 1 
None None  None None None 
 13 5' of  Ankrd32 + Ankyrin repeat 
domain 32 
Protein binding None None None None 
 4 Int 8 of NfI/B + Nuclear factor I/B  DNA binding; 
transcription activator 
protein; transcription 
factor activity;  
Development, regulation of 
cell proliferation and 
transcription  
None 3 hits Oncogene; Blm TSG associated 
 19 17288 bp at 5' 
side: Pdcd1lg2 
 
+ Programmed cell 
death  1 ligand 2 
protein binding, 
receptor activity 
regulation of T-cell 
proliferation 
None None None 
 18 27028 bp at 5' 
side: CX39/Gjd4  
 
- Connexin 39/Gap 
junction protein delta 4  
 
Gap junction channel 
activity 
Cell communication None None None 
 18 7093 bp at 3' side: 
Similar  to Cyclin 
fold protein 1- 
humans 
- Cyclin fold protein 1  Cyclin dependant 
protein kinase 
regulator activity; 
protein kinase binding 
Cell cycle, cell division, 
Wnt signaling pathway 
None None None 
pLIONhAATGFP 
Fiona T1 
3 Int 6 of Pglyrp4  - Peptidoglycan 
recognition protein 4 
N-acetylmuramoyl-L-
alanine amidase 
activity; protein 
binding 
Immune response; 
petidoglycan catabolic 
process 
None None None 
1 5' of Terf1                                                          - Telomeric repeat 
binding factor 1 
DNA binding, protein 
binding, telomeric 
DNA binding 
cell cycle, division, mitosis, 
regulation of transcription, 
telomere maintenance 
None None Associated with 
hepatocarcinogenesis 
5 5' of  Mob1 + Mps One Binder 
kinase activator-like 
1A 
kinase activity; 
protein, metal ion 
binding 
protein modification 
process 
None None Activates LATS1 TSG 
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 11 LOC627244 5’ of 
Cob1 
3’Stk16 
+ 
 
+ 
Cordon Bleu 
 
Serine/threonine 
protein kinase 
Protein binding 
 
Kinase activity, DNA 
binding, ATP binding 
Neural tube closure 
 
Control of 
growth/development 
None 
 
None 
None 
 
None 
Associated with microsatellite 
instability in colorectal tumours 
Putative oncogene 
 1 3‘ of Tram1 - Translocating chain-
associating protein 1 
Protein targeting Intracellular trafficking and 
secretion 
None None None 
pLIONhAATGFP 
Fiona T2 
 
5 Int 1 of Pscd3 + Pleckstrin homology, 
Sec7 and coiled-coil 
domains 3 
ARF guanyl-
nucleotide exchange 
factor activity 
regulation of ARF protein 
signal transduction 
None 2 hits Associated with suppression of 
metastasis 
 5 5' of Usp42 + Ubiquitin specific 
peptide 4 
 
ubiquitin cycle None None None None 
 5 
 
5 
5'  of  Slc16a4 
 
3'  of  Rbm15 
+ 
 
+ 
Solute carrier family 16, 
member 4 
RNA binding motif 
protein 15 
None 
 
nucleic acid binding 
None 
 
Positive regulation of Notch 
receptor 
None 
 
None 
None 
 
None 
None 
 
Regulator of cMyc oncogene 
pLIONhAATGFP 
Flora Ovarian Cyst 
14 3’ of Sacs + Sacsin ATP binding, heat 
shock protein binding 
and lipoprotein 
receptor binding 
None None None None 
14 5’ of Tnfrsf19 + Tumour necrosis 
factor receptor 
superfamily, member 
19  
Receptor activity  Hair follicle development  None 
 
None Associated with gastric 
carcinogenesis 
13 5’ of Prl2c3, 3’ of 
LOC226089 
+ Prolactin family 2, 
subfamily c, member 
3 
Growth factor 
activity; hormone 
activity;  
Positive regulation of cell 
proliferation 
None 
 
None Associated with breast cancer 
pLIONhAATGFP 
Frank N 
6 1053bp at 3’side 
of  Clec2d 
 C-type lectin domain 
family 2 member d 
Natural killer cell 
lectin-like receptor 
binding, protein 
binding, 
transmembrane 
receptor activity, 
sugar binding 
Cellular defense response, 
negative regulation of 
osteoclast differentiation, 
protection from natural 
killer cell mediated 
cytoxcity, signal 
transduction. 
None 1 hit  None 
 6 93876bp at 5’side: 
Clec2e 
 C-type lectin domain 
family 2 member e 
Sugar binding, 
receptor activity. 
Signal transduction None None None 
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Table 44. Vector integration analysis: a list of integration sites were mapped to the nearest RefSeq genes using the MGI database. The gene ontology of 
mouse chromosomes and genes identified by BLAST analysis were used to provide the molecular functions and biological processes listed in mouse 
genome databases. These generated GO terms for molecular function including binding, receptor activity and transferase activity and biological 
processes such as cell proliferation. The functional relationship of these genes to cancer was found using the RTCGD (retroviral tagged cancer gene 
database) and literature searches. Ori = orientation of vector into the host genome.  Chr = chromosome identity. 
 
 
 
pLIONhAATGFP 
Frank T1 
12 Int 6 of Nek9 - NIMA(never in 
mitosis gene A)- 
related expressed 
kinase 9 
Metal ion binding, 
nucleotide binding, 
serine/threonine 
kinase activity and 
transferase activity 
Cell cycle; cell division; 
mitosis; protein amino acid 
phosphorylation 
None 
 
None Nek family involved in cancer 
3 Int 6 of Pglyrp4  - Peptidoglycan 
recognition protein 4 
N-acetylmuramoyl-L-
alanine amidase 
activity; protein 
binding 
Immune response; 
petidoglycan catabolic 
process 
None None None 
pLIONhAATGFP 
Frank T2 
16 Int 9 of Coro7 + Coronin 7 ND ND None 3 hits 
 
  
None 
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4.1 Provirus integration can influence gene expression. 
 
Provirus insertion has been shown to influence normal transcription of cellular genes 
through the use of potent regulatory regions (Coffin et al, 1997; Montini et al, 2006; 
Nienhuis, Dunbar and Sorrentino, 2006; Pajer et al, 2006; Coffin and Jern, 2008). 
The integration of RV DNA into the host-cell genome may result in insertional 
mutagenesis as discussed in chapter 1. The integrated provirus may affect adjacent 
genes through promoter insertion or enhancer (Uren et al, 2005; Martin-Hernández 
et al, 2006).  
Gene expression changes are often a direct result of LTR insertions found upstream 
of genes in the antisense orientation and downstream in the sense direction (Coffin et 
al, 1997; Boonyaratanakornkit et al, 2004 Coffin and Jern, 2008). The danger is that 
interaction between the integrated RV LTR sequence and cellular transcription 
factors may result in activation of adjacent cellular proto-oncogene’s and oncogenes 
(Gonda et al, 1987; Coffin et al, 1997; Montini et al, 2006; Coffin and Jern, 2008; 
Bosticardo et al 2009). Several proto-oncogenes encode transcription factors that are 
deregulated by mutation or elevated in human tumours (Degado et al, 2006). 
Girad et al (1996) reported increased levels of Notch1 in 52% of tumours as a result 
RV transduction in transgenic mice. This study showed that provirus insertion 
upstream of the Notch1 oncogene was linked to elevated levels of full length and 
truncated Notch1 proteins (Girad et al, 1996).  Martin-Hernández et al, 2001 also 
demonstrated LTR mediated activation of N-ras and induced lymphoma 
development following provirus integration into the N-ras/unr locus.  
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4.1.1  Provirus and splicing mechanisms: the effect on gene 
expression 
 
Other studies have shown that proviral insertions can knock out or truncate a gene 
(Harbers et al, 1984; Pajer et al, 2006; Voigt et al, 2008). Splicing is a cellular 
mechanism used to assemble genetic molecules and is crucial to the synthesis of 
genes and proteins in eukaryotes.  RNA splicing describes the process by which 
introns are removed and exons joined to yield a primary transcript (Norton, 1994; 
Black, 2003; Matlin, Clarke and Smith, 2005). Several factors can contribute to 
alternative splicing including exon skipping, the presence of alternative donor sites 
and intron retention (Fackenthal and Godley, 2008). Introduction of provirus 
insertions can also induce genomic rearrangements through splicing and 
recombination mechanisms. This process is facilitated by the inclusion of viral splice 
donor and acceptor sites within the vector construct (Raineri and Senn, 1992; Brandt 
et al, 2005). The production of chimeric transcripts often results in altered expression 
of host genes. Gonda et al (1987) showed that RV integration can induce high levels 
of aberrant transcripts derived from the C-myb gene. A viral splice acceptor site was 
used to generate an alternative RNA product which encodes a truncated Myb protein 
and may contribute the oncogeneity of Myb in these tumours (Gonda et al, 1987). 
Overexpression of the cKI-ras protooncogene was observed in murine bone marrow 
derived cells following RV promoter insertion (Trusko et al, 1989). Trusko et al 
(1989) reported the production of an unexpected splicing event caused by the 
presence of a cryptic splice site positioned at the junction between and cellular DNA 
sequences.  
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4.1.2   Target site selection and gene expression patterns 
 
The choice of RV used in transduction protocols is also known to influence the 
pattern and levels of transcription in host cells (Hu et al, 2008). De Palma et al 
(2005) used RV promoter traps to study integration site selection in primary 
haemopoetic cells. Results showed that MLV based vectors trapped cellular 
promoters more efficiently than HIV vectors. Previous observations have shown 
MLV based vectors to associate with promoter regions and HIV based vectors to 
associate with actively transcribed regions of the host genome (Schröder et al, 2002; 
Mitchell et al, 2004; Nowrouzi et al, 2006).  
Provirus insertion may also be influenced by the nuclear architecture of chromatin 
(Albanese et al, 2008) and is also associated with epigenetic modifications (Wang et 
al, 2007). Gene expression is influenced by chromatin structure and recruitment of 
co factors (Delgado and Leon, 2006). Chromatin can be subdivided into open 
euchromatin and compact heterochromatin structures. The latter chromatin structure 
prevents interaction with transcription factors and disrupts transcription mechanisms 
(Delgado and Leon, 2006). An early study conducted by Conklin and Groudine 
reported varied integration patterns between provirus structures and adjacent host 
chromatin (Conklin and Groudine, 1986). However, this study demonstrated 
localised integration into euchromatin, exclusion of provirus insertions into 
heterochromatin regions and silencing of HIV-1 proviruses in the nuclear periphery. 
This suggests that integration sites are important to the expression of proviral and 
host cellular sequences (Dieudonné
 
et al, 2009).  
Proviral sequences may exert their effects on genes located away from the 
integration sites. Singhal et al (2011) reported long distance effects of retroviral 
vectors in mouse embryonic fibroblasts. This study showed a direct relationship 
between proviral insertions and aberrant gene expression in several mutant clones. 
Results showed that increased levels of RIPK1 and NF-ĸB expression were linked to 
provirus insertion (Singhal et al, 2011).   
In some cases provirus insertion may have little effect on neighbouring genes. 
Recchia et al (2006) studied the impact of retroviral integration on gene expression 
in transplanted T cells. T-lymphocytes were transduced with retroviral vectors 
carrying the HSV-TK (Herpes Simplex Virus –Timidine Kinase) suicide gene and 
the truncated nerve growth factor receptor (ΔLNGFR).This study measured the 
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effect of gene expression in T cell clones and found that 1/5 of target genes located 
in the vicinity of promoter regions were upregulated. These target genes were shown 
to be expressed at low levels in T cells. Interestingly this study suggests that the 
upregulation of target genes was not influenced by the distance and orientation of the 
integrated vector (Recchia et al, 2006). A long term follow up study of ex-vivo 
transduced patients found that only around 2% of the >16,000 genes measured 
showed changes in expression (Recchia et al 2006). Furthermore changes in gene 
expression failed to effect normal T cell function (Recchia et al, 2006). Another 
study by Cassani et al (2009) performed quantitative transcript analysis on T cell 
clones taken from ADA-SCID patients.  Microarray analysis was performed on 120 
genes within a 200kb radius from integrated RV sites and results showed modest 
dysregulation of 5.8% genes in 18.6% of T cell clones when compared to controls.  
 
4.2   Proviral insertions and the construction of cancer gene 
pathways 
 
Proviral tagging has been used to retrieve cancer genes in oncogene bearing and 
transgenic mouse models (Jonkers et al, 1997; Sourvinos et al, 1999; Shi et al, 2002; 
Sivasubu et al, 2007; Kool and Berns, 2009). Mutational profiling of tumours and 
RV/LV integrations from genotoxicity models and insertional mutagenesis screens 
has revealed hundreds of genes which may contribute to oncogenesis. Cancer is 
indeed a complex disease that can arise from multiple spontaneous and or inherited 
mutations that result in dramatic changes in gene expression patterns and protein 
function (Thorgeiresson, Lee and Grimsham, 2006).  It was recently reported that 
384 human genes may have a causal role cancer in cancer development. 
Furthermore, cancer associated genes compromise almost 2% of the human genome 
(Santarius et al, 2010). In evaluating the relationship between RV and  LV provirus 
insertions scientists can build potential gene pathways involved in signalling and 
cancer development (Callahan and  Smith, 2000; Kool and Berns, 2009). 
 
 
 
INTRODUCTION CHAPTER 4 
 
108 
 
4.2.1 Hepatocellular carcinoma (HCC) 
 
HCC is the fifth most common cancer worldwide and the third most common cause 
of cancer related deaths globally (Marrero and Marrero, 2007; Vinciguerra and Foti, 
2008; Olsen, Brown and Siegel, 2010). The development of HCC is associated with 
various underlying liver diseases including autoimmune hepatitis, hepatitis virus 
infection, mycotoxins, hemochromatosis and cirrhosis (Llovet and Bruix, 2008). 
Studies have also reported aflotoxin B1 ingestion as a major risk factor in HCC 
development within sub-Saharan Africa and Asia but not in Western countries 
(Clavien and Breitenstein, 2009). Other studies have shown HCV infection to be a 
major pre-determinant - accountable for 70% of HCC cases in Japan (Clavien and 
Breitenstein, 2009). Several genetic mutations exist in HCC patients including that 
of p53 (Tannapfel and Wittekind, 2002). Disruptive mechanisms which contribute to 
these mutations include epigenetic events activation of oncogenes, inactivation of 
tumour suppressor genes and or loss of function mutations.  Further work is needed 
to improve understanding of the molecular pathogenesis which contribute to HCC 
and identify key targets/markers for therapeutic treatment (Thorgeirsson, Lee and 
Grisham, 2006). Despite these multifactorial challenges recent experimental studies 
in animal and human models have been able to identify some mechanisms which are 
frequently disrupted in HCC and link common genetic mutations. Transcriptional 
analysis of HCC has identified that this disease is associated with several pathways 
including immune responses and protein deregulation (Thorgeirsson and Grimsham, 
2006). Genome wide analysis performed by Lee and Thorgeiresson (2004) found 
clusters in genes including anti-apoptosis, cell proliferation and cell survival.  
The main objective of this study is to test the hypothesis that LV integration alters 
the expression of RefSeq genes flanking the provirus site. The expression of these 
genes in liver tumours was compared to that of normal tissue and gender matched 
tumour samples. The second objective of this study was to investigate the possibility 
that multiple proviral insertions could induce HCC development. 
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4.3   Investigation of vector associated genotoxicity in mice 
following in utero delivery of EIAV, FIV and HIV vectors.  
 
4.3.1  RT PCR analysis of tumour gene expression linking 
pLIONhAATGFP FIV derived vector insertions with alterations in 
gene expression 
 
After retrieving FIV integration sites from the mouse tumours a study of the 
relationship between vector insertion and gene expression was investigated using RT 
PCR. RT PCR reactions were performed in normal and tumour DNA samples 
derived from FIV infected liver and gonad tissue. Preliminary amplification 
reactions of the GAPDH house keeping gene was used to measure the quality and 
integrity of the cDNA samples. RT amplifications showed clear bands that 
demonstrated the cDNA to be of high quality (Figure 19).  
 
 
Figure 19. An example of GAPDH expression is shown for female normal liver (5, 9 and 13), 
Flora Ovarian Cyst (lane 6, 10 and 14), Fiona T1 (lanes 7, 11 and 15) and Fiona T2 (lanes 8, 
12 and 16) samples. 
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Band intensities between tumour samples and respective normal livers were used to 
reveal differences in gene expression levels. Relative gene expression levels were 
calculated by measuring the fluorescence peaks produced by single bands on an 
agarose gel.  Each peak provided an area value. The average area value for each gene 
was taken and average area values were normalised against GAPDH area values to 
produce relative gene expression levels.  In Flora ovarian cyst (20b) Tnfrsf19 was 
found knocked down completely. Interestingly Cx39 (Fanny T1), Nek9 (Frank T1) 
also showed reduced expression in tumour samples containing insertions when 
compared to normal livers.  
C-protein (Similar to Cyclin fold protein 1- humans), Pscd3 and Coro7 expression 
was increased when compared to gender matched normal samples. However, Coro7 
expression was also increased in Frank T2 samples. Sacs gene expression remained 
the same in samples with insertions and the tumour reference sample. However, Sacs 
expression in the tumour with insertion in this gene was lower than that in normal 
liver (Figure 20a). 
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Figure 20 a – g. The expression levels of genes were measured in samples where FIV 
insertions were found. All gene expression amplification reactions were performed in 
triplicates. Average triplicate readings obtained from each insertion gene was normalised 
against the average reading obtained from GAPDH expression. Error bars represent standard 
deviation values obtained from triplicate readings. Gender matched normal liver and tumour 
samples were used as reference samples for changes in gene expression.  
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The association between FIV insertions and differential gene expression suggested 
FIV integrations could be involved in oncogenesis. QPCR is a highly sensitive assay 
also used to investigate differential gene expression and is an ideal tool to use to 
measure small changes in gene expression that RT PCR may not have identified. 
TaqMan probes and primer sets were obtained and used on the FIV infected samples. 
Controls consisting of gender matched normal and tumour samples were used for 
comparison of gene expression. In Frank T1 samples Nek9 was found reduced when 
compared to normal liver (Table 45; P <0.05) and a gender matched tumour control 
sample (P <0.01). This reduction in expression was in agreement with that found for 
Nek9 in Frank T1 by RT PCR.  
QPCR also showed that Pscd3 was up regulated in Frank T2 samples by 29%. This 
also agreed with RT PCR measurements. Coro7, Nek9 and Tnfrsf19 were 
downregulated in Tumour 1 samples by over 19%, 3 and 2% respectively and was 
also found by RT PCR. QPCR failed to identify the expression of cx39 and pdcd1lg2 
in tumour samples and yielded very low (CT > 36) in normal liver samples. 
RT PCR did not identify expression of Pdcd1lg2 this suggests that this gene is 
expressed at very low amounts in this sample. 
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4.3.2 Real time PCR measurement of transcription levels of genes 
with FIV provirus insertions using QPCR analysis 
 
Gene name Tumour 1 +/-SEM Tumour 2 Insertion change 
FIV    
 Frank T1 Frank T2  
Nek9 0.11 (0.22)    3.78 (0.11) Down-regulated  
 Frank T2 Frank T1  
Coro7 0.11 (0.19) 19.48 (0.02) Down-regulated 
 Flora ovarian cyst Fiona T1  
Tnfrsf19  0 (0)    2.69 (0.20) Down-regulated 
 Fiona T2 Fiona T1  
Pscd3 33.67 (0.06) 3.88 (0.02) Up-regulated 
 
 
Fanny T1 Fanny T2  
Cx39 0 (0) 0 (0) No change  
(no expression) 
Pdcd1lg2 0 (0) 0 (0) No change 
Total deregulated 4   
 
Table 45.  All gene expression experiments were performed in quadruplets and repeated on 
separate occasions. The conditions for all amplification reactions were optimised and a 
validation efficiency test was performed. 18sRNA expression was used to normalise gene 
expression for all samples FIV infected samples. Tumour 1 and tumour 2 represent samples 
with and without insertions, respectively.  Statistical analysis including the Student T test and 
95% confidence interval testing was performed on all QPCR data.  P. values were calculated for 
comparison between normal vs Tumour 1 and Tumour 1 vs Tumour 2.  
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4.3.3 QPCR analysis in EIAV infected samples 
 
 
EIAV insertion genes were also observed for changes in gene expression to 
determine whether this pattern also occurs for genes carrying EIAV insertions. 
Several insertion genes showed changes in their tumour of origin (described in Table 
45 and 46 as tumour 1). Park7 was identified as a hotspot for EIAV insertion genes 
in previous (Themis et al, 2005) and current data described in this study. This 
putative oncogene is known to be over expressed in cancer (Nagakubo et al, 1997; 
Sitaram et al, 2009; Vasseur et al, 2009). Upregulation of Park7 was seen in the 
tumour without insertion but in tumour 1 was downregulated when measured by 
QPCR and in the microarray of this tumour (Table 46). Preparation of RNA and 
collation of raw data for microarray analysis was conducted by Dr Manfred Schmidt 
(National Center for Tumor Diseases and German Cancer Research Center, 
Heidelberg, Germany). Acvr2a belongs to a family of activins involved in 
transforming factor beta (TGFβ) signaling. Disregulation of activins such as Acvr2a 
has been shown in diseases such as cancer (Chen et al, 2006; Li et al, 2006; 
Tsuchida et al, 2009). This gene was upregulated by 13% in tumour 1. This level of 
gene expression was higher than that found in normal liver (P<0.05) but lower than 
the tumour without the insertion (P <0.01). The Pah gene was shown to produce a 
high sequence count in Adame T1 samples. QPCR showed down regulation of this 
gene in the tumour containing the insertion when compared to normal liver (P <0.05) 
and the tumour without the insertion (P <0.01). Reduced expression of the Pah gene 
was also found by microarray of this tumour (Table 46).  
 
Rabgef1 and Mrlp23 were both upregulated in tumour 1 (Jonas Large tumour) and 
tumour 2 (Table 49).  Upregulation of this gene was also observed in microarray 
analysis (Table 49).  
The expression of Park7, Rabgef1, Mrlp23 and Uvrag was measured in additional 
male mouse uninfected liver samples (Cat and Uninfected liver sample shown in 
Table 49; Appendix 4) and a gender matched FIV infected tumour (Frank T2). These 
additional reference samples (shown in red) produced variable changes in gene 
expression when compared to tumour 1 (Jonas large tumour).  
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Bre plays a role in the DNA damage response and repair pathways and in 
inflammation. QPCR showed this gene to be down regulated in the tumour 1 sample 
(Jonas large tumour) when compared to normal (P <0.05) and the tumour without 
insertion in this gene (P<0.01). Deregulation of Bre was also shown in microarray of 
Jonas large tumour samples (Table 46). Mark3 and Katna were not analysed by 
microarray analysis however QPCR showed upregulation and downregulation of 
each gene, respectively, in tumour 1 when compared to normal liver (P <0.05) and 
the tumour without insertion in this gene (<0.01).  
 
Mrpl1 and Setd5 showed high sequence counts of 743 and 267, respectively. 
Microarray data (not shown) revealed upregulation of Mrpl1 but showed 
insignificant changes (P >0.05) in gene expression for Setd5. QPCR analysis was 
also performed on these genes, however, the integrity of RNA in Gerry tumour 1 
samples appeared reduced due to the occurrence of degradation as found by gel 
electrophoresis (data not shown). The poor integrity of this sample was also reflected 
by high 18sRNA CT values (> 16 cycles). Consequently QPCR could not be 
performed reliably on these genes. 
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Gene name Tumour 1 +/-SEM Tumour 2 +/-SEM Insertion change* Microarray 
EIAV     
 Adame T1 Fiona T2   
Acvr2a 1.30 (0.19) 10.79 (0.07) Up-regulated Nr 
Pah 0.35 (0.18) 3.70 (0.06) Down-regulated        -0.19 
 Adame T1 Fanny T2   
Hnf1a• 0.55 (0.10) 0.20 (0.26) Down-regulated Nr 
Hnf4a• 0.62 (0.10) 0.18 (0.28) Up-regulated -0.53 
Foxa2• 1.57 (0.06) 0.75 (0.23) Up-regulated Ns 
 Jonas large tumour Jonas small tumour   
Park7 0.55 (0.04) 
 
Cat 
502.61 (0.24) 
 
Uninfected liver 
Down-regulated 0.39 
 
 
 
 
 
 
0.31 (0.17) 
 
Frank T2 
2.71 (0.07) 
 
3.04 (0.12) 
 
 
 
 
 
 
 
 
 
Rabgef1 
Jonas large tumour 
2.32 (0.05) 
Jonas small tumour 
27.87 (0.13) 
 
Up-regulated 
 
Ns 
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Cat Uninfected liver 
 0.23 (0.10) 
Frank T2 
1.80 (0.41) 
 
4.69 (0.16) 
 
  
 Jonas large tumour Jonas small tumour   
Mrpl23 5.11 (0.22) 
Cat 
27.53 (0.08) 
Uninfected 
Up-regulated 0.74 
 0.40 (0.15) 
Frank T2 
14.93 (0.28) 
 
 
6.12 (0.06) 
 
  
Uvrag Jonas large tumour Jonas small tumour   
 1.28 (0.20) 
Cat 
17.85 (0.13) 
Uninfected liver 
Up-regulated 0.78 
 0.21 (0.18) 
 
2.64 (0.12) 
 
  
 Frank T2 
2.84 (0.05) 
 
   
 Jonas large tumour Monika tumour   
Bre 0.50 (0.04) 0.99 (0.07) Down-regulated -0.12 
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 Gina T1 Monika tumour   
Mark3 1.44 (0.53) 1.13 (0.03) Up-regulated Nr 
Katna 0.81 (0.06) 0.57 (0.11) Down-regulated Nr 
Total deregulated 12    
 
Table 46.  Gene expression (2ΔΔCT) were calculated for each gene and compared to gender matched tumour and normal samples. All of the top differentially  
expressed genes  (n = 500). These differentially expressed were subjected to Benjamini Hochberg correction to allow multiple comparisons of microarray data. 
Only genes that showed significant (P <0.05) after Benjamini Hochberg correction were selected. Nr and Ns were used to describe insertion genes where 
microarray data was not available and genes where p. values obtained were above significant levels (<0.05) respectively.   
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4 genes (Pah, Park7, Bre and Katna) showed reduced levels of expression following 
EIAV vector integration into these genes. Acvr2a appears upregulated when 
compared to normal liver samples. However, results show that Acvr2a was also 
downregulated in tumour 1 when compared against a tumour control. Several genes 
(Rabgef1, Mrpl23, Uvrag and Mark3) were also up regulated in tumour 1.  
 
 
 
Figure 21. Histograms were used to represent gene expression data (2-ΔΔCT). Error bars 
represent standard error of the means taken from quadruplet readings. Relative gene 
expression data for all normal liver samples were taken as 100%. The relative quantification 
(RQ) levels calculated for calibrator samples (normal liver sample) are equal to 1. The blue line 
is used to represent 100% RQ levels in calibrator samples. 
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4.3.4 Analysis of FIV insertion gene pathways by ‘STRING’ 
 
 FIV insertions that showed differential expression by QPCR and microarray 
analysis were investigated to find networks of interacting genes in pathways that are 
known to be implicated in oncogenesis and HCC development. To do this, inserted 
genes were investigated using STRING (string-db.org/) analysis. STRING provides 
networks between proteins obtained from literature as images. For example Tnfrsf19 
and Pscd3 were found to associate with the transformation related protein 53 - Trp53 
(Figure 22 a-b).  
Trp53 is a known tumour suppressor gene that regulates genes involved in several 
mechanisms including DNA repair, apoptosis and cell cycle control. Tnfrsf19 is a 
functional partner closely related to the TNF receptor associated factor 6 (Traf6) and 
is an important member of the TNFR superfamily. This gene also functions as a 
signal transducer of NF-kappa B genes involved in inflammation.  
Traf6 interacts with several cancer associated genes involved in cell cycle 
progression in response to DNA damage and cellular proliferation (Cdkn1a, Cdkn2a 
and Bcl2) and the Atm gene that is involved in DNA damage and repair mechanisms. 
Tnfrsf19 expression was found to be reduced in the Flora ovarian cyst tumour sample 
suggesting this gene to be possibly involved in oncogenesis.  
Pscd3 (Cyth3) associates closely with the RAS superfamily member ADP-
ribosylation factor 6
 
(Arf6) (Figure 22b). Arf6 interacts with the protoocogene v-akt 
murine thymoma viral oncogene homolog 1 (Akt1). Moreover Akt1 relates to the key 
tumour suppressor gene phosphatase and tensin homolog
 
(Pten). This suggests that 
Pscd3 is an important member of an oncogenesis pathway that may lead to HCC. 
Nek9 and Coro7 were also investigated in STRING, however no pathways were 
found relating these genes to other cancer associated genes.
 
 
 
 
 
 
 
 
 
 
RESULTS CHAPTER 4 
 
122 
 
 
 
 
a 
RESULTS CHAPTER 4 
 
123 
 
 
 
Figure 22 a-b. STRING analysis was used to predict protein-protein interactions between FIV 
insertion genes. The STRING database was also used to identify cancer associated genes. 
QPCR analysis was used to investigate insertion genes that interacted with known cancer 
associated genes or formed part of an oncogeneic network. 
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4.3.5 Analysis of EIAV insertion gene pathways using the STRING 
database and microarray analysis. 
 
 
EIAV insertion genes that were represented as clonal in tumours by high 454 
sequence counts with altered expression by QPCR and microarray analysis were 
entered into the STRING program as was performed for FIV inserted genes. Park7, 
Uvrag, Mrlp23, Acvr2a, Bre and Pah were each found associated with cancer genes. 
Acvr2a was found to share common activation pathways with Smad proteins 
including Smad1, 6 and 7. (Figure 23a) Inhiba/b genes are also known to be 
functional partners of Acvr2a. Smad 7 expression was not investigated in Adame T1 
samples. However, the P. Value for Smad1, Inbba and Inhibb was above the 
significance value (<0.05) used to correct samples. Park7 was found to be associated 
with the apoptotic regulator gene Bax (BCL2- associated X protein) and the tumour 
suppressor gene Trp53 (Figure 23b). Bax is a functional partner of Trp53 and the 
oncogene Bcl2. Interestingly, Bax was found to be upregulated by 18.8% in Jonas 
Large tumour compared to the normal liver control. The tumour suppressor gene 
Becn1 was also found to be associated with Bax. The tumour suppressor gene Becn1 
was found to be associated with Uvrag (Figure 23d). Microarray also showed Becn1 
was upregulated by 2.1% in Jonas large tumour however, another important gene 
included in this network is Pik3c3. Pik3c3 plays a key role in protein sorting and the 
mTOR signaling pathway and was downregulated by 17.6% by microarray. Cancer 
associated genes found in the Bre protein-protein network also include Smad and 
Brca1. Interestingly the proto-oncogene - Hras (v-Ha-ras Harvey rat sarcoma viral 
oncogene homolog) was also found in the STRING network of Mrpl23. This gene 
was not found in the microarray but shows the potential link between EIAV 
integration genes and oncogenesis.  
The Pah gene was shown to have a close interaction with hepatic nuclear factor 1 
alpha (Hnf1a), Hnf 4 alpha (Hnf4a) and fork head box a2 (Foxa2) (Figure 23f). Each 
gene was shown to be altered with QPCR analysis. Because Hnf4a is reduced in 
HCC and liver cancer, QPCR was performed on this gene and this revealed a 
reduction in its expression by 62% (P. Value <0.05) and a reduction of Hnf1a by 55 
% (P. Value <0.05) in Adame T1 tumour sample. Interestingly, a 15.7% increase in 
Foxa2 expression was found in Adame T1. 
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Figure 23 a-f. Gene pathways associated with genes flanking the EIAV provirus. Several 
SMART2 insertions were found in this study. 454 sequencing revealed 7 unique hot spots 
(repeated insertions in the same tumour) for Acvr2a, Park7, Uvrag and Bre.  These genes were 
found to be differentially expressed in the tumour of insertion using QPCR and microarray 
analysis.  Protein-protein interaction between SMART2 insertions was investigated using the 
STRING database. STRING analysis revealed important interactions with cancer associated 
genes. A) Acvr2a, B) Park7, C) Uvrag, D) Bre E).  
 
IPA analysis software was used to demonstrate the role of insertional mutagenesis 
and its role in HCC development in EIAV infected mice. Q-PCR and microarray 
showed that Uvrag and Park7 had differential gene expression in Jonas large 
tumour. STRING analysis also showed that the interaction between Bax and Trp53 is 
an important link connecting Uvrag and Park7 with several cancer associated genes 
(Figure 24). IPA analysis showed that Uvrag form part of a oncogenenic network 
with important cancer genes including Trp53, Atg7 and Bcl2 which are involved in 
proliferation of hepatocytes, tumorigenesis of mice and liver cancer respectively 
(Figure 25). This supports the role of EIAV integration into Park7 and Uvrag as 
possibly contributing to HCC. Fisher’s exact test was conducted to determine the 
statistical significance of genes enriched within a given GO category and validate 
genes overrepresented in data sets. P-values<10
−20
 or lower were used to select 
highly significant overrepresentation after Benjamini Hotchberg correction. 
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Figure 24. The relationship between Uvrag and Park7 demonstrated using STRING analysis. 
Park7 interacts with Uvrag through a common network of genes. This includes important 
cancer associated genes such as Tp53, Bax and Bcl2. 
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Figure 25. IPA analysis: Cooperation between Park7 and Uvrag was found using IPA analysis. Both genes were identified in the Jonas large tumour. 
Black lines represent interaction between Park7, Uvrag and their associated genes. Boxes are used to represent key biological processes and 
mechanisms associated with this pathway.  IPA analysis demonstrates the importance of these genes in liver cell growth, cell cycle progression and liver 
cancer and HCC.
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4.3.6 The effects of SMART2Z integration on normal splicing of the 
Pah gene 
 
In Adame T1 tissue the SMART2Z vector was found in intron 2 of the Pah gene 
(Figure 26). As aberrant splicing has been shown to occur between integrated vector 
sequences and host genes (Coffin, Hughes and Varmus, 1997; Nienhuis et al, 2006) 
this potential was investigated for SMART2Z and the Pah gene as a possible cause 
for the reduction in Pah gene expression. An in silico construct was designed in 
collaboration with Dr Evgeny Makarov (Brunel University, Uxbridge, UK) to 
represent the virus integration site (see Appendix 11). Amplification reactions were 
designed to identify the junction between the upstream region of intron 2 and the 
SMART2Z vector sequence (Figure 26). 
 
Figure 26. Predictions of the posssible splice combinations were made to repersent normal and 
abnormal splicing between the vector and all 13 exons found in the pah gene. (see Appendix 
11). Predicted fragments were generated  taking into account the presence of splice donor 
(SD) and splice acceptor (SA) sequences present in the SMART2Z vector construct. 
Oligonucleotide primers were designed to amplify genomic and cDNA samples including vir-L-
R2, In2/1.f2, Wpre forward and reverse sequences and In2/2.R1.  
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Figure 27. Several PCR reactions were designed to identify aberrant splicing leading to 
virus/host mRNAs between SMART2Z and the Pah gene. RT PCR was used to amplify the 
junction (1010bp) between the downstream region of intron 2 and the SMART2Z sequence 
using in2/2.r1 and WPRE foward oligo sequences (lanes 1 and 2). A 485bp region was 
amplified using in2/r.f2 and vir-l.r2 oligo sequences (lanes 3 and 4). Clear bands demonstrated 
the presence of these regions. Ampliflication of the WPRE domain was performed as a control 
to confirm the presence of vector in infected samples. A 356bp reaction was shown on a gel 
(data not shown). All amplification reactions were sequenced by Dundee sequencing service.  
 
RT PCR amplification reactions were performed using oligo sequences that 
hybridise to the Pah gene (Figure 27). PCR amplification products were purified and 
sequenced (see Appendix 11). These results confirmed the presence of exons 1-13. 
However, these results failed to identify viral sequences attached to the Pah gene 
cDNA in Adame T1. This suggests that following viral integration normal splicing 
was not altered Adame T1. However, this does not rule out that splicing between 
Pah and SMART2Z was not detected.  
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5.1  The relationship between viral integration and E2F target genes  
 
Eukaryotic and viral gene expression may be regulated by transcription factors, 
regulatory elements, promoters or epigenetic modifications (Bartholomew and Ihle, 
1991; Nevins 1992; Weber and Cannon, 2007; Roy, Sen and Roeder, 2011).  
Interaction between E2F transcription factors and E2F responsive promoters is one 
mechanism used to regulate gene expression (Chen, Tsai and Leone, 2009; Singh et 
al, 2010).  
The E2F superfamily consists of eight proteins (E2F 1-8); the structure of all E2F 
proteins (excluding E2F7 and 8) consists of an E2F component and a DP1/2 subunit 
(Fig 28; Bracken et al, 2004; Carcagno et al, 2011). E2F transcription factors bind to 
specific DNA sequences (‘TTTCGCGC’) located in the promoter region of E2f 
target genes (Nevins, 1992; Shirodkar et al, 1992; Tao et al, 1997). The adenovirus 
was originally used to investigate the activity of E2F transcription factors over 20 
years ago (Kovesedi et al, 1986; Yee et al, 1987; Levine et al, 2009; Chen, Tsai and 
Leone, 2009). These studies reported specific binding between the adenoviral gene 
promoter and cellular factors in adenovirus infected cells.  
E2f target genes are involved in several biological processes including cell cycle 
control (Cam and Dynlacht, 2003; Blais and Dynlacht, 2004; Chen et al, 2009; 
Carcagno et al, 2011), DNA damage and repair mechanisms (Field et al, 1996; 
Huang et al, 1997; Stiewe and Pützer; 2001; Hsieh et al, 2002) and cellular 
differentiation (Nevins, 1992; Field et al, 1996; DeGregori et al, 1997; Riz and  
Hawley, 2005).  E2F family members also demonstrate dual functions including the 
ability to exert both oncogenic and tumour suppressor activity (Table 47; Bracken et 
al, 2004). This dual activity allows E2F to take part in several mechanisms involved 
in cancer development (Müller and Helin, 2000; Nevins, 2001).   
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5.1.1  E2f and Rb1 interaction is fundamental to E2F activity 
 
Early observations reported E2F as the functional link between the tumour 
suppressor gene - Rb (retinoblastoma) and the E1A (early region 1 A) oncoprotein 
present in the adenovirus genome (Chellapan et al, 1992; Nevin, 1992). In 1991 
Chellapan et al reported that increased adenovirus infection correlated with the 
dissociation of the E2F-Rb complex (Chellapan et al, 1991; 1992).  Rb is a key 
tumour suppressor gene that regulates the G1 to the S phase of the cell cycle 
DeGregori et al, 1997; Stevens and La Thangue, 2003). The RB proteins (pRB) are 
collectively known as pocket proteins that include p107 and p130 (Lee et al, 2002). 
In G0-G1 cells pRB binds to E2F family members and suppress E2F activity (Lee et 
al, 2002).  Mitogenic signals activate pRB and induce phosphorylation of pRB (Lee 
et al, 2002). As a result the E2F-RB complex dissociates, E2F is released and 
allowed to promote the transcription of E2F target genes (Stevens and La Thangue, 
2003; Bracken et al, 2004; Calzone et al, 2008).  Several studies have shown that Rb 
interacts with oncoproteins and is frequently mutated or deleted in cancers such as 
HCC (Ceccarelli et al, 1998; Lohmann et al, 1997; 1999; Müller et al, 2001; Nevins, 
2001; Classon and Harlow, 2002; Calzone et al, 2008; Ozturk et al, 2009; Reed et al, 
2009; Bremner and  Zacksenhaus, 2010).   
 
Subgroup E2f members Function 
1 E2f1-3 Interacts with pRb 
Activates gene expression   
2 E2f4-5 Interacts with pRb  
Represses gene expression  
- Rb dependant activity 
3 E2f6-8 Represses gene expression 
- Rb independent activity 
 
Table 47. E2f family members can be categorised into three major groups according to their 
sequence homology and biological activity. 
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Figure 28. E2F mediated activation of cellular genes. Dissociation of E2F: pRB complexes allow 
E2F to perform transcriptional activation. DP (E2F dimerisation partner) represents a 
heterodimersation domain that binds to E2F family members. DP allows E2F to bind to DP1 and 
DP2 proteins and interacts with RB1 and RB related proteins. Cyclin/Cdk complexes interact to 
regulate cell cycle progression and the activity of pRB and E2F proteins. In normal cells pRb is 
hypophosphorylated. External signals act on cyclin and CDK complexes. These active 
complexes phosphorylate the Rb gene; this in turn cause the release of E2F.   
5.1.2  E2F and DNA damage 
 
During DNA damage responses E2F is able to regulate the cell cycle, apoptosis and 
associate with DNA repair proteins (Figure 29; DeGregori et al, 1997). DeGregori et 
al, (1997) inserted E2F family members into an adenoviral construct. These 
recombinant viral constructs were used to infect REF52 cells. Results showed that 
E2F family members were able to induce apoptosis and suggests that E2F1 may 
function as a signal for the induction of the apoptotic pathway. E2F1 has been shown 
to play an important role in controlling cell cycle control and apoptotic cell death in 
response to DNA damage and oncogene activation (Carcagano et al, 2009). 
Mutations in E2F1 results in the suppression of apoptosis (Tsai et al, 1998) and over 
expression of E2F effectively promotes apoptosis and subsequent malignant growth 
(Pierce et al, 1999).  Carcagano et al (2009) investigated the effect of genotoxicity 
on E2F in a human fibroblast cell line.  Results showed that E2F1 is over expressed 
in response to genotoxic stress in an ATM/ATR dependant manner. Whilst other 
studies report that E2F1 can suppress apoptosis (Denchi and Helin, 2005). Huang et 
al (1997) also reported the activation of E2F1 during DNA damage and apoptosis. 
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Other studies have also demonstrated a link between DNA damage and other E2F 
family members such as EF2 and E2F3 (Martinez et al, 2010).  
 
 
 
 
Figure 29. E2f plays a role in the DNA damage pathway. This image shows the close interaction 
between components involved in the cell cycle and DNA damage. Image taken from Stevens 
and La Thangue, 2003. 
 
Aberrant regulation of E2F activity may facilitate tumour progression by activating 
the mutation of crucial tumour suppressor genes such as Rb and p16ink4a. Whilst 
E2F mutations exist these are not as frequent as the deregulation of E2F target genes 
in tumours. Therefore deregulation of E2F targets may provide a useful marker of 
cancer development. Coordination exists between E2F regulation and epigenetic 
mechanisms. E2F binding sites contain 1 or 2 CPG dinucleotides that are potential 
targets for regulation by DNA methylation (Campanero, Armstrong and Flemington, 
2000). Campanero et al (2000) investigated the effect of CPG methylation occurring 
in the promoter region of several E2F target genes.  
Velasco et al, 2010 demonstrated a functional relationship between Dnmt3b and the 
transcriptional repressor E2F6 in Dnmt3b mutant mice. This study showed that 
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Dnmt3b target genes were dependant on the binding of E2F6. Moreover, E2F6 has 
been shown to interact with repressive chromatin-modifying enzymes which play a 
role in methylation & epigenetic regulation of transcription. 
5.2  Epigenetic modification of host genes following 
lentiviral vector delivery: TSG methylation in HCC 
and non tumour liver 
 
5.2.1  Epigenetic regulation of transcription  
 
The term epigenetics is used to describe stable heritable changes in gene expression 
that have no affect on the nucleotide sequence of DNA (Jaenisch and Bird, 2003; 
Jiang et al, 2004; Rodenhiser and Mann, 2006). The biological significance of 
epigenetics in normal development, cell proliferation, gene expression and the 
aeitology of disease have become increasingly apparent since epigenetics was first 
introduced by Conrad Waddington in the 1940′s (Waddington, 1942; Devaskar and 
Raychaudhuri, 2007; Matouk and Marsden, 2008).   
 Epigenetic modifications which are shown to influence chromatin structure and 
transcriptional regulation include DNA methylation, chromatin remodelling and 
histone modifications (Bernstein and Hake, 2006; Berger, 2007; Dolinoy, Weidman 
and Jirtle, 2007). 
DNA methylation in mammals is a post replication modification which primarily 
involves the covalent addition of a methyl group (CH3) to the C-5 position of 
cytosine bases (Montero et al, 1992; Wolffe, Jones and Wade, 1999).  
Since its discovery research has revealed the role of methylation in gene regulation 
and several biological processes including x-chromosome inactivation, genomic 
imprinting and ageing (Surani, 1998). It has already been established that aberrations 
in epigenetic mechanisms can give rise to several disorders such as cancer, 
autoimmune disease, imprinting disorders, neurological disorders and aging 
(Robertson and Wolffe, 2000; Jones and Baylin, 2002; Chen et al, 2010).  
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DNMT’s are specialised DNA polymerases that catalyse cytosine methylation 
(Figure 30). The three DNMT’s responsible for DNA methylation are DNMT1, 3a 
and 3b.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Cytosine methylation describes the addition of methyl group cytosine residues in DNA. 
Cytosine methylation is catalysed by DNA methyltransferase 1, 3a and 3b activity. 
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5.2.1.1 Dnmt1 
 
Dnmt1 is ubiquitous in somatic cells and fundamental to the maintenance of DNA 
methylation patterns with each round of replication (Figure 31; Li, Bestor and 
Jaenisch, 1992; Lei et al, 1996; Robertson et al, 1999; Kanai et al, 2001). However, 
studies have reported that Dnmt1 performs de novo methylation under carcinogenic 
conditions.   
The catalytic activity of Dnmt1 is carried out by the carboxy-terminal domain and 
the long N terminus regulatory region this allows the enzyme to distinguish between 
methylated and non-methylated DNA (Fang et al, 2001). The regulatory domain of 
Dnmt1 also interacts with various cellular components including transcription factors 
(i.e. E2F1), tumour suppressor proteins (i.e. Rb) and histone deacetlylases 
(Robertson et al, 2000). The knockdown of Dnmt1 results in genomic instability, 
impaired cell development and cell death (Lee et al, 2001; Brown and Robertson, 
2007; Chen et al, 2007). The link between E2F mutation and genomic instability is 
helped by several proteins. Disruption of DNA binding activity between Dnmt, Rb1 
and E2F1 is associated with several cancers (Robertson et al, 2000). 
Dnmt1 interacts closely with the pRb/E2F1 complex. Studies showed that the 
absence of pRB elevated levels of Dnmt1 expression (McCabe, Davis and Day, 
2005). This interaction between pRB, E2F and Dnmt1 is facilitated by the existence 
of E2F binding sites in the Dnmt1 promoter. Binding between E2F and its targets 
sites is sequence specific. Moreover Dnmt1 can also influence the expression of 
genes involved in cell cycle control, DNA damage and repair and chromosomal 
instability (Brown and Robertson, 2007; Tan and Porter, 2009). This suggests that 
Dnmt1 and E2F complexes produce DNA methylation effects in E2F binding sites 
(Robertson and Wolffe, 2000; Mortusewicz et al, 2005).  
5.2.1.2  Dnmt3a and Dnmt3b 
 
 Dnmt3a and Dnmt3b were first identified in mammals and are responsible for de 
novo methylation and helps restore methylation patterns in imprinted genes (Figure 
31; Okano et al, 1999). Extensive mouse studies have shown that deficiency of 
Dnmt3a and 3b results in embryonic lethality and multiple organ death (Okano et al, 
1999; Dodget et al, 2005). Studies have shown that increased Dnmt3a levels 
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promote polypopsis and may be involved in the development of several cancers 
including colon and HCC (Zhao et al, 2010).  
Dnmt3a can suppress cell proliferation in HCC cell lines (Shafiei et al, 2008) and 
melanoma growth in mouse melanoma models (Deng et al, 2009). Zhao et al (2010) 
described the regulation of the TSG – PTEN and suppression of cell proliferation in 
Dnmt3a deleted cells.  Dnmt3b is specifically required for the methylation of 
pericentric satellite repeats (Wienholz et al, 2010). Mutations in this gene is also 
detrimental and results in the development of the immunodeficiency disorder ICF 
(immunodeficiency, centromeric instability and facial anomalies). Shah et al (2010) 
found that truncated Dnmt3b isoforms commonly found in human tumours can 
disrupt embryonic development by inducing changes in DNA methylation. Other 
studies suggest that Dnmt3b interacts with Dnmt1 to inactivate gene expression 
(Rhee et al, 2002; Leu et al, 2003). 
CpG methylation exists in approximately 70% of the mammalian genome with the 
exception of CPG islands (Sadikovic et al, 2008; Illingworth et al, 2010).  CpG 
islands are unmethylated GC rich domains ranging from 0.5 -5kb (Sadikovic et al, 
2008).  Although these regions account for only 1-2% of the mammalian genome, 
they have specific properties (Das and Singal, 2004).  CpG islands provide 
epigenetic marks for the open chromatin (euchromatin) configuration which contains 
transcriptionally active genes (Bird, 1986; Illingworth et al, 2008).  
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Figure 31. Inheritance of cytosine methylation patterns in DNA. Methylation patterns are 
crucial to gene expression and the maintenance of specific biological functions within a cell. 
Methylation patterns are passed onto daughter cells during mitosis. This enables methylation 
patterns to be maintained from cell to cell. However de novo methylation can disrupt the 
inheritance of DNA methylation patterns which exist in parent cells. Alternative DNA 
methylation mechanisms (*) can produce stable maintenance of methylation patterns even in 
the absence of Dnmt′s. Unfortunately further insight is required to understand the mechanisms 
behind these alternative route. Methylated cytosines are represented as red dots. 
 
5.2.1.3  Interaction between DNA methylation and chromatin  
 
The interaction between DNA methylation and DNA-protein interaction plays a key 
role in chromatin structure, initiation of replication, and mismatch repair (Adams, 
1990). However, DNA methylation may have a negative effect on DNA protein 
interactions as Dnmt’s target sequences required for DNA cleavage, transcription 
factor binding and DNA protein binding (Watt and Molloy, 1988). This interaction 
between chromatin, DNA methylation may influence transcriptional regulation. 
Complexes consisting of binding proteins and methylated CpG’s can stimulate the 
= Methyl groups      
(CH3) 
 
 
 
(CH₃ )  
* 
* 
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recruitment of histone deacetylases (HDAC), de novo methylation and gene 
silencing (Figure 32; Bird and Wolfe, 1999; Billard et al, 2002; El-Osta, 2003). 
Histone modifying proteins such as HDAC promote heterochromatin configuration 
which is associated with gene silencing.  
In addition histone methylations such as H3-K9 have been linked to pathological 
conditions such as cancer. Several studies have also reported the association between 
methylation of histone H3 at lysine 9 (H3-K9), heterochromatin formation and gene 
silencing (Oakes et al, 2007; Chen, Odenike and Rowley, 2010). 
 
 
 
Figure 32. This model shows the association between Dnmt, HDAC’s, methyl binding proteins 
and methylated cytosines. Aberrations in these complexes can influence chromatin and may 
result in the inactivation of adjacent cellular genes.  
 
5.2.2  Detection of DNA methylation changes 
 
Various methods are currently used to asses global and gene specific methylation 
including bisulphite reaction based methods (Frommer et al, 1992; Preuss and 
Pikard, 2007), chromatography (i.e HLPC), CPG island microarray (Khulan et al, 
2006; Schumacher et al, 2006), TaqMan PCR (Kimura et al, 2009), Restriction 
Landmark Genomic Scanning (RLGS-M) and methyl sensitive restriction enzyme 
treatment (Bird and Southern, 1978). Bisulphite treatment is considered the gold 
standard of epigenetic studies.  
Methylation abnormalities are subdivided into two categories: hypermethylation and 
hypomethylation. 
Hypermethylation mostly occurs regionally within CPG islands and promoter 
regions. Hypermethylation is a major contributor to transcriptional repression (Bird 
and Wolffe, 1999).   
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Several studies have shown that genes affected by hypermethylation and gene 
silencing are implicated in several processes including cell cycle regulation, DNA 
repair, apoptosis, detoxification and drug resistance.  
Gene specific methylation patterns have been identified in several cancers including 
esophageal squamous cell carcinoma (Yamashita et al, 2008), prostate cancer, HCC 
(Yang et al, 2003) and breast cancer (Feng et al, 2007). These cancers often present 
aberrant methylation within the vicinity of exon 1 or promoter regions of key tumour 
suppressor genes such as P16ink4a (Sharpless et al, 2002; Choi and Wu, 2005; Yang 
et al, 2005). Interestingly, ICF patients that exhibit abnormal DNA hypermethylation 
patterns fail to develop cancer (Tao et al, 2002; Ehrlich, Jackson and Weemaes, 
2006). Hypomethylation occurs genome wide and affects highly and moderately 
repetitive DNA sequences present within transcription control regions, 
heterochromatin regions, endogenous retroviral elements or interspersed repeats 
(Takai et al, 2000; Ehrlich, 2002a,b; Saito et al, 2010). 
Hypomethylation has also been observed in various cancers including HCC (Lapeyre 
and Becker 1979; Ehrlich et al, 1982; Lu et al, 1983; Bedford and van Helden, 
1987). It is thought that hypomethylation and inactivation of genes involved in DNA 
damage repair and tumour suppression may trigger malignant transformation.  
5.2.3  Methylation, mutagenesis and DNA damage 
 
Several studies have suggested that key interactions exist between DNA damage 
homology, directed repair and DNA methylation (Cuozzo et al, 2007). Global 
deficiencies in methylated cytosines may activate DNA damage or create an 
environment which contributes to genomic instability and carcinogenesis. Lindahl, 
(1993) described the ability of cytosine methylation to increase the risk of 
mutagenesis.  
Methylated cytosines interfere with DNA damage repair enzyme activity and may 
increase the risk of spontaneous point mutations originating from cytosines (Lindahl, 
1993).  
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5.2.4  The role of viral integration in methylation  
 
 The introduction of foreign DNA into chromosomes can increase or reduce cellular 
methylation patterns and influence transcription of cellular genes (Remus et al, 1999; 
Heller et al, 1995). Provirus sequences such as the LTR, transgene and flanking 
genomic sequence may be subject to epigenetic mechanisms in the host genome 
(Harbers et al, 1981; Pannell and Ellis, 2001; Lavie et al, 2005). Non-integrating 
virus’s such as HCV exhibits similar methylation patterns to the integrating HBV 
virus (Lee et al, 2003).Methylation is believed to have developed as a host genome 
defence mechanism against the uptake, integration or expression of foreign DNA 
(Karlin, Doerfler and Cardon, 1994; Tao and Robertson, 2003). Methylation can 
contribute to retroviral latency (Saggioro, Forino and Chieco-Bianchi, 1991; Finzi et 
al, 1997; Fang et al, 2001). Epigenetic mechanisms are also thought to have silenced 
the activity of endogenous retroviruses millions of years ago (Lavie et al, 2005).  
The viral genome is usually methylated in the LTR to suppress viral gene expression 
and prevent viral replication close to genes flanking the proviral integration site 
(Challita and Kohn, 1994; Karlin et al, 1994). Challita et al, (1995) investigated the 
effect of RV vectors. Results showed that modification of the RV vector construct 
and inclusion of a demethylating fragment increased proviral expression and reduced 
DNA methylation levels following transduction of embryonic carcinoma cells 
(Challita et al, 1995).  
The idea that viral integration is responsible for methylation changes in host 
genomes supports the concept of methylation as a host defence mechanism. 
However, viral induced methylation does not affect the ability of retroviruses to 
produce replication competent proviral DNA. Several studies have demonstrated the 
role of retroviruses and integration defective lentiviruses in methylation (Fang et al, 
2001). Jahner and Jaenisch (1985) describe the ability of provirus integration to alter 
the methylation patterns of host DNA. Research shows that 20-25% of all retroviral 
integrations are found within 10kb of promoter elements and transcriptionally active 
genes involved in processes such as cell proliferation (Nienhuis, Dumbar and 
Sorrentino, 2006). This suggests that a high frequency of promoter methylation may 
be mediated by viral integration.   
Integration site selection is dependent on various factors including GC content and 
distance of provirus insertion site from CpG islands (Hacker et al, 2006).  
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Hacker et al, (2006) found that LV and RV vectors favoured integration into regions 
within 10kb and 1kb of CPG islands respectively.  
These studies suggest that RV and LV favoured sites are prone to epigenetic changes 
and play a role in gene expression and molecular signaling 
Hacker et al (2006) also found a 1% increase in GC content could increase the 
probability of HIV-1 integration by 8.7%. In a separate study Kitamura, Lee and 
Coffin (1992) found that methylated CPG dinucleotides were favoured target sites of 
integration by avian leukosis virus. Other studies have shown that viral integration 
can induce de novo methylation within 1kb of the integration site. This suggests that 
epigenetic modification is an important factor in integration site selection.  
The association between virus integration, DNA methylation and gene expression 
could present a serious danger to gene therapy patients treated with viral vectors.  
Fang et al (2001) investigated the relationship between HIV-1 infection and 
methylation levels in genomic DNA. HIV-1 infection was shown to correlate with 
elevated Dnmt1 levels and induce hypermethylation of cellular genes (including 
gamma interferon and P16ink4a) neighbouring proviral integration sites. This study 
also reported silencing of several genes.  Tsai et al, (2002) also describe the ability 
of an oncogenic virus to stimulate hypermethylation and repress e-cadherin 
expression via activation of Dnmt’s.  
Hejnar et al (2003) investigated the role of RV provirus integration on DNA 
methylation patterns following transduction of Syrian hamster cells. This study 
reported a transient demethylation step that is followed by de nova methylation 
(Hejnar et al, 2003).  In contrast Doerfler et al, (2001) described the existence of 
demethylation and de novo methylation at specific sites caused by viral transfection 
of murine cells.  
The complex interaction between target site selection and viral mediated methylation 
and insertional mutagenesis suggests that several mechanisms involved in 
oncogeneis may also be deregulated by viral integration. This also supports the role 
of viral integration in oncogenesis (Doerfler et al, 1997 and 2001). 
It is clear that understanding the epigenetic pathways in health and disease will 
facilitate novel approaches to the diagnosis and treatment of various diseases.  
Genome wide studies were conducted to detect gene expression using microarray 
analysis.  
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It is clear that viruses exploit natural epigenetic mechanisms that can escape immune 
detection and increase their survival (Tao and Robertson, 2003). Viral integration 
influenced gene expression levels by interacting with E2F transcription factors and 
disrupting Dnmt activity.  
The main hypothesis of this study was that LV infection induced methylation 
changes in the mouse genome. This study measured global methylation levels in 
EIAV, FIV and HIV samples infected in vivo and in vitro. In addition gene promoter 
methylation changes were measured via bisulphate sequencing and methylation 
specific PCR analysis. It was also hypothesised that Dnmt expression would be 
elevated in LV infected samples when compared to controls. Dnmt expression levels 
were measured in mouse liver tissue samples using Dnmt specific TaqMan probes.  
Dnmt levels can directly or indirectly regulate the expression of E2F transcription 
factors and E2F target genes. It was hypothesised that changes in Dnmt levels may 
induce global dysregulation of E2F target genes. Microarray analysis was used to 
investigate the effect of LV integration on the expression of E2F target genes.   
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5.3.1   Microarray analysis of E2F targets in vivo to investigate the 
changes in E2F targets following LV integration  
 
LV integration can greatly affect cellular mechanisms by altering the expression of 
host cellular genes. Analysis of differential expression of E2F target genes was 
carried out to determine the possible role of E2F transcription factors in vector 
mediated oncogenesis. The expression of E2F target genes was measured in EIAV 
associated tumours and compared to the expression of normal livers. EIAV infected 
liver tumours used in this study were found in Gerry, Adame and Jonas. Normal 
liver samples (n = 3) was also taken from Gerry, Adame and Jonas mice.  Several 
E2F target genes without virus integrations were found differentially expressed in 
normal liver samples. To evaluate whether these changes could be associated with 
proviral infection tumour gene expression was compared to a spontaneous tumour 
liver that developed HCC at 568 days old. Spontaneous tumour liver was identified 
in a male mouse (mouse x). This mouse did not receive LV infection therefore it was 
used as an uninfected control for this study. In this analysis E2F 1, 2 and 3 
transcription factors were differentially expressed in Gerry and Jonas normal 
samples when compared to when compared to normal liver (SpN) derived from 
mouse x. (Table 48). In addition, elevated levels of E2F 1 and 3 were found in Gerry 
normal liver when compared to SpN. In comparison Jonas normal liver showed a 
reduced level of E2F1 and E2F2 (P < 0.05) despite the elevated levels of the E2F 3 
(P <0.05). 
Differential expression of E2F target genes in normal Adame, Gerry and Jonas liver 
samples was also obvious. Jonas showed the highest number of elevated E2F target 
genes (n = 31) followed by Gerry (n = 23) and then Adame (n = 13).   
In contrast, only 11 E2F target genes were found to be upregulated in spontaneous 
tumour liver samples. All three E2F transcription factors (E2F1, 2 and 3) were 
upregulated in Gerry tumour samples. As E2F transcription factors are involved in 
activation of gene expression (such as tumour suppressor genes) it was interesting to 
see that 74 of the 94 E2F target genes were upregulated in Gerry tumour samples. Of 
these genes the tumour suppressors Rb1 and Trp53 are included.  The expression of 
E2F3 was also increased in Adame and Jonas tumour samples. However E2F1 and 
E2F2 genes were downregulated in Jonas tumour samples (Table 48).  Prc1, Cd6 
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and Cdt1 are important genes that play a key role in cytokenesis, T cell activation 
and initiating DNA replication, respectively, and these genes can also exert 
oncogenic activity. Functional partners associated with Prc1, Cd6 and Cdt1 include 
DNA damage and repair genes, HCC target genes and Dnmt target genes. Prc1, Cd6 
and Cdt1 were all upregulated in Gerry T1 and Jonas tumour samples. Interestingly 
Prc1 was also increased in Adame and Jonas normal liver samples. This suggests 
that these genes are influenced by EIAV integration and may play a role in vector 
mediated oncognesis.  Interestingly Brac1 and Brac2 were also differentially 
expressed in Gerry and Jonas tumour samples but failed to show significant changes 
in Gerry, Adame and Jonas normal livers (Table 48). This supports the involvement 
of these genes in carcinogenesis.  
Bcl2 was previously shown by STRING and IPA analysis to belong to an oncogenic 
network that includes the EIAV insertion genes Park7 and Uvrag (Figure 24).  The 
increased expression of Bcl2 in Gerry tumour (29.9%) and spontaneous tumour liver 
(10.3%) supports the importance of this gene in tumorigenesis and HCC 
development. However, results showed similar expression of Bcl2 in Gerry normal 
liver (29.65) and Jonas normal liver (10.4%).  
Pten is an important tumour suppressor gene and potent regulator of the P13K/Akt 
signalling pathway.  Kim et al (2005) have demonstrated negative regulation of Pten 
by the Park7 oncogene (Kim et al, 2005). QPCR analysis revealed reduced levels of 
Park7. Microarray analysis also revealed reduced levels of Pten in Gerry, Adame 
and Jonas tumour samples (Table 48). This suggests that viral integration disrupted 
the interaction between Park7 and Pten.  
Of the 94 E2F target genes analysed 77.7% were involved in DNA damage and 
repair mechanisms, 21.3% were oncogenes or known to exert oncogenic activity and 
80.9% were categorized as HCC target genes.  
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5.3.1.1  E2F transcription factors and target genes are differentially expressed in EIAV infected tissues 
 
No. Gene 
symbol 
Oncogene DDR E2F 
targets 
HCC 
targets 
DNMT 
targets 
SpT vs 
SpN  
G.N vs 
SpN 
 
A.N  vs 
SpN 
 
J.N vs 
SpN 
 
G.T vs 
SpN 
 
A.T vs 
SpN 
 
J.T vs 
SpN 
 
1 Jun      -0.237 
 
1.062 
 
0.718 
 
0.943 
 
3.241 
 
0.894 
 
1.018 
 
2 Ccne1      -0.014 
 
0.003 
 
-0.037 
 
-0.010 
 
0.632 
 
-0.014 
 
-0.029 
 
3 Ccne2      0.047 
 
0.038 
 
0.074 
 
0.012 
 
-0.017 
 
0.042 
 
0.118 
 
4 Cdc25a      -0.026 
 
0.034 
 
-0.061 
 
-0.057 
 
0.287 
 
-0.054 
 
-0.027 
 
5 Cdk2 
 
    -0.101 
 
0.373 
 
-0.227 
 
-0.179 
 
0.287 
 
-0.203 
 
-0.219 
 
6 E2f1 
 
    0.015 
 
0.309 
 
-0.042 
 
-0.078 
 
1.451 
 
0.008 
 
0.069 
 
7 E2f2 
 
    -0.053 
 
0.111 
 
-0.073 
 
-0.079 
 
0.210 
 
-0.031 
 
-0.045 
 
8 E2f3 
 
    -0.009 
 
0.118 
 
-0.045 
 
0.028 
 
0.123 
 
0.097 
 
0.064 
 
9 Tfdp1      -0.083 
 
-0.102 
 
-0.021 
 
-0.023 
 
0.215 
 
-0.036 
 
-0.140 
 
10 Aurkb      0.041 
 
0.067 
 
0.056 
 
0.081 
 
0.370 
 
0.012 
 
0.055 
 
11 Cdc20      -0.057 
 
-0.022 
 
0.049 
 
0.017 
 
0.190 
 
0.068 
 
-0.103 
 
12 Prc1 
 
    -0.053 
 
0.095 
 
0.155 
 
0.174 
 
2.472 
 
0.135 
 
0.064 
 
13 Cdc6 
 
    -0.006 
 
0.040 
 
0.013 
 
0.008 
 
0.108 
 
0.013 
 
0.113 
 
14 Cdt1 
 
    0.037 
 
0.130 
 
0.035 
 
-0.008 
 
1.086 
 
-0.011 
 
0.126 
 
15 Dck      -0.021 
 
-0.064 
 
0.031 
 
0.004 
 
0.223 
 
-0.001 
 
-0.042 
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16 Rrm2      0.078 
 
0.032 
 
0.282 
 
0.301 
 
0.503 
 
0.307 
 
-0.407 
 
17 Tk1      0.514 
 
-0.342 
 
0.812 
 
0.634 
 
1.552 
 
0.559 
 
0.185 
 
18 Top2a      -0.041 
 
-0.042 
 
0.047 
 
0.033 
 
0.721 
 
-0.008 
 
-0.033 
 
19 Tyms      -0.090 
 
-0.139 
 
0.057 
 
0.122 
 
0.827 
 
0.128 
 
-0.235 
 
20 Cdkn1c      0.388 
 
-0.141 
 
0.077 
 
0.070 
 
-0.569 
 
0.125 
 
-0.116 
 
21 Cdkn2c      0.015 
 
-0.018 
 
0.059 
 
0.033 
 
1.925 
 
0.021 
 
-0.078 
 
22 Cdkn2d      0.033 
 
0.051 
 
-0.037 
 
-0.035 
 
0.143 
 
-0.053 
 
-0.070 
 
23 Rbl1      -0.029 
 
-0.031 
 
-0.026 
 
-0.016 
 
0.526 
 
0.016 
 
-0.038 
 
24 Brca1      0.016 
 
0.049 
  
0.040 
 
0.013 
  
-0.069 
 
-0.017 
 
0.115 
 
25 Brca2      0.015 
 
0.010 
 
-0.046 
 
-0.017 
 
0.199 
 
-0.035 
 
0.039 
 
26 Bub1b      -0.031 
 
-0.016 
 
0.004 
 
0.004 
 
0.243 
 
-0.002 
 
-0.005 
 
27 Bub3      -0.022 
 
-0.044 
 
-0.095 
 
-0.038 
 
-0.032 
 
-0.118 
 
0.022 
 
28 Mad2l1      0.002 
 
0.044 
 
0.027 
 
0.052 
 
0.202 
 
0.025 
 
0.029 
 
29 Cstf1      0.168 
 
0.360 
 
-0.068 
 
0.029 
 
0.066 
 
0.164 
 
0.564 
 
30 Fen1      -0.123 
 
0.083 
 
-0.109 
 
-0.048 
 
1.724 
 
-0.049 
 
-0.022 
 
31 Mgmt      0.197 
 
-0.012 
 
-0.244 
 
-0.018 
 
-0.935 
 
0.025 
 
-0.191 
 
32 Mlh1      -0.117 
 
-0.077 
 
-0.046 
 
-0.161 
 
0.026 
 
-0.135 
 
0.221 
 
33 Msh2      0.042 
 
-0.004 
 
0.006 
 
0.020 
 
0.091 
 
0.002 
 
0.015 
 
34 Msh6      -0.452 -0.395 -0.492 -0.622 0.737 -0.599 -0.276 
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35 Pms2      -0.020 
 
0.000 
 
-0.050 
 
-0.045 
 
0.112 
 
-0.059 
 
0.024 
 
36 Prkdc      -0.127 
 
-0.068 
 
-0.207 
 
-0.122 
 
0.129 
 
-0.205 
 
0.062 
 
37 Rad51      0.029 
 
0.018 
 
0.046 
 
0.051 
 
0.159 
 
0.027 
 
0.022 
 
38 Rad54l      0.033 
 
0.107 
 
-0.013 
 
0.018 
 
0.852 
 
-0.010 
 
0.081 
 
39 Apaf1      0.002 
 
-0.023 
 
0.086 
 
0.004 
 
0.129 
 
0.049 
 
-0.030 
 
40 Bad      0.109 
 
0.062 
 
-0.036 
 
0.136 
 
0.212 
 
0.073 
 
-0.166 
 
41 Bak1      0.034 
 
-0.052 
 
-0.096 
 
-0.084 
 
-0.098 
 
-0.076 
 
0.057 
 
42 Bcl2      0.103 
 
0.296 
 
0.035 
 
0.104 
 
0.299 
 
0.063 
 
-0.104 
 
43 Bid      0.191 
 
0.015 
 
-0.029 
 
-0.070 
 
0.210 
 
-0.055 
 
0.153 
 
44 Bok      0.026 
 
0.834 
 
0.051 
 
0.114 
 
1.657 
 
0.169 
 
1.049 
 
45 Casp3      0.150 
 
-0.009 
 
0.072 
 
-0.017 
 
0.113 
 
0.007 
 
-0.130 
 
46 Casp7      0.096 
 
-0.371 
 
-0.280 
 
-0.223 
 
-0.149 
 
-0.268 
 
-1.046 
 
47 Casp8      0.039 
 
0.197 
 
0.063 
 
0.012 
 
0.898 
 
0.106 
 
-0.006 
 
48 Map3k14      0.216 
 
0.576 
 
0.080 
 
0.156 
 
0.601 
 
0.143 
 
0.231 
 
49 Map3k5      -0.041 
 
-0.020 
 
-0.011 
 
-0.060 
 
0.124 
 
-0.024 
 
-0.069 
 
50 Eed      -0.033 
 
0.223 
 
-0.081 
 
-0.058 
 
0.061 
 
-0.060 
 
0.152 
 
51 Fos      -0.028 
 
0.305 
 
0.663 
 
0.964 
 
0.304 
 
0.694 
 
0.440 
 
52 Hey1      0.000 
 
-0.012 
 
0.000 
 
0.013 
 
0.195 
 
0.006 
 
-0.004 
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53 Hoxa5 
 
    -0.049 
 
-0.028 
 
0.049 
 
0.245 
 
0.037 
 
0.245 
 
-0.035 
 
54 Fst      -0.131 
 
-0.104 
 
0.030 
 
-0.006 
 
-0.309 
 
-0.073 
 
0.107 
 
55 Junb      -0.171 
 
0.299 
 
0.139 
 
0.767 
 
1.278 
 
0.334 
 
1.110 
 
56 Mki67      -0.181 
 
-0.216 
 
-0.211 
 
-0.225 
 
0.790 
 
-0.179 
 
-0.263 
 
57 Pold1      0.047 
 
0.144 
 
-0.021 
 
-0.088 
 
1.404 
 
-0.135 
 
0.388 
 
58 Rad51ap1      -0.032 
 
0.021 
 
0.009 
 
0.002 
 
0.091 
 
0.027 
 
0.069 
 
59 Rfc3      0.018 
 
0.038 
 
-0.039 
 
0.000 
 
0.506 
 
0.028 
 
-0.034 
 
60 Rfc4      0.051 
 
0.295 
 
-0.046 
 
-0.057 
 
0.782 
 
-0.005 
 
0.267 
 
61 Rrm1      -0.071 
 
-0.054 
 
-0.024 
 
0.001 
 
0.125 
 
0.011 
 
-0.109 
 
62 Ccnb1      -0.024 
 
0.045 
 
0.037 
 
0.027 
 
0.310 
 
0.026 
 
0.025 
 
63 Foxm1      -0.029 
Ns 
-0.010 
 
-0.026 
 
-0.063 
 
0.278 
 
-0.021 
 
-0.016 
 
64 H2afx      -0.060 
 
0.153 
 
-0.226 
 
-0.160 
 
1.280 
 
-0.080 
 
0.073 
 
65 Tpx2      -0.014 
 
-0.002 
 
0.000 
 
0.001 
 
0.183 
 
-0.009 
 
-0.019 
 
66 Uhrf1 
 
    -0.011 
 
0.160 
 
-0.013 
 
0.012 
 
1.965 
 
-0.004 
 
0.085 
 
67 cdk1      * 
 
-0.018 
 
0.053 
 
0.044 
 
0.872 
 
0.110 
 
-0.009 
 
68 H2afz      * 
 
0.771 
 
0.131 
 
0.290 
 
1.842 
 
0.218 
 
0.491 
 
69 Mcm5      0.035 
 
0.263 
 
0.235 
 
0.240 
 
3.045 
 
0.258 
 
0.022 
 
70 Lig1      -0.034 
 
0.151 
 
0.058 
 
0.196 
 
1.739 
 
-0.024 
 
0.133 
 
71 Mcm2      -0.003 0.016 -0.037 -0.016 2.021 -0.088 -0.088 
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72 Mcm6      0.060 
 
0.088 
 
0.128 
 
0.161 
 
2.725 
 
0.056 
 
0.035 
 
73 Pcna      -0.022 
 
-0.002 
 
0.020 
 
-0.012 
 
0.011 
 
-0.021 
 
0.051 
 
74 Tacc3      -0.008 
 
-0.027 
 
-0.016 
 
-0.008 
 
-0.013 
 
-0.029 
 
-0.039 
 
75 Dmap1 
 
     0.016 
 
0.091 
 
-0.243 
 
-0.225 
 
0.054 
 
-0.182 
 
0.352 
 
76 Mat1a 
 
     0.081 
 
-0.066 
 
-0.358 
 
-0.408 
 
-0.985 
 
-0.535 
 
-0.178 
 
77 Hdac2 
 
     0.031 
 
0.065 
 
-0.058 
 
-0.078 
 
0.135 
 
-0.040 
 
-0.002 
 
78 Daxx 
 
     0.019 
 
0.084 
 
-0.083 
 
-0.026 
 
0.121 
 
-0.101 
 
0.266 
 
79 Mat2a 
 
     0.239 
 
0.405 
 
0.124 
 
0.081 
 
0.108 
 
0.159 
 
0.304 
 
80 Trdmt1 
 
     0.101 
 
-0.025 
 
-0.022 
 
-0.034 
 
0.013 
 
-0.029 
 
0.011 
 
81 Dnmt1 
  
    0.022 
 
-0.884 
 
-0.702 
 
-0.762 
 
0.317 
 
-0.016 
 
0.022 
 
82 Dnmt3b 
  
    -1.021 
 
-0.884 
 
-0.702 
 
-0.762 
 
-0.812 
 
-0.715 
 
-0.560 
 
83 Cyclin D1 
 
     -0.209 
 
-0.451 
 
-0.270 
 
-0.267 
 
-0.198 
 
-0.239 
 
-0.683 
 
84 Cdkn2a 
 
     0.054 
 
0.006 
 
0.025 
 
0.033 
 
0.083 
 
0.083 
 
0.029 
 
85 Igf2r 
 
     -0.003 
 
-0.215 
 
-0.502 
 
-0.338 
 
-0.341 
 
-0.510 
 
-0.319 
 
86 Igf2 
  
    -0.038 
 
-0.126 
 
0.359 
 
0.393 
 
-0.084 
 
0.313 
 
2.388 
 
87 Smad2 
 
     0.149 
 
0.025 
 
0.005 
 
-0.033 
 
0.192 
 
0.097 
 
-0.140 
 
88 Pten 
 
     -0.054 
 
-0.085 
 
-0.042 
 
-0.093 
 
-0.017 
 
-0.048 
 
-0.112 
 
89 Ctnnb1 
 
     -0.274 
 
-0.502 
 
-0.148 
 
-0.416 
 
-0.774 
 
-0.327 
 
-0.789 
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90 Socs1 
 
     -0.046 
 
-0.021 
 
-0.153 
 
-0.120 
 
-0.253 
 
-0.124 
 
0.162 
 
91 Gstp1 
 
     -1.171 
 
1.629 
 
0.625 
 
0.613 
 
1.071 
 
0.760 
 
1.083 
 
92 Cdkn2b 
 
     -0.131 
 
-0.080 
 
-0.166 
 
-0.138 
 
-0.027 
 
-0.159 
 
-0.068 
 
93 Rb1 
 
     -0.039 
 
0.097 
 
0.124 
 
-0.004 
 
0.169 
 
0.019 
 
-0.136 
 
94 Trp53      -0.004 
 
0.065 
 
-0.247 
 
-0.191 
 
1.050 
 
-0.156 
 
-0.096 
 
 
Table 48. Changes in the expression of E2F target genes in EIAV infected liver and tumour samples.  Spt = Spontaneous tumour liver. SpN = normal 
liver derived from mouse X. G.N, A.N, J.N represent Gerry normal, Adame normal and Jonas normal tissue samples respectively. G.T, A.T and J.T 
represents Gerry tumour, Adame tumour and Jonas tumour tissue samples respectively. Gene expression data recorded are all relative to spontaneous 
tumour liver samples. Fold changes in gene expression (logFC) were calculated and statistical analysis performed on raw data.  Values annotated in red 
font represents gene expression levels with statistically significant P. Values (<0.05).   is used to represent genes that are not classified as 
oncogenes but known to possess oncogenic activity. HCC targets and DNMT target genes include known functional partner genes. Genes not included in 
the microarray are marked with an asterix (*). 
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5.3.2  Changes in DNA methylase expression in LV infected tissues 
 
Microarray data showed altered expression of Dnmt1 and Dnmt3b in the EIAV 
infected liver samples included in this study (n = 3). A marked reduction in the de 
nova methyltransferase enzyme - Dnmt3b was found in Gerry, Adame and Jonas 
normal liver samples. In comparison the maintenance methyl transferase Dnmt1 was 
found to be down regulated in EIAV infected normal livers (n = 3) and 2 out of 3 
liver tumours (Table 48). 
DNA methylation is dependant on Dnmt activity to initiate, maintain and establish 
DNA methylation. This chapter presents data to support a possible link between viral 
integration and Dnmt expression in the mouse samples infected in utero with EIAV, 
FIV and HIV vectors. To accurately evaluate gene expression, QPCR was used to 
detect changes in Dnmt levels using gender matched liver samples (uninfected) as 
calibrator samples with the ΔΔCT method of gene expression analysis. Results 
showed elevated levels of Dnmt1 in Fiona normal liver (P<0.001) and all 5 FIV 
infected tumour samples (P<0.05) when compared to uninfected livers (Table 49).  
The existence of de novo methylation was demonstrated by the observation of 
elevated levels of Dnmt3a in FIV treated normal liver samples (P<0.001) and in 3 
out of 5 liver tumour samples (P<0.01). This suggests that Dnmt genes and 
methylation patterns are altered as a result of FIV integration.  Dnmt3b levels were 
also measured in FIV infected liver samples and elevated levels were found in all 
normal livers (P<0.05) and in 4 out of 5 liver tumours (P<0.001; Table 49 and Figure 
33 and 34). These results correlate with the expression levels of Dnmt1 and Dnmt3a 
expression found using microarray and supports the involvement of LV infection in 
epigenetic mechanisms that are known involved in oncogenesis. 
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Sample name Dnmt1  
(+/-SEM) 
Dnmt3a  
(+/-SEM) 
Dnmt3b  
(+/-SEM) 
FIV normal    
    
Fiona N 15.98 8.17 53.05 
Flora N 0.71 8.46 3.24 
FIV tumour    
    
Fiona T1 24.81 (0.19) 73.52 (0.12) 30.77 (0.31) 
Fiona T2 61.26  (0.23) 16.11 (0.14) 7.68 (0.15)* 
Fanny T1 1.79 (0.49) 0.89 (0.06) 8.89 (0.18) 
Fanny T2 3.42  (0.14)* 4.35  (0.11) 47.38 
Frank T2 1.96 (0.29) 0.83  (0.18) 0.13 (0.16)* 
Table 49.  Dnmt expression in mouse tissue samples after FIV infection. 
(*) Is used to denote that the P. Value obtained were above 0.05 confidence levels. All 
P.Values obtained were relative to a gender matched uninfected liver sample. Dnmt levels are 
described as relative methylation levels (2ΔΔCT) calculated by ΔΔCT analysis.  
 
Figure 33. Histogram representing Dnmt levels in FIV infected samples. Each bar represents 
2ΔΔCT values produced by FIV infected normal liver samples compared to uninfected livers. A) 
N1 & N2 represents Fiona normal and Flora normal liver samples respectively. UF and UM 
represents Uninfected female and male liver samples respectively. 
a 
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Because aberrant methylation patterns are often associated with cancer the 
expression of Dnmt gene expression levels were evaluated in tumour samples 
associated with FIV infection (Figure 34 and table 49). Fiona T1 and T2 samples 
showed consistently higher levels of Dnmt expression when compared to uninfected 
male and other tumour samples (Figure 34).   
 
 
 
Figure 34. Histogram representing the relative gene expression values of Dnmts in tumour 
samples infected with the FIV vector. T1-T5 represents Fiona T1 and T2, Fanny T1 and T2 and 
Frank T2 tumour samples described in Table 49. UF and UM represents Uninfected female and 
male liver samples respectively. 
 
 
QPCR analysis found that Dnmt1 was not expressed in Ikea and Gerty normal liver 
samples (Figure 35). However both Ikea and Gerty showed elevated expression of 
Dnmt3a and Dnm3b as shown in Figure 35.  Analysis of EIAV infected tumour 
samples showed elevated levels of Dnmt1, Dnmt3a and Dnmt3b as shown in Table 
50 and Figure 36. As HIV infected mice did not develop tumours Dnmt expression 
could only be examined in normal liver samples. QPCR analysis showed elevated 
expression of Dnmt1 and Dnmt3b in HIV infected normal livers (Figure 37 and 
Table 51). 
 
 
a 
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Sample name Dnmt1  
(+/-SEM) 
Dnmt3a  
(+/-SEM) 
Dnmt3b  
(+/-SEM) 
EIAV normal    
Ikea  normal liver 0.15 (0.08) 21.36 (0.20) 3.36 
Gerry  normal liver 0.71(0.20) 30.17 (0.26) 2.96 (0.51) 
EIAV tumour    
Adame  T1 685.63 (0.21) 50.56  (0.18) 30.77 (0.31) 
Gerry T1 61.26  (0.23) 19.20  (0.26) 65.64  (0) 
Table 50. Dnmt gene expression data obtained from EIAV infected mice. 
 
 
 
 
 
 
 
 
Figure 35. Dnmt gene expression data obtained from EIAV infected mice. N1 and N2 represent 
Ikea and Gerry normal liver samples. UF and UM represents Uninfected female and male liver 
samples respectively. 
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Figure 36. Dnmt gene expression data obtained from EIAV infected mice. 
T1 and T2 represent Adame tumour 1 and Gerry tumour 1 samples, respectively. UF and UM 
represents Uninfected female and male liver samples respectively. 
 
 
Figure 37. Dnmt gene expression data obtained from HIV infected normal liver samples N1 and 
N2 represents Tiggy and Bruce liver samples respectively. UF and UM represents Uninfected 
female and male liver samples respectively.  
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Sample name Dnmt1  
(+/-SEM) 
Dnmt3a  
(+/-SEM) 
Dnmt3b  
(+/-SEM) 
HIV     
Tiggy 22.15 (0.16) 7.21 (1.50)  3.36 (0.80) 
Bruce 0.06 (0.45) 30.17 (0.08) 2.96 (0.30) 
Table 51. Expression of Dnmt genes in HIV infected samples.  
 
 
 
To investigate whether DNA methylation was increased globally in the mouse 
genome methylation levels were measured in LV infected samples. A global 
methylation kit was used to detect methylated cytosines present in DNA samples. 
Global changes in methylation levels are shown in Figures 38 and 39. Average levels 
in methylation are also shown. Increases in global methylation were seen in normal 
livers obtained from EIAV (44.84%); FIV (60.73%) and HIV (100%) infected mice 
respectively (Figure 38a). Global DNA methylation was also examined in the LV 
associated tumours of EIAV (n=5) and FIV (n=7) including an FIV associated 
ovarian cyst. Global methylation levels in these tumours increased to 90% and 110% 
for EIAV and FIV, respectively, compared to no increases in methylation found in 
uninfected controls (Figure 39). These results suggest DNA methylation levels may 
be influenced by LV infection and could represent a potentially independent 
mechanism of genotoxicity leading to oncogenesis.   
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5.3.3   Observations of global methylations associated with in utero application of LV vectors 
 
 
 
Figure 38. DNA methylation levels in normal tissues are associated with LV transduction.  Global methylation status was compared between normal 
hepatic tissue (a-d) and a control group of a spontaneous tumour sample and male and female uninfected liver samples. Ching liver was extracted from 
a female mouse that did not receive LV infection. Relative methylation values (%) were calculated from average absorbance values. Error bars 
represent the standard error of means derived from triplicate assays. Global methylation was significantly higher in EIAV (b) and HIV (d) samples 
(<0.001). FIV infected samples also showed an increase in global methylation (<0.05). 
-20.00
0.00
20.00
40.00
60.00
80.00
100.00
120.00
R
e
la
ti
ve
 m
e
th
yl
a
ti
o
n
 le
ve
ls
 
n
o
rm
a
l l
iv
e
r 
(%
) 
-
A
ll 
ve
ct
o
rs
-10.00
0.00
10.00
20.00
30.00
40.00
50.00
60.00
70.00
80.00
R
e
la
ti
ve
 m
e
th
yl
at
io
n
 le
ve
ls
 
EI
A
V
 in
fe
ct
e
d
 s
am
p
le
s 
(%
)
-20.00
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
R
el
at
iv
e 
m
et
h
yl
at
io
n
 le
ve
ls
 
FI
V
 in
fe
ct
ed
 s
am
p
le
s 
(%
)
-20.00
0.00
20.00
40.00
60.00
80.00
100.00
120.00
140.00
R
el
at
iv
e
 m
et
h
yl
at
io
n
 le
ve
ls
 
H
IV
 in
fe
ct
ed
 s
am
p
le
s 
(%
)
a 
c 
b 
d 
RESULTS CHAPTER 5 
 
163 
 
 
 
 
Figure 39. DNA methylation changes in hepatocellular carcinoma tissues transduced with LV vectors.                       
Relative methylation levels are represented as black bars in the graph. Error bars represent standard deviations between triplicate absorbance values. 
The global methylation status of FIV infected (1-7) and EIAV infected tumour samples (1-5) varied. The control groups are a spontaneous tumour and 
two uninfected liver samples (Uninfected male and Ching liver). These were found without elevated levels of methylation.   
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5.3.4  Measurement of the effects of LV infection on methylation in 
vitro 
 
To determine whether LV infection increased DNA methylation at early time points 
after infection  Dnmt expression and global methylation levels were investigated in 
vitro directly after LV infection of the HepG2 liver cell line. If this was to occur this 
would support the data presented from in vivo analysis and would suggest that LV 
integration or infection influences the epigenetic regulation of gene expression and 
could contribute to oncogenesis.  
HepG2 cells were infected and methylase expression and levels of methylation 
examined at 3 time points (6 hours, 24 hours and 30 hours) post infection by EIAV, 
FIV, HIV and MLV vectors.  To determine whether changes in methylation were 
associated only with integration 2 integrase negative HIV vectors were used for 
infection that contained either the CMV or SFFV promoters driving eGFP 
expression.  DNA and RNA were harvested from infected and uninfected tissue 
samples immediately after each timepoint. Global methylation assays performed on 
EIAV vectors carrying the CMV promoter showed a small increase in methylation 
when compared to uninfected control DNA samples extracted at this point (6 hrs, 
24hrs and 30 hrs). These samples showed increased methylation levels in all LV and 
RV treated cells (excluding EIAV at 6hrs). In all LV and RV treated cells (excluding 
EIAV – 6hrs) small levels of DNA methylation was seen when compared to 
uninfected cells taken at 24 hours (2.67) and 30 hrs (5.00). Several LV infected 
samples showed high global methylation levels. These included HIV integrase 
negative (CMV and SFFV), HIV, FIV and MLV infected HepG2 cells (Table 52; 
Figure 40). 
 
 
 
 
 
 
 
 
RESULTS CHAPTER 5 
 
165 
 
 
5.3.4.1   Global methylation levels: In vitro study  
 
 
Figure 40. Global methylation levels in uninfected, LV treated and RV treated HepG2 cells at 
6hrs, 24hrs and 30 hrs post infection. Absorbance readings at 450nm were used to detect 
methylated cytosines. Standard error bars represent SEM values obtained from triplicate 
absorbance readings. 
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Global methylation levels: In vitro study 
Sample Time point (hrs) Relative 
methylated levels 
(%) SEM (%) 
Controls *   
 6 hours 0 (0.30) 
Uninfected (blank)* 24 hours 2.67 (0.13) 
 30 hours 5.00 (0.20) 
 6 hours 5.50 (0.59) 
CMV* 24 hours 90.00 (1.50) 
 30 hours 38.33 (2.36) 
 6 hours 3.67 (0.38) 
SFFV* 24 hours 62.50 (1.45) 
 30 hours 132.50 (0.05) 
 6 hours 8.67 (0.55) 
MLV 24 hours 99.00 (0.40) 
 30 hours 106.50 (3.65) 
 6 hours 14.33 (0.37) 
HIV 24 hours 66.00 (0.10) 
 30 hours 64.00 (1.90) 
 6 hours 6.50 (0.75) 
FIV 24 hours 59.67 (1.30) 
 30 hours 65.00 (0.065) 
 
 
6 hours -0.67 (0.30) 
EIAV 24 hours 51.67 (0.87) 
 
 
30 hours 72.67 (2.58) 
Spontaneous tumour* * -2.50 (0.39) 
Table 52. Global methylation levels. DNA methylation levels measured at early time points (6, 
24 and 30hrs) in uninfected or post LV/RV infection (integrase negative, MLV, FIV. HIV and 
EIAV). * is used to represent uninfected and HIV integrase negative vector infected samples. 
These control samples were used as references of normal global methylations levels. 
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5.3.4.2  Dnmt methylation levels: In vitro study 
 
QPCR showed low levels of Dnmt3a expression in HepG2 cells infected with the 
integrase negative vector (CMV promoter), FIV, HIV (P <0.05) and EIAV (P 
<0.001) 6 hours after LV infection (Table 53). These results were compared to data 
obtained from uninfected HepG2 cells (6 hrs post infection).  Results suggest that de 
novo methylation did occur at early time points (6 hrs) after LV infection but at very 
low levels. Dnmt3a levels also appeared to peak 30 hrs after treatment with FIV 
(P<0.001) and EIAV (P<0.01) vectors. SFFV infected cells also showed higher 
levels of Dnmt3a expression between 6 and 24hrs after infection.  
Interestingly HIV and MLV infected cells showed unique patterns of Dnmt 
transcription levels. MLV infected cells showed a rise in Dnmt3a expression at 6 
hours after infection. This rise was followed by a 98.74% reduction in transcription 
levels from 26.0 at 6hrs to 0.32 at 30 hrs post infection. HIV infected cells also 
demonstrated a rise in Dnmt3a expression at 6hrs post infection (P<0.05) and again at 
30 hrs post infection (P<0.001) (Table 53; Figure 41). 
 
 
Figure 41. Dnmt3a levels seen in negative (uninfected) and vector treated (MLV, FIV, HIV and 
EIAV) HepG2 cells. CMV – Cytomegalovirus & SFFV = Spleen Focus-Forming Virus Integrase 
negative vectors carrying CMV or SFFV vectors are described as CMV or SFFV respectively. 
QPCR analysis failed to detect Dnmt1 and Dnmt3b expression in infected HepG2 cells.  
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Sample name Dnmt3a P values N6 
Compared to n6 
P values V6 
 
Negative 6 hrs 1 * * 
Negative 30 hrs 0.316 * * 
Integrase negative (CMV) 6 hrs 0.175 NS * 
Integrase negative  (SFFV) 30 hrs 2.342 <0.01 * 
MLV 6 hrs 25.987 <0.05 * 
MLV 24 hrs 17.85 <0.01 NS 
MLV 30 hrs 0.321 <0.001 <0.01 
FIV 6 hrs 2.134 NS * 
FIV 24 hrs 4.608 <0.001 <0.01 
FIV 30 hrs 8.007 <0.001 <0.05 
HIV 6 hrs 2.506 <0.05 * 
HIV 24 hrs 0.07 <0.001 <0.001 
HIV 30 hrs 0.556 <0.001 <0.05 
EIAV 6 hrs 0 <0.001 * 
EIAV 24 hrs 0.463 NS <0.001 
EIAV 30 hrs 2.408 <0.01 <0.001 
Table 53. Dnmt gene expression data represented as relative methylation levels (2ΔΔCT). 
Student Test analysis was used to determine P. values when compared to negative 6 and 
vector matched CT values for Dnmt3a at 6hrs post infection (V6).  NS was used to describe P. 
Values above significant levels (<0.05). Values marked with an asterix (*) were excluded from 
study due to poor 18sRNA readings. 
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5.3.5  Analysis of VCN following the delivery of LV vectors to liver cell 
in vitro 
 
Sample name Time point Copy Number 
per Diploid 
(SEM) 
 6 hours 0.00 (0) 
Uninfected 24 hours 0.35 (0.35) 
 30 hours 1.94 (0.32) 
 6 hours 482.86 (0.25) 
CMV 24 hours 16458.86 (0.58) 
 30 hours 6561.14 (0.18) 
 6 hours 11.76 (0.05) 
SFFV 24 hours 2132.46 (0.36) 
 30 hours 578.91 (0.02) 
 6 hours 1733.40 (0.02) 
HIV 24 hours 6834.20 (0.53) 
 30 hours 2405.51 (0.01) 
 6 hours 147.74 (0.45) 
FIV 24 hours 898.37 (0.24) 
 30 hours 6054.66 (0.16) 
 6 hours 20.70 (0.08) 
EIAV 24 hours 77.70 (0.09) 
 30 hours 58.96 (0.13) 
Table 54. VCN data obtained using QPCR analysis. 
 
VCN analysis was measured in genomic DNA extracted from HepG2 cells treated 
with LV and RV. Results showed an increase in VCN derived from cells collected at 
6 to 30 hrs post infection (Table 54). Most VCN values were above 12.  QPCR failed 
to detect viral sequences in uninfected cells as expected.  
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6.1   Oncogenesis associated with differential gene expression with 
in utero and in vitro application of LV vectors  
 
Haematopoietic stem cells (HSC) infected with RV vectors have been successfully 
used to treat several immunodeficiencies such as ADA-SCID (Hacein-Bey-Abina et 
al, 2002; Gaspar et al, 2004). However, an early French gene therapy clinical trial 
conducted by Cavazzana-Calvo and Fischer reported leukaemia development in 
patients that received gene modified HSC’s (Cavazzana-Calvo et al, 2005). The trial 
involved transduction of autologous CD34+ bone marrow cells with RV vectors 
containing the γC gene that were transduced ex vivo and returned to each patient. 
Vector insertions in the vicinity of the LMO2 oncogene induced spontaneous T cell 
leukaemia (Nienhuis et al 2006). 
Since these observations were made in HSC’s these cells have been used as models 
of leukemogenesis and several studies have sought to understand the molecular 
mechanisms of vector mediated genotoxicity (Montini et al, 2006). However 
comparisons between solid tumours and malignant haematopoiesis are limited by 
differences in these molecular mechanisms and oncogenic networks underlying these 
pathogenic disorders. This makes it difficult to estimate the potential risk of vector 
mediated genotoxicity from results obtained in malignant haematopoiesis. 
It is hope that the development of genotoxicity models will improve the safety of 
gene therapy using non-viral and viral vectors (Von Kalle et al, 2004). Despite the 
advantages of using HSC’s for gene therapy somatic gene transfer could offer 
genetic modification for various cell types in situ. Thus far, however, models to 
establish a link between LV and RV integration and its associated side effects 
following somatic gene therapy have not been created and with the evidence that 
genotoxicity may be influenced by gene expression the potential for vector 
associated genotoxicity following in vivo gene transfer is, as yet, unknown 
(Kustikova et al, 2010).    
Extensive retroviral insertion site mapping has been used to reveal vector insertion 
site preferences some of which include integrations into well known protoncogenes 
such as Ccdn2 and Bmi1 (Qasim et al, 2009; Hacein-Bey-Abina, 2008). Highlighting 
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these insertion preferences is useful to predict the likelihood of vector mediated 
oncogenesis and therefore in this study insertion site analysis was carried out.  
The concept of fetal (in utero) gene therapy is based on the prevention of genetic 
conditions before birth and to achieve permanent correction of such diseases by 
stable transduction of cell populations before they manifest in the unborn child 
(Coutelle et al, 2005).  
 
The application of somatic gene transfer to the foetus is relatively new to the field of 
gene therapy. RV vectors prefer to insert into actively transcribing genes (Hacker et 
al, 2006; Ambrosi et al, 2008; Persons, 2010), however, in the foetus several genes 
that are known oncogenes are present in this state (switched on), this means in the 
foetus the potential for IM is greater. Key genes involved in processes such as cell 
cycle metabolism and differentiation are also highly expressed in the foetus and 
therefore it is important to know if these genes are also capable of contributing to 
oncogenesis if they become mutated after integration. Indeed, the potential for 
carcinogenesis induced by IM of viral vectors in utero highlights the usefulness of 
the foetus as a potentially useful genotoxicity model.  
A previous study conducted by Themis et al (2005) investigated the correlation 
between LV integration and vector mediated insertional mutagenesis using the foetal 
mouse. EIAV (SMART2 EIAV) and HIV (HR’SIN-cPPT-S-FIX-W) vector 
constructs were used to treat haemophiliac MF-1 mice in utero at 16 days gestation.  
These experiments demonstrated a relationship between the insertion sites of the 
EIAV vector and the development of HCC (Themis et al, 2005) with 80-90% of 
foetal EIAV treated mice developing clonally derived HCC. In the same study mice 
treated with HIV based vectors were not found to develop tumours. These results 
demonstrated the foetal mouse to be a useful in vivo system that can be used for the 
analysis of vector safety. 
The oncogenesis observed in LV treated mice was believed, initially to be caused by 
the inclusion of the woodchuck post translation regulatory element (WPRE) in the 
vector construct. The WPRE element has been included in viral vectors in several 
studies to improve transgene expression and the performance of viral vectors in gene 
transfer (Zufferey et al, 1999). In the wild-type configuration the WPRE domain 
consists of an X gene (coding for an 140 amino acid peptide) and has been shown to 
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play a role in HCC (Zufferey et al, 1999; Kingsman et al, 2005; Higashimoto, et al, 
2007; Schambach et al, 2007). In gene therapy vectors such as HR’SIN-cPPT-S-
FIX-W a truncated form of the X gene is present, however, the promoter and start 
codon for the X gene is mutated to prevent X expression. Hence, this was believed to 
be the reason why mice treated with HR’SIN-cPPT-S-FIX-W failed to develop 
tumours. In the EIAV vector these mutations do not exist and therefore it was X gene 
expression that was suspected to be the cause of oncogenesis. 
In the Themis laboratory the role of the X protein in oncogenesis was further 
investigated through the use of non primate FIV based vectors (pLIONhAATGFP) 
and modified EIAV vectors (SMART2ΔW) that also included the truncated X gene 
with a mutated promoter and start codon.  Mice treated with pLIONhAATGFP and 
SMART2ΔW induced clonal HCC but HR’SIN-cPPT-S-FIX-W treated mice once 
again failed to show signs of tumour development.  Mice treated with these LV 
vectors (excluding HIV) developed tumours at a frequency of 4/6 (SMART2 
unmodified), 4/10 (SMART2 modified vector) and 4/8 (pLIONhAATGFP). These 
results implicated the role of LV integration site selection in vector mediated 
oncogenesis. Research described in this thesis focused on retrieving LV integration 
sites (within a window of 100kb of the proviral insertion) in FIV and EIAV infected 
samples. Integration sites retrieved from foetal mice were used to identify common 
insertion sites (CIS) and predict the risk of vector mediated oncogenesis associated 
with in vivo gene transfer.  
 
Proviral insertions sites were retrieved from EIAV and FIV infected mouse samples 
using LAM PCR retrieval and 454 or Automated DNA (www.dnaseq.co.uk) 
 sequencing to provide sequence data for BLAST analysis using the NCBI database. 
This identified RefSeq genes with vector integrations and gave information for 
vector integration profiling. The identity of these genes supports the possibility that 
LV integration may be associated with HCC. The EIAV vector appeared to integrate 
into genes associated with cellular proliferation and cancer and several oncogenes 
were found with EIAV insertions. FIV also showed a preference for integration into 
genes associated with cell growth and proliferation.  
To investigate whether insertional mutagenesis was implicated in oncogenesis the 
expression of EIAV and FIV insertion genes were examined to detect alterations in 
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their expression. RT PCR analysis was first used to show the trends in expression for 
FIV insertion genes and this data was validated using QPCR analysis. The 
expression of EIAV insertion genes retrieved was quantified using QPCR analysis 
and microarray analysis. 
High density microarray analysis is often used to validate and confirm gene 
expression data obtained from QPCR analysis.  However, QPCR analysis is often 
believed to yield a more accurate measure of changes in gene expression (Dorak, 
2006; Pallas et al, 2008). This increased sensitivity is particularly useful to studies 
that measure transcription levels in heterogeneous cell populations as observed in the 
HCCs found in this study.  
 
By identifying genes altered in expression with EIAV LV vector insertions and 
relating these to genes in pathways associated with these insertion genes 
bioinformatic analysis was able to reveal potential oncogenic pathways that could be 
assigned to HCC and the vector insertion site (s). STRING and IPA networks were 
therefore most valuable for this and provided evidence suggestive of insertional 
mutagenesis being the cause of HCC in the treated mice. These networks included 
genes such as Tnfrsf19, Pscd3, Park7, Uvrag, Pah, Mrlp23 and Bre.  
 
Correlations between two SMART2 insertions identified in Jonas large tumour were 
investigated.  These genes included the Uvrag and the oncogene Park7. The latter 
gene plays a key role in oxidative stress responses (Clements et al, 2006; Vasseur et 
al, 2009). Several studies have reported that overxpression of Park7 in cancer may 
facilitate the ability of tumour cells to sustain cellular proliferation (Clements et al, 
2006; Sitaram et al, 2009; Vasseur et al, 2009). Interestingly both Uvrag and Park7 
were retrieved from the same tumour sample in a previous study. QPCR analysis 
showed that the SMART2 insertion into intron 12 of the Uvrag gene resulted in up 
regulation of the tumour suppressor gene Uvrag by 128%. Microarray analysis also 
revealed an increase in Uvrag by 78%. This contradicts studies that show suppressed 
expression of Uvrag in liver metastasis (Goi et al, 2003). In contrast Park7 was 
found to reduced in QPCR analysis. Both Uvrag and Park7 form part of an 
oncogeneic network that includes key cancer associated genes including Trp53, Bax, 
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and Bcl2. Interestingly, all of these genes were also shown to be deregulated in Jonas 
tumour samples by microarray analysis.  
 
In Jonas large tumour Bre (Brain and reproductive organ-expressed protein) was 
shown to be downregulated when compared to gender matched normal and tumour 
control samples.  This antiapoptotic gene shows multiple roles in several cellular 
processes including cellular differentiation and regulation of the inflammatory 
cytokine TNF-alpha through its interaction with the TNF receptor 1 (microarray 
Tnf1a). Several studies have described the overexpression of Bre in HCC (Chan et 
al, 2008; 2010). Bre has also been described as a RIS hit (n = 2) in the RTCGD 
database. Interestingly several cancer associated genes were found in the bre protein-
protein network. These genes include Smad (1 and 4) and Brac (1 and 2) proteins.  
Although Smad 1 and 4 were not found in the microarray analysis data for Smad2 
was included in this study. Levels of Smad2 expression were shown to be 
downregulated by microarray analysis. Bre is a component of the BRCA1-A 
complex that specifically recognises histones H2A and H2AX at DNA lesion sites. 
This interaction between BRAC1-A and H2A/H2AX histones recruits BRACA1-
BARDI heterodimers to sites of DNA damage at double stranded breaks. This 
implicates Bre in DNA damage response and repair pathways.  Indeed, this pathway 
to HCC was supported by increased levels of Brac1 (11.5%) and Brac2 (3.9%) in the 
Jonas tumour sample. The levels of Brac1 and Brac2 were not seen in Adame and 
Gerry tumour samples. However, the results of this study showed that EIAV 
integration into Bre reduced its expression and possibly disrupted stress responses 
and led to a reduction in Smad2 and elevated levels of Brac1 and 2. Mark3 
(Map/microtubule affinity-regulating kinase) was also retrieved from Jonas large 
tumour samples where it was found to be increased. Mark3 plays a role in 
phosphorylation of microtubule associated proteins, ATP binding, nucleotide 
binding, and protein serine/threonine kinase activity.  Mark3 share a close homology 
with Markl1 that is often ovexpressed in HCC.  Integration of the EIAV provirus 
into Katna1 in Jonas large tumour resulted in the reduction of this gene. However an 
association between Katna1 and cancer associated genes was not found by 
bioinformatics. Other SMART2 inserted genes that were shown upregulated in Jonas 
large tumour included Mrlp23 and Rabgef1. However, these genes were also 
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increased by greater levels in the Jonas small tumour sample. Similar expression of 
Rabgef1 shown by microarray analysis supported the role of the Ras signalling in 
this tumour development. The implication of these findings in Jonas large tumour 
suggests that cooperation between EIAV insertions may occur.   
 
In the Adame tumour sample QPCR analysis revealed upregulation of Acvr2a 
(Activin type II receptor) following an EIAV integration into this gene. However, 
microarray did not reveal differential expression of this gene. Activins belong to a 
family of important signalling proteins known as transforming growth factor-beta 
(TGFβ) (Phillips et al, 2001; Chen et al, 2006).  TGFβ possess several functions and 
are thought to repress tumour progression through its inhibition of the proto 
oncogene c-Myc and hTERT (Li et al, 2006). Activins can also suppress cancer cell 
growth in early cancer development (Tsuchida et al, 2009).  Signalling for Activin 
and TGFβ occur through different serine/threoinine kinase receptor subunits. 
However, both pathways share common activation of Smad proteins (Phillips et al, 
2001). Deregulation of TGFB and activin signalling has been implicated in cancer 
and metastasis (Li et al, 2006; Tsuchida et al, 2009). 
In the same tumour the expression of the Pah gene was found downregulated. Pah 
catalyses the catabolism of the essential amino acid phenylalanine. Aberrant 
regulation of Pah activity results in the metabolic disorder phenylketonuria. 
Interactions between Pah and several genes including Hnf4a, Slco1a4 and Pcbd1 
were found using STRING analysis. Interestingly, Slco1a4 and Pcbd1 were found 
differentially expressed in the microarray data of Adame tumour. 
Hnf4a is related to Hnf1a and known to be important functional partners that 
regulate the expression of the Pah gene. QPCR analysis revealed downregulation of 
both Hnf4a and Hnf1a genes by 55% and 62% respectively. This correlates with 
findings that describe reduced Hnf4a levels in HCC and liver cancer (Lazarevich and 
Alpern, 2008). Furthermore, Hnf4a was reduced in microarray analysis of Hnf4a by 
53% in this tumour.  
 
Networks relating insertion genes to cancer genes were not only found in the EIAV 
infected tumours. In Fiona T2 pLIONhAATGFP FIV insertions were found in intron 
1 of the Cyth3 gene. Cyth3 also known as Pscd3 was shown to be significantly 
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upregulated by RT PCR and QPCR analysis when compared to a gender matched 
tumour without a proviral insertion into this gene.  Pscd3 is involved in activation of 
the P13K/AKT signalling pathway (Hafner et al, 2006; Kolanus, 2007). Aberrations 
of the P13K/AKT signalling pathway is thought to play a critical role in cancer 
development (Fuss et al, 2006; Hafner et al, 2006). Arf can induce p53 and interact 
with Ras and Myc genes to suppress cellular proliferation. Moreover aberrations in 
Arf activity are implicated in the activation of cancer (Hashimoto et al, 2004). 
STRING analysis provided strong evidence for the role the pLIONhAATGFP 
insertion into Pscd3 and oncogenesis. Pscd3 was found to interact with several 
cancer associated genes via an oncogeneic network that included Akt1, Trp53 and 
Pten.  
Tnfrsf19 was retrieved from Flora Ovarian Cyst samples. The expression of Tnfrsf19 
was completely silenced following integration of pLIONhAATGFP upstream of this 
gene. Tumour necrosis factor-α receptors are capable of activating necrosis (via 
caspase-independant cell death mechanisms) which results in oxidative stress. 
However, aberrant expression of Tnfrsf19 may implicate this gene in the escape of 
cancer cells from cell death. Moreover, overexpression of Tnfrsf19 can activate JNK 
signalling. Studies show that JNK signalling may be activated by the non-canonical 
Wnt signalling pathway which is already implicated in tumour development  
(Weston and Davies, 2002). Therefore, aberrant expression of JNK signalling 
induced by Wnt signalling may be a possible mechanism of oncogenesis in these 
mice.  
Gene expression studies failed to find an association between Nek9 (Frank T1) and 
Coro7 (Frank T2) insertions and cancer associated genes.  
 
In conclusion, therefore, from these analyses no common insertion sites (CISs) could 
be found. However, several pathways to tumour development were obvious. These 
data suggest pathways to HCC are complex and that several pathways may exist for 
solid tumour development. Many more mice would therefore need to be treated 
before CISs are discovered using the foetal mouse model. 
Montini et al (2009) showed that VCN can contribute to vector mediated 
oncogenesis. By investigating the role of VCN in HCC development in EIAV, FIV 
and HIV treated mice it was hoped that increasing numbers of vector copies may 
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correlate with the frequency of oncogenesis or at least tumours would be expected to 
have similar copy numbers since each mouse received the same dose of vector. 
Southern blot analysis was used to establish the copy number of each tumour and 
this was used as a standard value for VCN analysis by QPCR of LV genomes in 
tumours and infected normal livers. VCN values varied widely regardless of the dose 
of vector used for infection. Several EIAV and FIV infected samples presented with 
above 10 LV copies in normal and tumour samples. The highest VCN values were 
obtained in Gerry normal (45.16) and tumour samples (86.34 and 202.13) which 
were also supported by Southern blot data. Hence, it was concluded that VCN was 
difficult to control in the foetal mouse.  
In comparison, VCNs in HIV treated mice were all below 3. This could explain the 
why no tumours were identified in HIV treated mice. 
 
Because CISs were not identified in the LV associated tumours and in many cases 
only a single oncogene could be identified with a provirus insertion, alternative 
mechanisms of vector mediated genotoxicity were suspected. Once of these 
mechanisms was host epigenetics involving methylation. The introduction of foreign 
DNA into chromosomes can increase or reduce cellular methylation patterns and 
influence transcription of cellular genes (Heller et al, 1995; Remus et al, 1999). 
Moreover provirus sequences such as the LTR, transgene and flanking genomic 
sequence may be subject to epigenetic mechanisms in the host genome (Harbers et 
al, 1981; Pannell and Ellis, 2001; Lavie et al, 2005). Indeed alterations in 
methylation can also contribute to cancer development (Robertson and Wolffe, 2000; 
Jones and Baylin, 2002). Therefore this study investigated the role of LV infection in 
liver cancer development by using in vivo and in vitro studies on methylation levels 
in tumours and normal infected livers.  
Firstly, global methylation levels were investigated as an indicator that host 
methylation had occurred following infection. Relative methylation levels for EIAV 
and FIV treated tumour samples were 95.43% & 104.79% respectively. In 
comparison uninfected control samples produced no changes in relative methylation 
levels. Despite the similarities in average methylation levels obtained from EIAV 
and FIV samples it was the Jonas large tumour that demonstrated the highest level of 
DNA methylation relative to uninfected liver and normal EIAV infected liver 
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samples. This may have contributed to the silencing of Park7 as discussed earlier via 
promoter methylation. In a previous study on this tumour (unpublished data) the role 
of promoter methylation of the cancer associated gene Hmgcs2 was measured and 
found not only that this gene was methylated but also that Hmgcs2 was down 
regulated in expression. Interestingly, Hmgcs2 is known downregulated in over 90% 
of c-Myc associated HCCs (Camarero et al, 2006; Ralph et al, 2010). 
Hypermethylation was found at 2 CpG islands located in the Hmgcs2 promoter. This 
hypermethylation was observed in Jonas normal samples whereas hypomethylation 
of Hmgcs2 was evident in the Jonas tumour sample. This is in line with 
hypermethylation followed by hypomethylation in specific genes and cancer. 
Moreover the altered methylation levels found in the Hmgcs2 promoter correlated 
with the downregulation of Hmgcs2 expression measured by QPCR of this gene.   
The global methylation analysis in normal liver samples also demonstrated increased 
relative methylation levels of 44.84% (EIAV), 60.73% (FIV) and 103.04% (HIV) 
respectively. This provided strong evidence for host defence against LV infection by 
epigenetic means. This study investigated the effect of LV infection on epigenetic 
(methylation) changes in the host genome. However, additional factors such as 
gender, age, environment differences (between experimental and control) or sickness 
in mouse samples may have contributed epigenetic changes observed. This effect 
could be investigated in future studies.  
 
DNA methyl transferases (Dnmts) play a key role in de novo methylation (Dnmt3a 
and 3b) and the maintenance (Dnmt1) of methylation patterns in the mammalian 
genome. It was therefore important to show that the observed changes in global 
methylation found in infected livers and tumours correlated with changes in Dnmt 
expression. Although tumour analysis was included in this study it was not assumed 
that methylation changes in these tumours could be clearly assigned to LV infection 
since hypermethylation followed by hypomethylation is a common hallmark of 
cancer and may not have been vector associated. However, QPCR analysis was used 
to measure the expression of Dnmt 1, 3a and 3b in clonally derived mouse tumours 
and their respective normal samples.  A marked reduction in Dnmt1 was found in 
EIAV infected normal liver in contrast to no change in the levels of Dnmt1 in 
uninfected livers. However increased levels of Dnmts3a and 3b were found in both 
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EIAV tumour and infected normal liver samples. A similar trend in Dnmt expression 
was shown in FIV infected samples suggesting this change could be related to LV 
infection and not only as a result of oncogenesis. Microarray data also showed 
altered expression of Dnmt1 and 3b in all EIAV infected normal liver samples 
included in this study (n = 3). A marked reduction in the de novo methyltransferase 
enzyme – Dnmt3b was found in Gerry, Adame and Jonas liver samples. In 
comparison the maintenance methyl transferase Dnmt1 was found to be down 
regulated in only 1 EIAV infected normal liver samples (n = 3) and 1 out of 3 liver 
tumour samples (Table 48). 
QPCR results showed elevated levels of Dnmt expression in FIV and HV infected 
liver samples in tumour samples and their respective normal livers when compared 
to uninfected liver.   
 
The evidence found for involvement of DNA methylation associated with LV 
infection and possibly tumour development required that this study be repeated in 
vitro. To study whether changes in DNA methylation could be identified at early 
time points after LV/RV infection HepG2 cells were infected with each several LV 
and a retroviral vector (RV). In addition, to determine whether methylation changes 
were associated only with integration HIV integrase minus vectors carrying either 
the CMV or SFFV promoters driving gene expression were used. 
Global rises in DNA methylation occurred after 6 hours however, these rises were 
small in comparison to the increased levels of methylation found at 24 and 30 hours 
after LV and RV infection (Table 52).  All levels of global DNA methylation were 
compared to results obtained from uninfected HepG2 cells at 6hrs where no increase 
was found. Interestingly, the greatest increases in global methylation changes were 
seen in cells infected with MLV and the CMV driven HIV integrase negative vector 
suggesting methylation was induced by infection and not only due to integration. 
HIV infected cells also showed consistently increasing levels of global DNA 
methylation at 24 and 30 hours post infection. Again levels of global methylation in 
uninfected control sample were unchanged.  The measurement of Dnmt levels in 
HepG2 infected cells concurred with global increases in methylation. Dnmt3a levels 
were mainly altered in expression following LV and RV infection and these 
increases were found highest at 24 and 30 hours post infection in MLV and HIV 
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infected cells. Importantly, since the Dnmt3a methylase establishes de novo 
methylation and this was found elevated rather than the Dnmt1 methylase that is 
responsible for maintaining methylation patterns this innate cellular response is most 
likely due to infection and is probably a mechanism aimed at silencing the vector. To 
strengthen the results of these studies similar experiments could be conducted in 
primary liver cells. 
Evidence of LV high VCN was shown by QPCR of vector specific sequences. This 
was especially true for non integrating vectors. 
 
Because coordination exists between E2F regulation and methylation it was 
suspected that the increased global methylation could ultimately cause alteration in 
the expression of this transcription factor and its target genes.  E2F binding sites in 
target genes contain CpG regions that also serve as targets for regulation by Dnmts 
(Campanero, Armstrong and Flemington, 2000). Other studies have also 
demonstrated that Dnmt3b target genes are also controlled by E2Fs such as E2F6 
(Velasco et al, 2010). Interestingly, E2F6 has also been shown to interact with 
repressive chromatin-modifying enzymes that play a role in methylation and 
epigenetic regulation of transcription. Moreover, Dnmts may interact with the 
regulation of several E2F family members and this could contribute to several cancer 
related changes in gene expression where oncogenes and tumour suppressor genes 
are involved (McCabe et al, 2005; 2006). 
 
94 E2F target genes were found disregulated by microarray analysis of tumours and 
infected normal livers of these mice. Of the 94 E2F target genes analysed 77.7% 
were involved in DNA damage and repair mechanisms, 21.3% were known 
oncogenes or shown to exert oncogenic activity and 80.9% were categorised as HCC 
target genes. Microarray analysis also showed that E2F 1, 2 and 3 transcription 
factors were differentially expressed in Gerry and Jonas clonally derived tumours 
and their respective normal livers. Jonas showed the highest number of elevated E2F 
target genes in normal liver samples (n = 31) followed by Gerry (n = 23) and Adame 
(n = 13). In contrast, only 11 E2F target genes were found to be upregulated in 
spontaneous tumour liver samples.  
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As E2F transcription factors are involved in the activation of gene expression (such 
as tumour suppressor genes) it was interesting to see that 74 of the 94 E2F target 
genes found in Gerry tumour liver included important cancer genes that are known to 
be associated with Rb1 and Trp53, Brac1 and Brac2. The expression of E2F1 and 3 
was also increased in Adame and Jonas tumour samples. However E2F2 expression 
was significantly downregulated in Jonas tumour samples (Table 48).   
These findings suggest that infection by proviruses may in some way cause these 
changes in E2F or its target gene expression and this may be via the methylation 
route. Several E2F targets are known to be involved in oncogenesis (Müller et al, 
2001; Nevins, 2001). Therefore viral integration into E2F target may be an indirect 
mechanism of vector mediated oncogenesis. Indeed, this may act in associated with 
insertional mutagenesis leading to HCC. 
 
Future studies will further explore lentiviral integration and its contribution to gene 
expression changes within the host genome in more control and infected mice. The 
generation of this data will significantly enhance the statistical power to detect 
changes in gene expression and methylation. The role of LV insertions and its 
involvement in cancer as shown by bioinformatics analysis could be further explored 
by using SiRNA to target cancer associated genes in zenograft models.  
 
Taken together the findings of this study demonstrate that LV vectors may mediate 
genotoxicity either directly by causing changes in gene expression of inserted genes 
or indirectly by causing methylation of important cellular genes following an innate 
immune response to the vector and this could lead to HCC. The fact that the HIV 
vector did not associate with HCC may be due to this vector not being mutagenic to 
inserted genes. This vector did, however, associate with changes in global 
methylation levels and could over time contribute to clonal expansion of infected 
cells and tumour development. Since no current long-term model exists to test this 
hypothesis this remains to be elucidated.  
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The fact that both the EIAV and FIV vectors used in this study are found to cause 
HCC in the fetally treated adult mice means these vectors, at least in the mouse, are 
genotoxic. The fact remains that all vectors used in this study alter methylation in the 
HepG2 human cell line and they should be modified to reduce this effect. This may 
be done using optimised vector sequences with reduce CpG sites used for 
methylation or by identifying what elements of these vector are causing the innate 
immune response. As for mutagenesis, thus far the cause of differential gene 
expression of the genes with insertions of these vectors has not been elucidated here 
and this requires investigation if these vectors are to be used confidently for gene 
therapy without side effects. 
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APPENDIX 1 
 
 
 
 
Lentiviral transduction of mice: a) Graphical image representing the dose and vector constructs 
used to treat MF-1 mice. EIAV and FIV treated mice received titers of approximately 1.2x107. 
Despite this both vectors generated highly variable VCN’s in infected mouse samples. b) The 
observations seen in this study included the development of liver tumours and the 
development of an ovarian cyst in one mouse.  
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APPENDIX 2 
 
 
Theoretical sequence of pLIONII hAAT GFP 
(FIV vector genome plasmid) 
 
CTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTAT 
CAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGA 
ACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGT 
TTTTCCATAGGCTCCGCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGT 
GGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGC 
GCTCTCCTGTTCCGACCCTGCCGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAA 
GCGTGGCGCTTTCTCATAGCTCACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCT 
CCAAGCTGGGCTGTGTGCACGAACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTA 
ACTATCGTCTTGAGTCCAACCCGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTG 
GTAACAGGATTAGCAGAGCGAGGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGC 
CTAACTACGGCTACACTAGAAGGACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTA 
CCTTCGGAAAAAGAGTTGGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTG 
GTTTTTTTGTTTGCAAGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTT 
TGATCTTTTCTACGGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGG 
TCATGAGATTATCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTA 
AATCAATCTAAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTG 
AGGCACCTATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCG 
TGTAGATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGC 
GAGACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCG 
AGCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGG 
AAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAG 
GCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGAT 
CAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTC 
CGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGC 
ATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAA 
CCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATAC 
GGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTT 
CGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTC 
GTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAA 
CAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCA 
TACTCTTCCTTTTTCAATATTATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGAT 
ACATATTTGAATGTATTTAGAAAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAA 
AAGTGCCACCTGACGTCTAAGAAACCATTATTATCATGACATTAACCTATAAAAATAGGC 
GTATCACGAGGCCCTTTCGTCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACA 
TGCAGCTCCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCC 
GTCAGGGCGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCTGGCTTAACTATGCGGCATCAG 
AGCAGATTGTACTGAGAGTGCACCATAAAATTGTAAACGTTAATATTTTGTTAAAATTCG 
CGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCC 
CTTATAAATCAAAAGAATAGCCCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGA 
GTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCG 
ATGGCCCACTACGTGAACCATCACCCAAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAG 
CACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGTAA 
GCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATC 
TTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGT 
CAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCT 
TTTGCTGGCCTTTTGCTCACATGGCTCGACAGATCTTCAATATTGGCCATTAGCCATATT 
APPENIDICES  
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ATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACGTTGTATCT 
 
ATATCATAATATGTACATTTATATTGGCTCATGTCCAATATGACCGCCATGTTGGCATTG 
ATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGCCCATATAT 
GGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCCAACGACCC 
CCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGGACTTTCCA 
TTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACATCAAGTGTA 
TCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCCTGGCATTA 
TGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTACGTATTAGTCAT 
CGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGGATAGCGGTTTGA 
CTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTTTGGCACCA 
AAATCAACGGGACTTTCCAAAATGTCGTAATAACCCCGCCCCGTTGACGCAAATGGGCGG 
TAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCTGTGAAACTTCGAGGAGTCTCT 
TTGTTGAGGACTTTTGAGTTCTCCCTTGAGGCTCCCACAGATACAATAAATATTTGAGAT 
TGAACCCTGTCGAGTATCTGTGTAATCTTTTTTACCTGTGAGGTCTCGGAATCCGGGCCG 
AGAACTTCGCAGTTGGCGCCCGAACAGGGACTTGATTGAGAGTGATTGAGGAAGTGAAGC 
TAGAGCAATAGAAAGCTGTTAAGCAGAACTCCTGCTGACCTAAATAGGGAAGCAGTAGCA 
GACGCTGCTAACAGTGAGTATCTCTAGTGAAGCGGACTCGAGCTCATAATCAAGTCATTG 
TTTAAAGGCCCAGATAAATTACATCTGGTGACTCTTCGCGGACCTTCAAGCCAGGAGATT 
CGCCGAGGGACAGTCAACAAGGTAGGAGAGATTCTACAGCAACATGGGGAATGGACAGGG 
GCGAGATTGGAAAATGGCCATTAAGAGATGTAGTAATGTTGCTGTAGGAGTAGGGGGGAA 
GAGTAAAAAATTTGGAGAAGGGAATTTCAGATGGGCCATTAGAATGGCTAATGTATCTAC 
AGGACGAGAACCTGGTGATATACCAGAGACTTTAGATCAACTAAGGTTGGTTATTTGCGA 
TTTACAAGAAAGAAGAGAAAAATTTGGATCTAGCAAAGAAATTGATATGGCAATTGTATA 
CATGTGGAATCAGGATATATATGGGCACAAATAATTTCTCAAGAAACTGCTGACTGTACA 
GTTAAAGCTGTCTTACAATTGTTGAGTGCTCATAATGTTACTGAATTACAAACAGATAAT 
GGACCAAATTTTAAAAATCAAAAGATGGAAGGAGTAATTGTGACATTAAAAGTCTTTGCG 
GTAGCAGGACTTTTAAATATGACGGCGCGCGTAATACGACTCACTATAGGGCGAATTGGG 
TACCGCGATGTACGGGCCAGATATAGCATTTTGGGGTGACTCAGTAAATGGTAGATCTTG 
CTACCAGTGGAACAGCCACTAAGGATTCTGCAGTGAGAGCAGAGGGCCAGCTAAGTGGTA 
CTCTCCCAGAGACTGTCTGACTCACGCCACCCCCTCCACCTTGGACACAGGACGCTGTGG 
TTTCTGAGCCAGGTACAATGACTCCTTTCGGTAAGTGCAGTGGAAGCTGTACACTGCCCA 
GGCAAAGCGTCCGGGCAGCGTAGGCGGGCGACTCAGATCCCAGCCAGTGGACTTAGCCCC 
TGTTTGCTCCTCCGATAACTGGGGTGACCTTGGTTAATATTCACCAGCAGCCTCCCCCGT 
TGCCCCTCTGGATCCACTGCTTAAATACGGACGAGGACAGGGCCCTGTCTCCTCAGCTTC 
AGGCACCACCACTGACCTGGGACAGTATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGG 
TGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGTGTCCG 
GCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCG 
GCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCT 
TCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAG 
GCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCG 
AGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCA 
AGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCT 
ATATCATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACA 
TCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACG 
GCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACC 
CCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTC 
TCGGCATGGACGAGCTGTACAAGTCCGGACTCAGATCTCGAGCTCAAGCTTCGAATTCTG 
CAGTCGACGGTACCGCGGGCCCGGGATCCACCGGATCTAGATAACTGATCATAATCAGCC 
ATACCACATTTGTAGAGGTTTTACTTGCTTTAAAAAACCTCCCACACCTCCCCCTGAACC 
TGAAACATAAAATGAATGCAATTGATCCAGCACAGTGGCGGCCGCTCGAGTGCGCCCTAA 
TAGAAGCTAGTAATAGGATTAAAAGTAGAAGCTATGGAAAAATTTTTGTATACAGCTTTC 
GCTATGCAAGAATTAGGATGTAATCAAAATCAATTTTTCTGCAAAATCCCTCCTGAGTTG 
TGGACAAGGTATAATATGACTATAAATCAAACAATATGGAATCATGGAAATATAACTTTG 
GGGGAATGGTATAACCAAACAAAAGATTTACAACAAAAGTTTTATGAAATAATAATGGAC 
APPENIDICES  
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ATAGAACAAAATAATGTACAAGGGAAGAAAGGGATACAACAATTACAAAAGTGGGAAGAT 
TGGGTAGGATGGATAGGAAATATTCCACAATATTTAAAGGGACTATTGGGAGGTATCTTG 
GGAATAGGATTAGGAGTGTTATTATTGATTTTATGTTTACCTACATTGGTTGATTGTATA 
AGAAATTGTATCCACAAGATACTAGGATACACAGTAATTGCAATGCCTGAAGTAGAAGGA 
GAAGAAATACAACCACAAATGGAATTGAGGAGAAATGGTAGGCAATGTGGCATGTCTGAA 
AAAGAGGAGGAATGATGAAGTATCTCAGACTTATTTTATAAGGGAGATACTGTGCTGAGT 
TCTTCCCTTTGAGGAAGGTATGTCATATGAATCCATTTCGAATCAAATCAAACTAATAAA 
GTATGTATTGTAAGGTAAAAGGAAAAGACAAAGAAGAAGAAGAAAGAAGAAAGCCTTCAT 
CAAGCTTATCGATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCT 
TAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGC 
TATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCT 
TTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGA 
CGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCGC 
TTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGAC 
AGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATCGTCCTT 
TCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGT 
CCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCC 
TCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCC 
GCCTGATCGATACCGTCGACCTCGAGGGGGGGCCCTCCTAAAAAAGAAAAAAGGGTGGAC 
TGGGATGAGTATTGGAACCCTGAAGGCCTTAACCAGTGCTTTGTGAAACTTCGAGGAGTC 
TCTTTGTTGAGGACTTTTGAGTTCTCCCTTGAGGCTCCCACAGATACAATAAATATTTGA 
GATTGAACCCTGTCGAGTATCTGTGTAATCTTTTTTACCTGTGAGGTCTCGGAATCCGGG 
CCGAGAACTTCGCACTGCAGGCATGCAAGCTTGGCGTAATCATGGTCATAGCTGTTTCCT 
GTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGT 
AAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCC 
GCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGG 
AGAGGCGGTTTGCGTATTGGGCGCT 
 
Sequence features: 
Length 7585 bp 
AmpR 1801-941 
CMV enhancer/promoter 2871-3458 
5’ LTR 3459-3611 
FIV non-coding sequence 3612-3883 
FIV gag remnant 1 3884-4135 
(Gag ATG in red) 3884-3886 
FIV pol remnant 4136-4296 
FIV gag remnant 2 4297-4345 
This it the theoretical bit… 
human α1-antitrypsin promoter 4432-4826 
remains of MluI site 4405 
possible extra sequence 5’ to promoter 4406-4431 
eGFP 4827-5624 
possible extra sequence 3’ to GFP 5625-5724 
remains of EcoRV site 5725-5727 
RRE region 5767-6479 
WPRE 6493-7085 
(mutated X promoter) 6883-6903 
(mutated WHx ATG) 6904-6906 
3’ LTR 7141-7334 
U5 7141-7165 
site of deletion 7166-7181 
R / U3 7182-7334 
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APPENDIX 3 
 
 
 
Sequence for pSmart2FIX 2 vector 
 
AGATCTTGAATAATAAAATGTGTGTTTGTCCGAAATACGCGTTTTGAGATTTCTGTCGCC 
GACTAAATTCATGTCGCGCGATAGTGGTGTTTATCGCCGATAGAGATGGCGATATTGGAA 
AAATTGATATTTGAAAATATGGCATATTGAAAATGTCGCCGATGTGAGTTTCTGTGTAAC 
TGATATCGCCATTTTTCCAAAAGTGATTTTTGGGCATACGCGATATCTGGCGATAGCGCT 
TATATCGTTTACGGGGGATGGCGATAGACGACTTTGGTGACTTGGGCGATTCTGTGTGTC 
GCAAATATCGCAGTTTCGATATAGGTGACAGACGATATGAGGCTATATCGCCGATAGAGG 
CGACATCAAGCTGGCACATGGCCAATGCATATCGATCTATACATTGAATCAATATTGGCC 
ATTAGCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCA 
TACGTTGTATCCATATCGTAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCC 
ATGTTGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCA 
TAGCCCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACC 
GCCCAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAAT 
AGGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGT 
ACATCAAGTGTATCATATGCCAAGTCCGCCCCCTATTGACGTCAATGACGGTAAATGGCC 
CGCCTGGCATTATGCCCAGTACATGACCTTACGGGACTTTCCTACTTGGCAGTACATCTA 
CGTATTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACACCAATGGGCGTGG 
ATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTT 
GTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTGCGATCGCCCGCC 
CCGTTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGT 
TTAGTGAACCGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAAAAGG 
CCTTTGTAATAAATATAATTCTCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTCGAGATC 
CTACAGTTGGCGCCCGAACAGGGACCTGAGAGGGGCGCAGACCCTACCTGTTGAACCTGG 
CTGATCGTAGGATCCCCGGGACAGCAGAGGAGAACTTACAGAAGTCTTCTGGAGGTGTTC 
CTGGCCAGAACACAGGAGGACAGGTAAGATTGGGAGACCCTTTGACATTGGAGCAAGGCG 
CTCAAGAAGTTAGAGAAGGTGACGGTACAAGGGTCTCAGAAATTAACTACTGGTAACTGT 
AATTGGGCGCTAAGTCTAGTAGACTTATTTCATGATACCAACTTTGTAAAAGAAAAGGAC 
TGGCAGCTGAGGGATGTCATTCCATTGCTGGAAGATGTAACTCAGACGCTGTCAGGACAA 
GAAAGAGAGGCCTTTGAAAGAACATGGTGGGCAATTTCTGCTGTAAAGATGGGCCTCCAG 
ATTAATAATGTAGTAGATGGAAAGGCATCATTCCAGCTCCTAAGAGCGAAATATGAAAAG 
AAGACTGCTAATAAAAAGCAGTCTGAGCCCTCTGAAGAATATCTCTAGAGTCGACGCTCT 
CATTACTTGTAACAAAGGGAGGGAAAGTATGGGAGGACAGACACCATGGGAAGTATTTAT 
CACTAATCAAGCACAAGTAATACATGAGAAACTTTTACTACAGCAAGCACAATCCTCCAA 
AAAATTTTGTTTTTACAAAATCCCTGGTGAACATGGTCGACTCTAGAACTAGTGGATCCC 
CCGGGCTGCAGGAGTGGGGAGGCACGATGGCCGCTTTGGTCGAGGCGGATCCGGCCATTA 
GCCATATTATTCATTGGTTATATAGCATAAATCAATATTGGCTATTGGCCATTGCATACG 
TTGTATCCATATCATAATATGTACATTTATATTGGCTCATGTCCAACATTACCGCCATGT 
TGACATTGATTATTGACTAGTTATTAATAGTAATCAATTACGGGGTCATTAGTTCATAGC 
CCATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCCC 
AACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATAGGG 
ACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAGTACAT 
CAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATGGCCCGCC 
TGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTACATCTACGTA 
TTAGTCATCGCTATTACCATGGTGATGCGGTTTTGGCAGTACATCAATGGGCGTGGATAG 
CGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAATGGGAGTTTGTTT 
TGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCCGCCCCATTGACGCAA 
ATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAGCTCGTTTAGTGAACCGT 
APPENIDICES  
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CAGATCGCCTGGAGACGCCATCCACGCTGTTTTGACCTCCATAGAAGACACCGGGACCGA 
TCCAGCCTCCGCGGCCCCACTAGAACTAGTGGATCCGTCGACCATGCAGCGCGTGAACAT 
GATCATGGCAGAATCACCAGGCCTCATCACCATCTGCCTTTTAGGATATCTACTCAGTGC 
TGAATGTACAGTTTTTCTTGATCATGAAAACGCCAACAAAATTCTGAATCGGCCAAAGAG 
GTATAATTCAGGTAAATTGGAAGAGTTTGTTCAAGGGAACCTTGAGAGAGAATGTATGGA 
AGAAAAGTGTAGTTTTGAAGAAGCACGAGAAGTTTTTGAAAACACTGAAAGAACAACTGA 
ATTTTGGAAGCAGTATGTTGATGGAGATCAGTGTGAGTCCAATCCATGTTTAAATGGCGG 
CAGTTGCAAGGATGACATTAATTCCTATGAATGTTGGTGTCCCTTTGGATTTGAAGGAAA 
GAACTGTGAATTAGATGTAACATGTAACATTAAGAATGGCAGATGCGAGCAGTTTTGTAA 
AAATAGTGCTGATAACAAGGTGGTTTGCTCCTGTACTGAGGGATATCGACTTGCAGAAAA 
CCAGAAGTCCTGTGAACCAGCAGTGCCATTTCCATGTGGAAGAGTTTCTGTTTCACAAAC 
TTCTAAGCTCACCCGTGCTGAGACTGTTTTTCCTGATGTGGACTATGTAAATTCTACTGA 
AGCTGAAACCATTTTGGATAACATCACTCAAAGCACCCAATCATTTAATGACTTCACTCG 
GGTTGTTGGTGGAGAAGATGCCAAACCAGGTCAATTCCCTTGGCAGGTTGTTTTGAATGG 
TAAAGTTGATGCATTCTGTGGAGGCTCTATCGTTAATGAAAAATGGATTGTAACTGCTGC 
CCACTGTGTTGAAACTGGTGTTAAAATTACAGTTGTCGCAGGTGAACATAATATTGAGGA 
GACAGAACATACAGAGCAAAAGCGAAATGTGATTCGAATTATTCCTCACCACAACTACAA 
TGCAGCTATTAATAAGTACAACCATGACATTGCCCTTCTGGAACTGGACGAACCCTTAGT 
GCTAAACAGCTACGTTACACCTATTTGCATTGCTGACAAGGAATACACGAACATCTTCCT 
CAAATTTGGATCTGGCTATGTAAGTGGCTGGGGAAGAGTCTTCCACAAAGGGAGATCAGC 
TTTAGTTCTTCAGTACCTTAGAGTTCCACTTGTTGACCGAGCCACATGTCTTCGATCTAC 
AAAGTTCACCATCTATAACAACATGTTCTGTGCTGGCTTCCATGAAGGAGGTAGAGATTC 
ATGTCAAGGAGATAGTGGGGGACCCCATGTTACTGAAGTGGAAGGGACCAGTTTCTTAAC 
TGGAATTATTAGCTGGGGTGAAGAGTGTGCAATGAAAGGCAAATATGGAATATATACCAA 
GGTATCCCGGTATGTCAACTGGATTAAGGAAAAAACAAAGCTCACTTAATGAAAGATGGA 
TTTCCAAGGTTAATTCATTGGAATTGAAAATTAACAGGGCCTCTCACTAACTAATCACTT 
TCCCATCTTTTGTTAGATTTGAATATATACATTCTATGATCATTGCTTTTTCTCTTTACA 
GGGGAGAATTTCATATTTTACCTGAGCAAATTGATTAGAAAATGGAACCACTAGAGGAAT 
ATAATGTGTTAGGAAATTACAGTCATTTCTAAGGGCCCAGCCCTTGACAAAATTGTGAAG 
TTAAATTCTCCACTCTGTCCATCAGATACTATGGTTCTCCACTATGGCAACTAACTCACT 
CAATTTTCCCTCCTTAGCAGCATTCCATCTTCCCGATCTTCTTTGCTTCTCCAACCAAAA 
CATCAATGTTTATTAGTTCTGTATACAGTACAGGATCCCCCGGGCTGCAGGAATTCGATA 
TCAAGCTTATCGATACCGTCGACCTCGAGGGGGGGCCCGACCTACTAGGGTGCTGTGGAA 
GGGTGATGGTGCAGTAGTAGTTAATGATGAAGGAAAGGGAATAATTGCTGTACCATTAAC 
CAGGACTAAGTTACTAATAAAACCAAATTGAGTATTGTTGCAGGAAGCAAGACCCAACTA 
CCATTGTCAGCTGTGTTTCCTGACCTCAATATTTGTTATAAGGTTTGATATGAATCCCAG 
GGGGAATCTGAACCCCTATTACCCAACAGTCAGAAAAATCTAAGTGTGAGGAGAACACAA 
TGTTTCAACCTTATTGTTATAATAATGACAGTAAGAACAGCATGGCAGAATCGAAGGAAG 
CAAGAGACCAAGAATGAACCTGAAAGAAGAATCTAAAGAAGAAAAAAGAAGTGGAAAATA 
GGTATGTTTCTGTTATGCTTAGCAGGAACTACTGGAGGAATACTTTGGTGGTATGAAGGA 
CTCCCACAGCAACATTATATAGGGTTGGTGGCGATAGGGGGAAGATTAAACGGATCTGGC 
CAATCAAATGCTATAGAATGCTGGGGTTCCTTCCCGGGGTGTAGACCATTTCAAAATTAC 
TTCAGTTATGAGACCAATAGAAGGTGACCAGTGGTGCAGGGTCCTCCGGCAGTCGTTACC 
TGAAGAAAAAATTCCATCACAAACATGCATCGCGAGAAGACACCTGGGACCAGGCCCAAC 
ACAACATACACCTAGCAGGCGTGACCGGTGGATCAGGGGACAAATACTACAAGCAGAAGT 
ACTCCAGGAACGACTGGAATGGAGAATCAGAGGAGTACAACAGGCGGCCAAAGAGCTGGG 
TGAAGTCAATCGAGGCATTTGGAGAGAGCTATATTTCCGAGAAGACCAAAGGGGAGATTT 
CTCAGCCTGGGGCGGCTATCAACGAGCACAAGAACGGCTCTGGGGGGAACAATCCTCACC 
AAGGGTCCTTAGACCTGGAGATTCGAAGCGAAGGAGGAAACATTTATGACTGTTGCATTA 
AAGCCCAAGAAGGAACTCTCGCTATCCCTTGCTGTGGATTTCCCTTATGGCTATTTTGGG 
GGCTAGTAATTATAGTAGGACGCATAGCAGGCTATGGATTACGTGGACTCGCTGTTATAA 
TAAGGATTTGTATTAGAGGCTTAAATTTGATATTTGAAATAATCAGAAAAATGCTTGATT 
ATATTAGCTTCGAATCACTAGTGAATTCGCGGCCGCAATCAACCTCTGGATTACAAAAAT 
TTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGC 
APPENIDICES  
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TGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTT 
GTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGG 
CGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTG 
TCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGC 
CGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGT 
GTTGTCGGGGAAGCTGACGTCCTTTCCATGGCTGCTCGCCTGTGTTGCCACCTGGATTCT 
GCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCG 
CGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCG 
GATCTCCCTTTGGGCCGCCTCCCCGCCTGATCGATGTCGAGAATCACTAGTGAATTCGCG 
GCCGCTCGACAGCTTATCGATACCGTCGAATTGGAAGAGCTTTAAATCCTGGCACATCTC 
ATGTATCAATGCCTCAGTATGTTTAGAAAAACAAGGGGGGAACTGTGGGGTTTTTATGAG 
GGGTTTTATAAATGATTATAAGAGTAAAAAGAAAGTTGCTGATGCTCTCATAACCTTGTA 
TAACCCAAAGGACTAGCTCATGTTGCTAGGCAACAATTGGGCACTCAGATTCTGCGGTCT 
GAGTCCCTTCTCTGCTGGGCTGAAAAGGCCTTTGTAATAAATATAATTCTCTACTCAGTC 
CCTGTCTCTAGTTTGTCTGTTCGAGATCCTACAGAGCTCATGCCTTGGCGTAATCATGGT 
CATAGCTGTTTCCTGTGTGAAATTGTTATCCGCTCACAATTCCACACAACATACGAGCCG 
GGAGCATAAAGTGTAAAGCCTGGGGTGCCTAATGAGTGAGCTAACTCACATTAATTGCGT 
TGCGCTCACTGCCCGCTTTCCAGTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCG 
GCCAACGCGCGGGGAGAGGCGGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTG 
ACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAA 
TACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGC 
AAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCC 
CTGACGAGCATCACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTAT 
AAAGATACCAGGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGC 
CGCTTACCGGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCT 
CACGCTGTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACG 
AACCCCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACC 
CGGTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGA 
GGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAGAA 
GAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTTGGTA 
GCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCAAGCAGC 
AGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTACGGGGTCTG 
ACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTATCAAAAAGGA 
TCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCTAAAGTATATATG 
AGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACCTATCTCAGCGATCT 
GTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAGATAACTACGATACGGG 
AGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAGACCCACGCTCACCGGCTC 
CAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGAGCGCAGAAGTGGTCCTGCAA 
CTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGGGAAGCTAGAGTAAGTAGTTCGC 
CAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTACAGGCATCGTGGTGTCACGCTCGT 
CGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCAACGATCAAGGCGAGTTACATGATCCC 
CCATGTTGTGCAAAAAAGCGGTTAGCTCCTTCGGTCCTCCGATCGTTGTCAGAAGTAAGT 
TGGCCGCAGTGTTATCACTCATGGTTATGGCAGCACTGCATAATTCTCTTACTGTCATGC 
CATCCGTAAGATGCTTTTCTGTGACTGGTGAGTACTCAACCAAGTCATTCTGAGAATAGT 
GTATGCGGCGACCGAGTTGCTCTTGCCCGGCGTCAATACGGGATAATACCGCGCCACATA 
GCAGAACTTTAAAAGTGCTCATCATTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGA 
TCTTACCGCTGTTGAGATCCAGTTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAG 
CATCTTTTACTTTCACCAGCGTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAA 
AAAAGGGAATAAGGGCGACACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATT 
ATTGAAGCATTTATCAGGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGA 
AAAATAAACAAATAGGGGTTCCGCGCACATTTCCCCGAAAAGTGCCACCTAAATTGTAAG 
CGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCA 
ATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAG 
TGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGG 
GCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTT 
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TTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAG 
AGCTTGACGGGGAAAGCCAACCTGGCTTATCGAAATTAATACGACTCACTATAGGGAGAC 
CGGC 
 
Sequence features: Length 9434 bp 
CMV enhancer 543-1150 
5' LTR 1151-1264 
R 1151-1225 
U5 1226-1265 
tat exon 1 1308-1403 
major splice donor CAG*GTAAGA 1403 
gag remnant 1409-1783 
(ATGs mutated to ATTGs 1409 & 1427) 
pol remnant 1796-1955 
(includes cPPT 1811-1824) 
CMV promoter 2030-2838 
FIX coding sequence 2864-4251 
FIX 3' UTR 4252-4657 
pol remnant 4719-4831 
major splice acceptor TTGTTGCAG*GAA 4844 
tat exon 2 remnant 4844-4901 
s2 remnant 4914-5057 
rev exon 1 remnant 5022-5110 
rev exon 2 remnant 5318-5699 
env remnants 4914-5892 
6579-6635 
WPRE 5927-6519 
(unmutated X promoter 6317-6337) 
(unmutated X start codon 6338-6349) 
3’ PPT 6637-6650 
3' LTR 6655-6883 
U3 6654-6768 
R 6769-6843 
U5 6844-6883 
AmpR 8930-8070 
 
pSmart2FIX 2 sequenced 2005 
Predicted amino acid sequence of Factor IX: 
MQRVNMIMAE SPGLITICLL GYLLSAECTV FLDHENANKI LNRPKRYNSG 
KLEEFVQGNL ERECMEEKCS FEEAREVFEN TERTTEFWKQ YVDGDQCESN 
PCLNGGSCKD DINSYECWCP FGFEGKNCEL DVTCNIKNGR CEQFCKNSAD 
NKVVCSCTEG YRLAENQKSC EPAVPFPCGR VSVSQTSKLT RAETVFPDVD 
YVNSTEAETI LDNITQSTQS FNDFTRVVGG EDAKPGQFPW QVVLNGKVDA 
FCGGSIVNEK WIVTAAHCVE TGVKITVVAG EHNIEETEHT EQKRNVIRII 
PHHNYNAAIN KYNHDIALLE LDEPLENTIVIRUSESLNSY VTPICIADKE 
YTNIFLKFGS 
GYVSGWGRVF HKGRSALENTIVIRUSESLQ YLRVPLENTIVIRUSESDRA 
TCLRSTKFTI YNNMFCAGFH 
EGGRDSCQGD SGGPHVTEVE GTSFLTGIIS WGEECAMKGK YGIYTKVSRY 
VNWIKEKTKL T• 
(461 residues) 
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APPENDIX 4 
 
 
 Observations in MF-1 mice treated with SMART2 vector  
 
 
Vector Mouse tissue  
samples  
Gender Phenotype at death 
- Uninfected  Male * 
- Cat Male Well appearance. Mouse tissues 
normal (age at death = 715). 
- Ching Female Large amounts of adipose tissue, large 
blood clot on the side of neck 
otherwise tissues appeared normal (age 
at death = 819). 
 Angus  Male Medium sized liver tumour palpable, 
very small lung tumour. Bleb on liver 
near gall bladder 
SMART2Z Agnus  Female Tumour palpable, very small lung 
tumour. Bleb on liver near gall bladder 
 Archie  Male Mouse very sick, Single small liver 
tumour 
 Adame  Female Solid mass attached to gut and four 
liver tumours. Lungs appeared wasted. 
 Gina  Male Well appearance, liver tumour by 
palpation 
 Gerty  Female Very small and ill looking (half weight 
of other mice), no tumour found 
 Golliath  Male Very sick, large kidneys, two liver 
tumours and multiple liver lumps, 
large spleen with blemishes 
SMART2ZWΔ Gladys  Female Well appearance but tumour palpable 
 Gerry  Male Healthy but a big bulgy, 8 liver 
tumours found 
 Gonzo  
 
Male Scabby, sore patches on face and ears. 
Hunch swollen abdomen fir on end. 
Six bone tumours on hind limbs. No 
abnormal liver or lungs. 
SMART2 hFIX Jonas  Male Well appearance but tumour palpable 
SMART2lacZ 
LCMV 
Monika  Male Well appearance but large tumour 
palpable 
SMART2lacZ 
rabies 
Rachel  Female Well appearance, no tumour palpable 
SMARTZ Ebola Mike  Male Ungroomed, huge tumour palpable 
* Is used to represent mice for which the phenotype was not given for this study. 
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APPENDIX 5 
 
 
Observations in MF-1 mice treated with pLIONhAATGFP vector  
 
Vector Mouse 
tissue  
samples 
Gender Phenotype at death 
 Flora   Female Scabby back of neck and ears and 
conjunctivitis in one eye. All tissue 
normal except for an ovarian cyst 
 Frank  Male Healthy looking but tumour visibly large 
and easily palpable 
pLIONhAATGFP 
 
Fanny  Female There were two tumours. Tumour 1 
glowed intense green with two extremely 
green foci, and tumour 2 glowed much 
less, but had foci or seams of more 
intense glowing than the surrounding 
liver. 
 Fiona  
 
Female` Healthy looking but two floppy green 
tumours inside on liver 
 
 
APPENDIX 6 
 
 
Observations in MF-1 mice treated with HR’SIN-cPPT-S-FIX-W vector  
 
Vector Mouse 
tissue  
samples 
Gender Phenotype at death* 
 Topsy  Female Neck mass was soft and necrotic, One dark 
ovary enlarged and one small also dark 
very bloody, Very enlarged spleen, 
 Tilley  Female Mouse tissues normal. Lung found with 
large tumour 
HR’SIN-
cPPT-S-FIX-
W 
Kostas  Male Scabby mouse around shoulder blades. 
Otherwise healthy. Liver normal. 
 Bruce  Female * 
 Pierre  Male * 
 
* Is used to represent mice for which the phenotype was not given for this study. 
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APPENDIX 7 
 
Southern analysis was also carried out prior to this thesis to determine the clonality 
of tumours. Southern analysis was performed on normal hepatic tumour tissue that 
was isolated from SMART2Z, SMART2ZWΔ and pLIONhAATGFP treated MF-1 
mice. This study showed that clonally derived liver tumours develop in mice 
following lentivirus delivery into fetal mice. VCN’s ranging from 1-10 was shown 
with varying intensities of vector signal following hybrisdisation of a radioactive 
WPRE probe to equal amounts of tumour DNA. The results produced by normal 
samples showed a smear. This confirms the heterogenous nature of the normal 
samples which contain numerous provirus insertions per sample.  
 
 
 
  
SMART2Z 
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SMART2ZWΔ 
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SMART2ZWΔ 
APPENIDICES  
 
196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pLIONhAATGFP 
SMART2ZWΔ 
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pLIONhAATGFP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The restriction enzyme Hind III was used to geneate DNA fragments . Integrated 
proviruses were detected and identified by hibridisation with a α-32P-CTP labelled 
WPRE probe (625bp).  Vector copy numbers were estimated according to the 
visibility of bands on autoradiographs following hybridisation. Intense fragments 
correlated to multiple bands.  No signal was obtained from control non-infected 
hepatic issue samples.   
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APPENDIX  8 
 
FIV integration sites sequences 
 
                       Flora Ovarian Cyst            1,166bp 
 
CCAAACTCTATACGACTCACTATAGGGAAAGCTCGGTACCACGCATGCTGCAGACGCGTT 
ACGTATCGGATCCAGAATTCGTGATTCTCAAAAGTCCTCAACAAAGGAGTACACGTGGCT 
CCAGCTTCATAGGTAGCAGAGGGTGGCTTTGTCATGCATCAGTGGAAGGAGAGGTCCTTG 
GTCCTATGAAGGCTTGATAGATGGCCCATTGTAGGGTAATTGAGGGCAGGGAGGTGGGAG 
TTGTTAGGTGGGTAGAGAAACACACTCATAGAAGCATGGAGAGGGAGGTTGAGATAGGGG 
TTTTCTGGGAGGGAGGAAAACCAGGAAAGGGGATACCATTTGAAATGTAAATAAGGAAAA 
TATCCTTTAAAAAATAAAACCTAACTGCTGTGCCACTGAATTCAGATCAATCTGAATTCG 
TCGACAAGCTTCTCGAGCCTAGGCTAGCTCTAGACCACACGTGTGGGGGCCCGAGCTCGC 
GGCCGCTGTATTCTATAGTGTCACCTAAATGGCCGCACAATTCACTGGCCGTCGTTTTAC 
AACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCC 
CTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGC 
GCAGCCTGAATGGCGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAA 
TTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAA 
ATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACT 
ATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCC 
ACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGGTCGAGGTGCCGTAAAGCACTAA 
ATCGGAACCCTAAAGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGACGTGGCG 
AGAAAGGAGGGAGAAAGCGAAGGAGCGGTCGCTTAGGCGCTGGCA 
 
      10 – 85 = pDrive vector 
    98 – 379 = Chr 13 (Prl4a1 or Prl2c3) 
  380 – 408 = LC3 linker  
410 – 1065 =  pDrive vector 
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                      Flora Ovarian Cyst             1,281bp 
 
CCAGCCCTATACGACTCACTATAGGGAAAGCTCGGTACCACGCATGCTGCAGACGCGTTA 
CGTATCGGATCCAGAATTCGTGATGATCTGAATTCAGTGGCACAGCAGTTAGGGATCATG 
AAGGCCATCTGCAGCTATCTTTGTTGAGGACTTTTGAGAATCTGAATTCGTCGACAAGCT 
TCTCGAGCCTAGGCTAGCTCTAGACCACACGTGTGGGGGCCCGAGCTCGCGGCCGCTGTA 
TTCTATAGTGTCACCTAAATGGCCGCACAATTCACTGGCCGTCGTTTTACAACGTCGTGA 
CTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAG 
CTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAA 
TGGCGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAA 
ATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCTTATAAATCAAAAGAA 
TAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGTCCACTATTAAAGAAC 
GTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGATGGCCCACTACGTGAA 
CCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCACTAAATCGGAACCCT 
AAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAACGTGGCGAGAAAGGAA 
GGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTAGCGGTCACGCTGCGC 
GTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCGTCAGGTGGCACTTTT 
CGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTAT 
CCGCTCATGAGACATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAGAGTATGAG 
TATTCAACATTTCCGTGTCGCCCTTATCCCTTTTTTGCGGCATTTTGCTTCCTGTTTTGC 
TCACCCAGAACGCTGGTGAAGTAAAGATGCTGAGATCAGTTGGGTGCCACGAGTGCTTAC 
ATCGAACTGATCTTAACAGCG 
 
        9 – 84 = pDrive vector 
    85 – 113 = LC1 linker 
  118 – 138 = Chr14 (Sacs/Tnfrsf19) 
  139 – 158 = FIV 
160 – 1161 = pDrive vector 
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                       Fiona T2                      1,177bp 
 
GCGCTCTATACGACTCACTATAGGGAAAGCTCGGTACCACGCATGCTGCAGACGCGTTAC 
GTATCGGATCCAGAATTCGTGATTGATCTGAATTCAGTGGCACAGCAGTTAGGGATCATA 
AAGATCTAGCTTTAAATACCTCACAAGAATTTTAAATAAATATGGTCCTCCTCTCCCATC 
AGTATCCTACACAAAATGCCACCTGCTTAAATACTTCCTAAAAAAGAGCTGGGGAGAGAA 
CTTCACTGGGGAAATGGGATGAGTATTGGAACCCTGAAGGCCCGATTGATCAGCTCCTAG 
GTAACCAGTGCTTTGTGAAACTTCGAGGAGTCTCTTTGTTGAGGACTTTTGAGAATCTGA 
ATTCGTCGACAAGCTTCTCGAGCCTAGGCTAGCTCTAGACCACACGTGTGGGGGCCCGAG 
CTCGCGGCCGCTGTATTCTATAGTGTCACCTAAATGGCCGCACAATTCACTGGCCGTCGT 
TTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACA 
TCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACA 
GTTGCGCAGCCTGAATGGCGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCG 
TTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCT 
TATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT 
CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGAT 
GGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGGTCGAGGTGCCGTAAAGC 
ACTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAA 
CGTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGCGCTGGCAAGTGTA 
GCGGTCACGCTGCGCGTACCACCACACCCGCCGCGCTTATGCGCCGCTAGAGGCGCGTCA 
GTGCACTTTTCGGGGAAATGTG 
 
        8 – 83 = pDrive vector 
    85 – 113 = LC1 linker 
  116 – 254 = Chr 5 (Pscd3) 
  255 – 353 = FIV 
355 – 1102 = pDrive vector 
 
 Fanny T1                     1,159bp  
 
ACGTCTTATACGACTCACTATAGGGAAGCTCGGTACCACGCATGCTGCAGACGCGTTACG 
TATCGGATCCAGAATTCGTGATTCTCAAAAGTCCTCAACAAAGAGACTCCTCGAAGTTTC 
ACAAAGCACTGGTTACCTAGGAGCTGATCAATCAGGCCTTCAGGGTTCCAATACTCATCC 
CAGTAACAAGTTAAACAATGACATCAAAAAGACTTGAAGATAAGGGACATTACTACCATA 
CTCCAAAATAAAAAGAATGGTTCAAAATGCCTTTCCCCCACTCTCCTCTGTCCACTGTAC 
TGTCAGTTCACCTTTAGGATTTGTCTTGGAGCTATTGATCCCTAACTGCTGTGCCACTGA 
ATTCAGATCAATCTGAATTCGTCGACAAGCTTCTCGAGCCTAGGCTAGCTCTAGACCACA 
CGTGTGGGGGCCCGAGCTCGCGGCCGCTGTATTCTATAGTGTCACCTAAATGGCCGCACA 
ATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTA 
ATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCG 
ATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGAAATTGTAAGCGTTAATAT 
TTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGA 
AATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCC 
AGTTTGGAACAAGAGTCCACTATTAAGAACGTGGACTCCAACGTCAAAGGGCGAAAACCG 
TCTATCAGGGCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTGGGGTCGAG 
GTGCCGTAAAGCACTAAATCGGACCCTAAAGGGAGCCCCGATTTAGAGCTTGACGGGGAA 
GCCGGCGACGTGGCGAGAAGGAGGGAGAAGCGAAAGGGCGGGCGCTAGGCGCTGCAAGTG 
TAGCGTCACGCTGCGCGTAACCACACACCGCGCGCTTATGCGCCGCTACAGGCGCGTCAG 
 
        8 – 82 = pDrive vector 
    84 – 182 = FIV 
  183 – 336 = Chr 18 (Cx39/similar to cyclin fold protein1) 
  341 – 369 = LC3 linker 
371 – 1080 = pDrive vector 
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                     Fanny T1                          684bp 
 
GGCGGCCCTATACGACTTCCTTATAGGGAAAGCTCGGTACCACGCATGCTGCAGACGCGT 
TACGTATCGGATCCAGAATTCGTGATTGATCTGAATTCAGTGGCACAGCAGTTAGGAATT 
ATATTAAACCTAGTGATGAGGATAAGAGAAAGAAACTTGCTAGGCAGTTAAGGGAAAGAA 
ACGTTGCAAACAAGCCCTTCTGCCGTGGCCAAAAGTATCCTTGGCTCCAATGACAGTTCT 
GGTCTGGCCAGAGGGCAGAACATACTGGTTTGTGTTCTTAGATGTTTACTTGTCTTTTTT 
CTTTAGTACAGTAATCTAATGAGCATAGCTGCCTGGAAGCTAGACATACTCTAATACTTC 
ATTGGTCCTTGGAGGTGTTTGGGATGAGTATTGGAACCCTGAAGGCCTGATTGATCAGCT 
CCTAGGTAACCAGTGCTTTGTGAAACTTCGAGGAGTCTCTTTGTTGAGGACTTTTGAGAA 
TCTGAATTCGTCGACAAGCTTCTCGAGCCTAGGCTAGCTCTAGACCACACGTGTGGGGGC 
CCGAGCTCGCGGCCGCTGTATTCTATAGTGTCACCTAAATGGCCGCACAATTCACTGGCC 
GTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCA 
GCACATCCCCCTTTCGCCAGCTGG 
 
 
    22 – 86 = pDrive vector 
  88 – 116 = LC1 linker 
117 – 380 = Chr 19 (Pdcd1lg2) 
381 – 478 = FIV 
480 – 684 = pDrive vector 
 
 
 
 Frank T1                   853bp  
 
ACTAAATTACGGGGGAAAAGCTCGGGTACCACGCATGCTAGCAGACGCGTTACGTATCGG 
ATCCAGAATTCGTGATCTCAAAAGTCCTCAACAAAGAGACTCCTCGAAGTTTCACAAAGC 
ACTGGTTACCTAGGAGCTGATCAATCAGGCCTTCAGGGTTCCAATACTCATCCCACTTGG 
GAACACACTGTTGGCTACACAATCCTAGTTTTGATCTCTGTCTTAGGATTCCCCTCATTC 
CATCTAATAGCAGCATCTCCCCTCTCCCAGACACTCTGACATAGTCTTATTCCATAGTCA 
CTAGTCACTCACTTCCATGAACTCTTAAGTGCCTCCACTTCTCCCTGTGACATCTGTACC 
CTCTTAGCTCTATAAACATCTTGCCTTGTCTGTATTGTCACAAATCTTAAACTCTCATTA 
CCCTCACCATTTTGTTCCCAAAGAATCATCCAAGTTGCCTTTCTCAAATACAAATCATGT 
AAAATCTTGCTCTTAGTCCTTTGTGCAGAATCTAAACTCCCAATTCCTAACTGCTGTGCC 
ACTGAATTCAGATCAATCTGAATTCGTCGACAAGCTTCTCGAGCCTAGGCTAGCTCTAGA 
CCACACGTGTGGGGGCCCGAGCTCGCGGCCGCTGTATTCTATAGTGTCACCTAAATGGCC 
GCACAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCA 
ACTTAATCGCCTTGCAGCACATCCCCCTTTCGCCAGCTGGCGTATAGCGAAAGAGGCCCG 
CACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAAATGGCGAATGGAATTGTAAGCGTT 
ATATTTTGTTAAA 
 
 
    25 – 76 = pDrive vector 
176 – 262 = Chr12 (Nek9) 
263 – 521 = Chr 3 (Pglyrp4) 
522 – 554 = LC3 linker 
556 – 853 = pDrive vector 
 
 
 
 
 
APPENIDICES  
 
202 
 
 Frank T1                  1,063bp   
 
AACTTAATAAGGGGGAAAAGCTTCGGTACCACGCATGCTGCAGACGCGTTACGTATCGGA 
TCCAGAATTCGTGATTCTCAAAAGTCCTCAACAAAGAGACTCCTCGAAGTTTCACAAAGC 
ACTGGTTACCTAGGAGCTGATCAATCAGGCCTTCAGGGTTCCAATACTCATCCCACTTGG 
GAACACACTGTTGGCTACACAATCCTAGTTTTGATCTCTGTCTTAGGATTCCCCTCATTC 
CATCTAATAGCAGCATCTCCCCTCTTCCTGACATGTACTGACAGTCCTACTATGAAATCA 
GCTAACGTGGAACTGTTGCCACATCTCTGAGTAGTCAGATACCTCGGGCCCCTGCCTAGT 
AGAGATAATGCTATATTTTTGTTTTAATTCCTAACTGCTGTGCCACTGAATTCAGATCAA 
TCTGAATTCGTCGACAAGCTTCTCGAGCCTAGGCTAGCTCTAGACCACACGTGTGGGGGC 
CCGAGCTCGCGGCCGCTGTATTCTATAGTGTCACCTAAATGGCCGCACAATTCACTGGCC 
GTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCA 
GCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCC 
CAACAGTTGCGCAGCCTGAATGGCGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAAT 
TCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAA 
TCCCTTATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACA 
AGAGTCCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGG 
GCGATGGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTA 
AAGCACTAATTCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGG 
 
      
      23 – 75 = pDrive vector 
    77 – 175 = FIV 
  176 – 385 = Chr 12 (Nek9)  
  386 – 418 = LC3 linker 
420 – 1011 = pDrive vector 
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                        Frank T2                     1,268bp  
 
ACGTCTTATCGACTCACTATAGGGAAGCTCGGTACCACGCATGCTGCAGACGCGTTACGT 
ATCGGATCCAGAATTCGTGATTGATCTGAATTCAGTGGCACAGCAGTTAGGAGATAGCTG 
AGACTCAGGTGGACTGGGATGAGTATTGGAACCCTGAAGGCCTGATTGATCAGCTCCTAG 
GTAACCAGTGCTTTGTGAAACTTCGAGGAGTCTCTTTGTTGAGGACTTTTGAGAATCTGA 
ATTCGTCGACAAGCTTCTCGAGCCTAGGCTAGCTCTAGACCACACGTGTGGGGGCCCGAG 
CTCGCGGCCGCTGTATTCTATAGTGTCACCTAAATGGCCGCACAATTCACTGGCCGTCGT 
TTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTGCAGCACA 
TCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACA 
GTTGCGCAGCCTGAATGGCGAATGGAAATTGTAAGCGTTAATATTTTGTTAAAATTCGCG 
TTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGAAATCGGCAAAATCCCT 
TATAAATCAAAAGAATAGACCGAGATAGGGTTGAGTGTTGTTCCAGTTTGGAACAAGAGT 
CCACTATTAAAGAACGTGGACTCCAACGTCAAAGGGCGAAAAACCGTCTATCAGGGCGAT 
GGCCCACTACGTGAACCATCACCCTAATCAAGTTTTTTGGGGTCGAGGTGCCGTAAAGCA 
CTAAATCGGAACCCTAAAGGGAGCCCCCGATTTAGAGCTTGACGGGGAAAGCCGGCGAAC 
GTGGCGAGAAAGGAAGGGAAGAAAGCGAAAGGAGCGGGCGCTAGGGCGCTGGCAAGTGTA 
GCGGTCACGCTGCGCGTAACCACCACACCCGCCGCGCTTAATGCGCCGCTACAGGGCGCG 
TCAGTGGCACTTTTCGGGGATATGTGCGCGGACCGCTATTTGTTATTTTTCGGACTACAT 
TCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCA 
 
    10 –     81  =  pDrive vector 
    83 –   111  =  LC1 linker 
  112 –   132  =  Chr16 (Coro7) 
  133 –   233  =  FIV  
  234 – 1067  = pDrive vector 
 
 
The BLAST sequence results were used to annotate the mouse genomic DNA flanking the 
provirus integration site. Purple, red and green were used to represent the pDRIVE cloning 
plasmid, mouse genomic DNA and linker cassette sequence (used to ligate restriction products) 
respectively. Mouse genomic sequences represented in LAM PCR products included – a) Prl4a1/ 
Prl2c3 b) Sacs/Tnfrs19 c) Pscd3, d) CX39/similar to cyclin fold protein1 e) Pdcd1lg2 f) Pglyrp4 
g) Nek9 h) Coro7. 
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APPENDIX 9 
 
 
454 pyrosequencing results: EIAV integration sites with high sequence counts  
 
Pah 
 
GATCTGAATTCAGTGGCACAGCAGTTAGGTTTCCAGAGCCTCCTGCTCCCTCCTAG
ATAGAATCTTTCAGTTTGGAAAAACTGCCATTCAGCAGCCTGAATTTGTGGCACTGA
GGAATAGAACCAAAGTGAAGAGTCTATTGTTTAGAACCAAACTCAGTTGATCCACTT
GTTATCGAGATGGGCAAAAGGAAGCTTTTAACCTCTTGGCTTAGTTTCCTTAGTTTC
TGTGGGGTTTTTATGAGGGGTTTTATAAATGATTATAAGAGTAAGAAGAAAGTTGCT
GATGCTCTCATAACCTTGTATAAC 
 
Acvr2a 
 
GATCTGAATTCAGTGGCACAGCAGTTAGGTGACAATTGAAGTTTAGAGATTAGGCA
CACCCAAGTCAGAAGGCAGATGAGACAGAGCATGAGCTGAAACATTGCATTTGGTT
TTTGATTTGTTTTGTTTTGTTTTATTGCTGGTGTCATTGTTTGGTTGGGTCTTTATTT
TGATTTTCTTTGTTTTGTTCACTGAGACAAGATCTCACCATGCAACTGTGGGGTTTT
TATGAGGGGTTTTATAAATGATTATAAGAGTAAGAAGAAAGTTGCTGATGCTCTCAT
AACCTTGTATAAC 
 
Setd5 
 
GATCTGAATTCAGTGGCACAGCAGTTAGGAATTCATGTTCTGGTGCTTCTAGTTAAG
TGTGTGGGGTTTTTATGAGGGGTTTTATAAATGATTATAAGAGTAAGAAGAAAGTT
GCTGATGCTCTCATAACCTTGTATAAC 
 
Mrpl1 
 
GATCTGAATTCAGTGGCACAGCAGTTAGGAATTTGTTTATGGTTATTGCTGAAGTAT
GTGCACAAAAATATTTTTTAAATATAAAAACTAATTTGAGCACTTTGGAAAGCCATG
ATACAGATGTAGCCAAGCTACGTCACCACCGTTGCTGCCGGATTTTGGATAAGAAA
ACAACCGAGGTCATAACTGATAGAGCACTTGCCTAATATTTGAAAGGCTCCTGGGG
TTTTTATGAGGGGTTTTATAAATGATTATAAGAGTAAGAAGAAAGTTGCTGATGCTC
TCATAACCTTGTATAAC 
 
Uvrag 
 
GATCTGAATTCAGTGGCACAGCAGTTAGGTTATGTTGTGGAATGTGACTTTGATCTA
CTTGGCAGGAATTTTATTTTACAAAACTTACTATTAAAAAAGACAGGTTTTCCATCC
TTTAATTATGCTGTGTTCACTGAACTTTGTTGGGGTTTTTATGAGGGGTTTTATAAA
TGATTATAAGAGTAAGAAGAAAGTTGCTGATGCTCTCATAACCTTGTATAAC 
 
Park7 
 
GATCTGAATTCAGTGGCACAGCAGTTAGGAATTGAACTCAGGACACCTGGAAGAGC
AGTCAGTGCTCTTAAGTGCTCTTAACTACTGAGTCATCTCTCCAACCCCAAAGGTCC
CTTACGTTTGGCCATCTTGGGGTTTTTATGAGGGGTTTTATAAATGATTATAAGAGT
AAGAAGAAAGTTGCTGATGCTCTCATAACCTTGTATAAC 
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Integration sites in tumour derived EIAV infected mice. 454 sequencing was conducted by 
Manfred Schmidt’s research group (Mannheim, Germany) on LAM PCR & non-restrictive PCR 
amplificons using the GS FLX system according to the manufactures instructions (Roche, 
Applied Science, USA). All sequences were conducted using Blas2seq & the Smith-Waterman 
algorithm. The raw sequences reads were aligned to the mouse genome using USL BLAT 
genome browser http://genome.ucsc.edu & the BLAST database. 
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Integration sites in tumour derived EIAV infected mice. 454 sequencing was conducted by Manfred Schmidt’s research group (Mannheim, Germany) on 
LAM PCR & non-restrictive PCR amplificons using the GS FLX system according to the manufactures instructions (Roche, Applied Science, USA). All 
sequences were conducted using Blas2seq & the Smith-Waterman algorithm. The raw sequences reads were aligned to the mouse genome using USL 
BLAT genome browser. Direct high sensitivity 454 pyrosequencing revealed several RefSeq genes with high sequence counts.  
The genomic positions and orientation of provirus integration sites were retrieved using alignment tools such as BLAST and BLAT.  
 
 
Tumou
r 
Sample 
RefSeq 
Gene 
RefSeq ID Sequenc
e Count 
Genomi
c 
Length 
Chromosom
e 
Sequence 
Orientatio
n 
Gene 
Orientatio
n 
Integratio
n Locus 
Intro
n 
Exon 
% in 
Gen
e 
Downstrea
m of Gene 
Adame 
T1  
Pah NM_008777 169 198 10 + + 86961567 In2 16.0
0 
0 
Adame 
T1  
LOC38204
4 
NM_00108137
2 
228 159 8 - - 95966933 In2 9.50 0 
Adame 
T1  
Acvr2a NM_007396 257 187 2 + + 48100522   0 
Gerry 
T1 
Setd5 NM_028385 267 32 6 + + 113057795 In1 18.9
7 
0 
Gerry 
T1 
Mrpl1 NM_00103908
4 
743 192 5 - - 96434622   0 
Jonas 
LT 
Rnf13 NM_011883 10 131 3 + + 57900377 In7 78.6
0 
0 
Jonas 
LT 
Uvrag NM_178635 29 1-
114(115
) 
7 - - 98830218 In12 73.1
6 
0 
Jonas 
LT 
Park7 NM_020569 33 1-
100(101
) 
4 - - 149728872   12070 
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APPENDIX 11  
The DNA sequence provided here is an ‘in silico’ construction of the EIAV 
integration site flanking the Pah gene 
 
 
MPAH Ex2-EIAV-Ex3 
 
Ex2:25-132(108); In2 (1):133-3494; LAM PCR id: 3297-3494(198); 3'LTR: 3495-
3575(g3539A); 5'LTR: 9113-9193; In2 (2):9194-15715 Ex3:15716-15899(184) 
 
 
taaccaagtgatctaattatgtagGAAACAAGTTACATCGAAGACAACTCCAATCAAAATGGTG
CTGTATCTCTGATATT 
CTCACTCAAAGAGGAAGTTGGTGCCCTGGCCAAGGTCCTGCGCTTATTTGAGgtaa
gtgtgtaatatatttcgatcacat 
tcagccttcctctgatttctgcttgatctatttcttcttctctacccttaacatcaaactttgttgacttgccaggacca 
cagcctcaaacaaacaaacaaacaaacaaacaaacaaaaacagaacaaaacaaaacaaaagaaccaacaacaacaacaac 
aaaaaccaaactcccctcctctaccagcaattatatgacaatagcgcctcagctaagagtggcacttctggtctacctcc 
actttctatagtgtagttttgcctggcttgagctccgcacaggtctcctgcctgctaccacaactgttttgagttcatat 
gcataattgcactgctaggtctggaaagtgctgttttgctttagtcatcgttcctttggctcttacagttgtcccggttc 
ttctgcaatgactctggcaatttccaaggaggggtgtgatacatacgactcattgaaggttgagcatgttagtccccctt 
tctcgaaaacttgaccagctgtgggcttctattaaccaccatctaccacaaacagaagtttatctgataatagttgagag 
atacactgatctgtaggcacgatagtgatacgttattaagtattggtttaatattatgtcaatttagctgaataaaagta 
aggaggttctcccctcaaagcctatgacttgcagacagaccttcacaaacacatccagatgtttgttttctaggccattg 
caaatccaatcaaattgataatgaagatcggccatcattatatgacattagatgcaattaacacaatatcaataacaatg 
gcttggtactgtgtttaaaatccagagtgtttcacctgtcaggcaagtgctgtaatgctgagagacaccttcagccctat 
ggctccatttcagacatctaaatctgctctagtaaagggagtgtatttagaacttaaaacccagttttctaaagtggtgg 
tgatagttgtgggtaaatgaatgcctaatagcgagtagaaggcagtggggagaaaaaaaaggtgttttctgagggacaaa 
ctgctcctgaaaatgatgtttttgtaaaatactccagtgcacttgcttagcctttgtatcagggaatcacatattcttga 
gcagttgccccttcggactgagttagttaatggattaaataataataaatgaagaaactgttgacaatataataaacaaa 
ccacaagcagaactggatgaagtgcacctaagaggtgtgtgtgtgcatgtttgtgcatgtttgtgtgtgtatttgtgtgt 
gtgtgtacattcatgcatgcatgtatgaactctccatgaattctttgatacattatccagatctcaattccttgaggatc 
tcactgtacccatcctgcagaggaagatatggtactcagcatgctgattggttggtggaaggctgttattagtgtatatt 
gatttttttctccaaaacaccctcagcagctatcatggaaactccccatcctggtacagcttttatacccttattaacag 
cctgataaaattcatagtactataactccaagtgagcaagttaatcaagaaagcaaattcttctacacatggcaccacac 
atatatgccaggcataaatcaggctcttgatttgatatccatgaaactcagaggtggaagccattcttttactgtatgga 
ggagggagctgaggctccaagaaatgttgaacaattcactgaagataagtcagggaatgtgcaggcagaagtgggtttaa 
aaccccgaaccccaggcttccaagtccatgatctgtctgtaacactcacccttctgccaaacaaagggagcttggcagcg 
ggaggaagaggggaagctgctgaggtcactgtgcatctgtgtgtttctatcttttattacaccatcatgttctgacaaag 
tttctggacataaaaagtgaaacttaaaagagtaaataacagagcaaatgaaaaaaaaagactcaactgtacaataaggc 
aatatgatctttaaaaaacattctagcaaattctatattgttaaaaaagcattctgacaatccattctacatctggattt 
tggagagccatagtgcacacacagacacttgcatgaccaggaagcctgcagtggaaagacccactcaatgtggtcacact 
ttatatttcttaaacacatttgaccatggtaccttcttttttttttaatttttttattaggtattttcctcgtttacatt 
ttcaatgctatcccaaaggtcccccatacccacccccccaatcccctacccacccactgtccctttttgaccctggtgtt 
cccctgtactggggcatataaagtttgcaagtccaatgggcctctctttgcagtgatgaccgactaggccatcttttgat 
acatatgcagctaaagacaagagctcccgggtactggttagttcatattgttgttccacctatagggttgcagttccctt 
tagctccttgggtaatttctctagctcctccataaggggccgtgtgacccatccaatagctgactgtgatcatccacttc 
tgtgtttgctaggccccggcatagtctcacaagagtgagctatatctggtcctttcagcaaccatggtaccttcttaaca 
tctaggtttcagtattgtggtggcttaagttttgagctctaaactatcagcaacagcatgtgtggtgtgaaagacttttc 
ctggggagacataactcacatagacaatgcagacctcttagcacatgaaagaccaaagtaaagactgcaacaaaggaatt 
tttgttggggtcactatatcaagtacgggggaggtgttagttacaggagcaggaaagcaggaatgatttaaaaaaaaaaa 
APPENDICES  
 
208 
 
agcagtcaagccattgcataaccaagcaaaaaacatcctgggcaaatcatatgagtgacagctctcaaaacttacaatcc 
tggagttcactgcaaaacttcctggtgatcactgttccaggataccaggctctttgcaacttagtaggtcagagcactct 
cctagcacagtggatgctataaacctgagggggaccttttagaatcttctgagttgtcactttccaggtcatgtgactct 
ttgtttccctctagagTTTCCAGAGCCTCCTGCTCCCTCCTAGATAGAATCTTTCAGTTTGG
AAAAACTGCCATTCAGCA 
GCCTGAATTTGTGGCACTGAGGAATAGAACCAAAGTGAAGAGTCTATTGTTTAG
AACCAAACTCAGTTGATCCACTTGTT 
ATCGAGATGGGCAAAAGGAAGCTTTTAACCTCTTGGCTTAGTTTCCTTAGTTTcT
GTGGGGTTTTTATGAGGGGTTTTAT 
AAATGATTATAAGAGTAAaAAGAAAGTTGCTGATGCTCTCATAACCTTGTATAA
CCCAAAGGACTAGCTCATGTTGCTAG 
GCAACAATTGGGCACTCAGATTCTGCGGTCTGAGTCCCTTCTCTGCTGGGCTGAA
AAGGCCTTTGTAATAAATATAATTC 
TCTACTCAGTCCCTGTCTCTAGTTTGTCTGTTCGAGATCCTACAgttggcgcccgaacagg
gacctgagaggggcgcaga 
ccctacctgttgaacctggctgatcgtaggatccccgggacagcagaggagaacttacagaagtcttctggaggtgttcc 
tggccagaacacaggaggacaggtaagattgggagaccctttgacattggagcaaggcgctcaagaagttagagaaggtg 
acggtacaagggtctcagaaattaactactggtaactgtaattgggcgctaagtctagtagacttatttcatgataccaa 
ctttgtaaaagaaaaggactggcagctgagggatgtcattccattgctggaagatgtaactcagacgctgtcaggacaag 
aaagagaggcctttgaaagaacatggtgggcaatttctgctgtaaagatgggcctccagattaataatgtagtagatgga 
aaggcatcattccagctcctaagagcgaaatatgaaaagaagactgctaataaaaagcagtctgagccctctgaagaata 
tctctagagtcgacgctctcattacttgtaacaaagggagggaaagtatgggaggacagacaccatgggaagtatttatc 
actaatcaagcacaagtaatacatgagaaacttttactacagcaagcacaatcctccaaaaaattttgtttttacaaaat 
ccctggtgaacatggtcgactctagaactagtggatcccccgggctgcaggagtggggaggcacgatggccgctttggtc 
gaggcggatccggccattagccatattattcattggttatatagcataaatcaatattggctattggccattgcatacgt 
tgtatccatatcataatatgtacatttatattggctcatgtccaacattaccgccatgttgacattgattattgactagt 
tattaatagtaatcaattacggggtcattagttcatagcccatatatggagttccgcgttacataacttacggtaaatgg 
cccgcctggctgaccgcccaacgacccccgcccattgacgtcaataatgacgtatgttcccatagtaacgccaataggga 
ctttccattgacgtcaatgggtggagtatttacggtaaactgcccacttggcagtacatcaagtgtatcatatgccaagt 
acgccccctattgacgtcaatgacggtaaatggcccgcctggcattatgcccagtacatgaccttatgggactttcctac 
ttggcagtacatctacgtattagtcatcgctattaccatggtgatgcggttttggcagtacatcaatgggcgtggatagc 
ggtttgactcacggggatttccaagtctccaccccattgacgtcaatgggagtttgttttggcaccaaaatcaacgggac 
tttccaaaatgtcgtaacaactccgccccattgacgcaaatgggcggtaggcgtgtacggtgggaggtctatataagcag 
agctcgtttagtgaaccgtcagatcgcctggagacgccatccacgctgttttgacctccatagaagacaccgggaccgat 
ccagcctccgcggccccactagaactagtggatccgtcgaccatgcagcgcgtgaacatgatcatggcagaatcaccagg 
cctcatcaccatctgccttttaggatatctactcagtgctgaatgtacagtttttcttgatcatgaaaacgccaacaaaa 
ttctgaatcggccaaagaggtataattcaggtaaattggaagagtttgttcaagggaaccttgagagagaatgtatggaa 
gaaaagtgtagttttgaagaagcacgagaagtttttgaaaacactgaaagaacaactgaattttggaagcagtatgttga 
tggagatcagtgtgagtccaatccatgtttaaatggcggcagttgcaaggatgacattaattcctatgaatgttggtgtc 
cctttggatttgaaggaaagaactgtgaattagatgtaacatgtaacattaagaatggcagatgcgagcagttttgtaaa 
aatagtgctgataacaaggtggtttgctcctgtactgagggatatcgacttgcagaaaaccagaagtcctgtgaaccagc 
agtgccatttccatgtggaagagtttctgtttcacaaacttctaagctcacccgtgctgagactgtttttcctgatgtgg 
actatgtaaattctactgaagctgaaaccattttggataacatcactcaaagcacccaatcatttaatgacttcactcgg 
gttgttggtggagaagatgccaaaccaggtcaattcccttggcaggttgttttgaatggtaaagttgatgcattctgtgg 
aggctctatcgttaatgaaaaatggattgtaactgctgcccactgtgttgaaactggtgttaaaattacagttgtcgcag 
gtgaacataatattgaggagacagaacatacagagcaaaagcgaaatgtgattcgaattattcctcaccacaactacaat 
gcagctattaataagtacaaccatgacattgcccttctggaactggacgaacccttagtgctaaacagctacgttacacc 
tatttgcattgctgacaaggaatacacgaacatcttcctcaaatttggatctggctatgtaagtggctggggaagagtct 
tccacaaagggagatcagctttagttcttcagtaccttagagttccacttgttgaccgagccacatgtcttcgatctaca 
aagttcaccatctataacaacatgttctgtgctggcttccatgaaggaggtagagattcatgtcaaggagatagtggggg 
accccatgttactgaagtggaagggaccagtttcttaactggaattattagctggggtgaagagtgtgcaatgaaaggca 
aatatggaatatataccaaggtatcccggtatgtcaactggattaaggaaaaaacaaagctcacttaatgaaagatggat 
ttccaaggttaattcattggaattgaaaattaacagggcctctcactaactaatcactttcccatcttttgttagatttg 
aatatatacattctatgatcattgctttttctctttacaggggagaatttcatattttacctgagcaaattgattagaaa 
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atggaaccactagaggaatataatgtgttaggaaattacagtcatttctaagggcccagcccttgacaaaattgtgaagt 
taaattctccactctgtccatcagatactatggttctccactatggcaactaactcactcaattttccctccttagcagc 
attccatcttcccgatcttctttgcttctccaaccaaaacatcaatgtttattagttctgtatacagtacaggatccccc 
gggctgcaggaattcgatatcaagcttatcgataccgtcgacctcgagggggggcccgacctactagggtgctgtggaag 
ggtgatggtgcagtagtagttaatgatgaaggaaagggaataattgctgtaccattaaccaggactaagttactaataaa 
accaaattgagtattgttgcaggaagcaagacccaactaccattgtcagctgtgtttcctgacctcaatatttgttataa 
ggtttgatatgaatcccagggggaatctgaacccctattacccaacagtcagaaaaatctaagtgtgaggagaacacaat 
gtttcaaccttattgttataataatgacagtaagaacagcatggcagaatcgaaggaagcaagagaccaagaatgaacct 
gaaagaagaatctaaagaagaaaaaagaagaaatgactggtggaaaataggtatgtttctgttatgcttagcaggaacta 
ctggaggaatactttggtggtatgaaggactcccacagcaacattatatagggttggtggcgatagggggaagattaaac 
ggatctggccaatcaaatgctatagaatgctggggttccttcccggggtgtagaccatttcaaaattacttcagttatga 
gaccaatagaaggtgaccagtggtgcagggtcctccggcagtcgttacctgaagaaaaaattccatcacaaacatgcatc 
gcgagaagacacctgggaccaggcccaacacaacatacacctagcaggcgtgaccggtggatcaggggacaaatactaca 
agcagaagtactccaggaacgactggaatggagaatcagaggagtacaacaggcggccaaagagctgggtgaagtcaatc 
gaggcatttggagagagctatatttccgagaagaccaaaggggagatttctcagcctggggcggctatcaacgagcacaa 
gaacggctctggggggaacaatcctcaccaagggtccttagacctggagattcgaagcgaaggaggaaacatttatgact 
gttgcattaaagcccaagaaggaactctcgctatcccttgctgtggatttcccttatggctattttgggggctagtaatt 
atagtaggacgcatagcaggctatggattacgtggactcgctgttataataaggatttgtattagaggcttaaatttgat 
atttgaaataatcagaaaaatgcttgattatattagcttcgaatcactagtgaattcgcggccgcaatcaacctctggat 
tacaaaaatttgtgaaagattgactggtattcttaactatgttgctccttttacgctatgtggatacgctgctttaatgc 
ctttgtatcatgctattgcttcccgtatggctttcattttctcctccttgtataaatcctggttgctgtctctttatgag 
gagttgtggcccgttgtcaggcaacgtggcgtggtgtgcactgtgtttgctgacgcaacccccactggttggggcattgc 
caccacctgtcagctcctttccgggactttcgctttccccctccctattgccacggcggaactcatcgccgcctgccttg 
cccgctgctggacaggggctcggctgttgggcactgacaattccgtggtgttgtcggggaagctgacgtcctttccatgg 
ctgctcgcctgtgttgccacctggattctgcgcgggacgtccttctgctacgtcccttcggccctcaatccagcggacct 
tccttcccgcggcctgctgccggctctgcggcctcttccgcgtcttcgccttcgccctcagacgagtcggatctcccttt 
gggccgcctccccgcctgatcgatgtcgagaatcactagtgaattcgcggccgctcgacagcttatcgataccgtcgaat 
tggaagagctttaaatcctggcacatctcatgtatcaatgcctcagtatgtttagaaaaacaaggggggaacTGTGGGGT 
TTTTATGAGGGGTTTTATAAATGATTATAAGAGTAAaAAGAAAGTTGCTGATGCT
CTCATAACCTTGTATAACccaaagg 
actagctcatgttgctaggcaacaattgggcactcagattctgcggtctgagtcccttctctgctgggctgaaaaggcct 
ttgtaataaatataattctctactcagtccctgtctctagtttgtctgttcgagatcctacAaaagtgaaggtagtggta 
aaccttcaccaatagggtttccacaaaaatcaaaccaaatcatttgtgaaaactaattataacagcaactgtcatagagt 
aagttctcaattagcattttttttcaaaagttgttgctgtgtactgtagcctaaagaactcttaaattcttggatatagg 
aaaacctgttgaagactgaggttcgtttggttggaaaggaaaagactctgtatgggaatgctcacctgtttgaggttgtc 
catggaaggaaacttctagatatttgttagtgtcaagacctcaatgagtagaaataccgggaatatacttcacatcattt 
acaagtgattctttaatatagaggacaatgggaggcgctcatttcaagtatcccttctgttaagttaaacccccaaagaa 
caacatcagagtaaaaactgtgatctaaatacacttttattttttttttcttttacagaaggtaaaaatctatattctca 
atattggtctgagagggaaaagtatttcatgtggggataatcacctatctactgatacttttcttattaaatagccttat 
aatgactctaggcttaatgagcagccccaacactcaatacttatagcatggcagtcatacaactggataattagccaact 
cttactaaatactcagaggactaaggagagactcacagtgatgtacagtctctagactagaatgcgaagggtcagactag 
atcaccttgtcctctggcctgctgaaagtggacactttcttgacttggctgctagtagaacatactaaagcatgcaggca 
tctcagagaaagaaaggcctgtagtatgtgtgtaggcccctcttggattagtcaggattacgtaccttccattcaacttc 
aaagccaccacctcataaaggaaccaattttttttctctttgggcttgtagacttcagctggtaactacatcagaatgca 
taccaatgtagcccatatttatttgtttttgtttcattttccagtaatttatttttattagctttgcatcctgatcatag 
cctcctctctcctcagtcccacttttacaaatcccttccccccaatacccctgcccttctcctcagagatagggagcccc 
cccttgggtaccatcctatccgggacataaagtctcagcgggactctgcacatcctctctcactgaggcccaaccaggaa 
gtccaggtcgggagaagggaatccaatggctgggaataagcaaagaaacagatccacaaaaacccgagttgtgcgaggtc 
atctcagtcattctccagcagcctcatctagactgtttaatcggtggcatcgaagagcttcaggacaagcaagttgccaa 
catctggagaggctcagctggatattgcttctgaatttatactccactttcgtggatatgattcatcttttagaaacaat 
tgaaaggaaactgactacatttattacgcagatttcctgtgccctactctcgtccagggaacacactcctgccacccctc 
cactgttggatgtagattctgctgttaggttctatagagacgatggagtcactgaagtgagctagtcatccctccttggt 
ggctatagcacttagactccttgctaccaggcaatacaaatagagttatcattgttaacttgtgttacgaaagctgttgt 
tacttgctttataggattttattggatgattgtgctataatccatttaaccattccccagctgagagtgtttaattagat 
APPENDICES  
 
210 
 
gacaaaatttggttgaaagactttgtgaatttttttccctgagttagatttccagtattataacaaatgaagtcattctg 
tataaactgttgttttgtggttattcccaaagcaaggagctggtactgcttccgcttcttctcttctccccctcttcctc 
ctcttctttttcctcctcctcttcctcctctttctcccccatctcttcctcttcctcctccttttcctcttattctcccc 
tcctccttccccatcttctcttcctttctcttctccttttgttttttattgggatggtgtctcattagatagctttagct 
gtcctggggctcatgtagagcaggttggcttcatacagaggcctcctgcctctacctccctagtatgctaccacttctgg 
agtacaaagagcttcttggagaaagtggctacttccagggatgtcttatgggtgggtggtcaagttgtcctaaagtgtgg 
tttgccttctggcatgtcttctaccatgtgcacacacatcttctctcttctgtccttgtaccttctcaaacggttagaca 
aatacatgagctcaccttgcttcttggctttactgtatccctttctctgatttttgccacatacataaactttcttgcca 
ttatttattaatttttatcatgcagtatattttgatcacatttccccatcccctcatgcctcgcagaccctccccacttt 
gctctatacagcatagaccttggttgcctcttaaattttaacagaagtcaataggggaggggatgtgaccccaggaaggg 
ttcacaaattctctttcttcctaagccaagaagcatgaccttgctttttgctttgtttaggaaatgacctctgtttgctc 
atagtagcttttgagttccagctgtctctctggtcctccctctgcagtatttctctgtcctgcttggggttttgatgttt 
cccacaccagatcagggttctctttgtctgcagatcaggatatagctctcagctgctgttccagcatatgctgccaaacc 
tctgaaactataagcaagcttctaatttaaatgctttcttttataagagttgcattggtcatgatgtctgtcttagtcag 
ggtttctattcctgcacaaacatcatgaccaagaagcaagttagggaggaaagggtttattcagcttacatttccatatt 
gctgttcatcaccaaaggatgcaggactggaactcaagcaggtcaggaagcaggagctgatgcagaggccatggagggat 
gttccttactagcttgcctctcctggcctcctcagcctgctctcttatcgaaccaagactaccagccccgagatcgtccc 
acccacaaggggcctttcccccttgatcactaattgagaaaatgccttacagctggatctcatggaggcatttcctcaac 
tgaagctcctttctctgtgataactccagctgtgtcaagttgacacaaaactagccagtacaatgtctcttcatagtaat 
agaacagtgactaagacccacaatcatacacatatgcacagaatcatttaagggaagctgtaaccagtggtaaaatcctg 
gggcctcaggggacacaaagaagtctcggcagaaagagagcatgtgtcaggttcattactctgttccttgtacccagaga 
ttctgatgcttttgtgtttgatgtcatattaatgataatgaaaaaaaatcaacattttaagagagcttactgtatccctg 
gaagagaaggcagtgtttacaaaagaaaaatgactttgctgtgaatcatgtgctttcttcctctgttcttcacaacagag 
ctttttcatctatgattttattgtttctcttcctcaatttcctcaaaggccaaaaagaagggcccataaatgaccttcat 
aggtggtatttgagaggaggagctatcaccattgtagtgacatatgttctcctcagcattgcattgtttataactggaca 
tacactgcttcaaccacaaaaagggtgaattttattttaagttttggatctattcaagttcctgcacctgcagtacaagc 
tttgtccatttgaatattggtatttatttttttaagttatgaattcatgatgtgtcctggttttctacttagtgaacact 
aacatagctgtactggtggaatcagtcatagtgtaaagcatatgttttttaaagtatttttaaatttgggagcccatgta 
agtgattctatatgtaggtgtttgtgtgtgtgtcttagtcattgttatttggcatgaagagacaccatgacaaatgcagc 
tcttatgaaagaaagcatttagttagaagcttgcataaagtttcagaggtttggtctaatatcatcatggcagggaacat 
gacagcatatgctggatcagtagctgacagctacatcctgaaatgaaggcccagagggagaacctgggcctggtgtcggc 
ttttgaaacatcaaagcttaaaaattgtttgtgtgaagatatttaaaaatagacaaggatagtattatcataaaaaataa 
tacacagtagaattaatatcaatctatacacaagtattactgatcagaaaatagaatataggttctctcatggagggtag 
aacagatgatgttgcccctttgagagcagcggggtaagtaagatacagaaactttaaggggtgaatactttctggttcac 
catggaggccccaaggcatttaatttgggaaatcatctaggtaatcagggacaagcatgcagacaatgtcagtcattgct 
tctagtggcaaagcatatgaggaaagtcacttgccagtcactaaaacactggttgtagaaatcaaggcacgtctagatag 
tgtactctagcaagtgctgaaaaattgtataatgggtccgctggcagattgaatctgcaggtaaaggcattttctgccaa 
gtctgatgacttgtttttatctctgagatccacagctatggtagatgtggctaatgacaaataagaagtatttgttcatc 
tctctagctttgctatagatttttttctttttttaattcaaagaagaaactctagggagatttttgtgtatgtgctggcc 
ccttaggaattctgaattctcactcagctgcacagtgtttctaaacagacgatgaaatgggacctactgatccctttccc 
attttgttatctacaaattcctctcatagtccttatcattttactctttgaggtcattacatgaaatatcagcctgtgac 
tcctgacgctgtcacacttgccaccatagttacacccactatcatatgggatttcagaagcaactttgcggcagaactta 
gtggttctgccaggtctacaagggttattctcaacatggatgacagattgatcattctaataccatgagatccggttttc 
tgtctgctcaaaacttcataaggacccctaaaagtttcagaatcaaggccagatccattcaaataatttgtctagctgtc 
cttcatcttttgtggctattccaacttatcagacttcttttattacttcttctaggacaatcccatccaccattcccatg 
gggtcatcctgtctgttaactcctttagaatgtgcatatggtttgctttttcaagaagacctcatgtgcagatcctctta 
aatactagactgtatcctaatgctaccccagggcagctcatccattttgtctgtcctgccttgtatttatttttatcccc 
tgacattataaaataatacttaagttaattgctttttatggctgctgtctttattacctcaacttgaatgtaaactttag 
aaagaaaaaaacatctaggtctgagttgtgattggcatttagtgaatactgcatatgtatttatataggttatatatgta 
tatgtacatgcattttcaaatataatacaaataatataccttacatagttatataacatatgatgatattaatagtagtt 
ctacaaattatgttgcagagtgtatgtatgtattaatttgtccaagacccccaaagagctcatggtgcagttattaatga 
gaccacccatgtgtagatggggaaactgaggctatgcagaagcatgaaaataaaatagctagcatttcatagatgataca 
atttagagattatgaatgcagagcctgtgccctggggattatattcaagcaaaacaatgttgtgtctatatgatttattg 
atttctgtggcatttcattgggtggaagggagactttcccatgccatacctttacaaccattgtcttagacatttgatcc 
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aaacccaagccttacacaggcaactgtaggctggtattagatttctgtgtgattaagtttggatgcacttgactcattct 
tcctatctcttgtcaattggcgcttggttttgcagaaggtaaaacagagtctaaatatttaagggtttccttattctcat 
gtaatacaaaatgtttttaaaccctgctcttcaactctagttgttctggctctgtatatttggactgtggtaataatgaa 
caccagactcccacacctataattttctctttcagGAGAATGAGATCAACCTGACACACATTGAATCC
AGACCTTCCCGT 
TTAAACAAAGATGAGTATGAGTTTTTCACCTATCTGGATAAGCGTAGCAAGCCC
GTCCTGGGCAGCATCATCAAGAGCCT 
GAGGAACGACATTGGTGCCACTGTCCATGAGCTTTCCCGAGACAAGGAAAAGA
ACACAGgtgagagtctgaagaatctcg 
tgacctaa 
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DNA sequences representing the potential splice combinations of the Pah gene 
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APPENDIX  12 
 
Bisulphite sequences used for methyl specific PCR and DNA sequencing 
 
 
Gene Fragmen
t 
Forward Primer Reverse Primer (5’ Biotin) Annealing 
Temperatur
e (°C) 
Hmgcs
2 
1 TGGTTTAGTTTTTTTTTAAGTAGG TCACCTCTACTAAACTACTAAAAAC
AA  
56 
 2 TGAGGGATTTTGAATTTTTTTAGT TTTTAATACCAACTCTTCAAACAAT
T 
48.1 
Park7 1 GTGGGGTTTAGGTTGTAGTTTAGT
TA 
TCATATCCCACTAAACCCAAAC 48.4 
 2 TTATTTTTATTTAGGGGTTTGGGTT
TA 
AATCACAACCCCACCTCTAACC 48.1 
 3 GGTTAGAGTTTTGGGGTTAGAGG TCTCTTTAAAAAATCAACCCTACTA
C 
61 
 
 
Gene Fragment Sequencing Primer Dispensation Order 
Hmgcs2 1 GTTTTTTTTTAAGTAGGTA CGGTCTGATAGTCTGAGTCTG 
  TTATAAAGTTTAATTTAGAA ATCAGTGTCGATT 
  GTTGATATTTTAGAGATGTA AGTCAGTGTTAGTCTGAGTCAGTTGTAGTGAGAGAGTCTGATGTA
GATCTG 
 2 TTTTTTAGTAGTATTTGTTG ATCAGTTGAGTTGTGAGTTGTGTAGTCGATATGATCTG 
  AGTTTTGTGTAAGTATAATG GATCTGATCGAT 
  TTTTATAGATTAAAGTTAGTTA CGTCAGTAGATGTGTCAGTATCGA 
Park7 1 TTTAGTTAGGTTTTAAATT ATCTGATATATCGATATCAGTCTG 
  AGAGGTAGAGAGGGGTAAT CTGTCAGTAGTCAGTCAGTAGTGTCAGTATCAGTGTGGTCTG 
  GGGGGAGAGATGGTATAAG ATCAGTGTCAGTAGTCAGTAGTAGTTATCAGTTATTATCTG 
 2 ATTTAGGGGTTTGGGTTTAGT ATCTGATATGATCAGTAGTCTGAGTCTGAGTCTGAGTGTGTCAG 
  AGGGGTTGTGAGTAGTTTTAG CTGTCAGTGTCAGTCAGTATGTCTG 
  GTATGAGTGTTGGGTATA ATCAGTCAGTGTCTGAGTTGTCTG 
  GGTGAGAGGTTTTTGAGGATTAG ATCAGTGTCAGTCAGTGTGAGAGTCAGTCTGTGTAGTAGTCAG 
 3 GTTTTGGGGTTAGAGGT ATCAGTGTGATCAGTCAGTGTCTGAGTCAGTGTCTG 
  TTGGGAGGGTTGGGGGTA AGTCAGTCAGTAGTGTATGTCAGTAGTTGTATAGTATCTGTGAGT
CTGAGTCAG 
  GTTTGATTAAAGTTGTGATG ATCAGTGGAGTCAGTGTAGAGTATCAGTCTGAGTGTCTG 
  GGAAAGTGTTTTAGAGTGG ATCAGTAGTGTCAGTC 
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